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Abstract
APOBEC3 proteins are important for antiretroviral defense in mammals. The activity of these factors has
been well characterized in vitro, identifying cytidine deamination as an active source of viral restriction
leading to hypermutation of viral DNA synthesized during reverse transcription. These mutations can
result in viral lethality via disruption of critical genes, but in some cases is insufficient to completely
obstruct viral replication. This sublethal level of mutagenesis could aid in viral evolution. A cytidine
deaminase-independent mechanism of restriction has also been identified, as catalytically inactive
proteins are still able to inhibit infection in vitro. Murine retroviruses do not exhibit characteristics of
hypermutation by mouse APOBEC3 in vivo. However, human APOBEC3G protein expressed in transgenic
mice maintains antiviral restriction and actively deaminates viral genomes. The mechanism by which
endogenous APOBEC3 proteins function is unclear.
The mouse provides a system amenable to studying the interaction of APOBEC3 and retroviral targets in
vivo. Virions packaging endogenous protein were isolated from mice for analysis of APOBEC3 without a
need for protein overexpression. Biochemical and molecular studies are possible using endogenous
protein and viral nucleic acids. Additionally, the effect of APOBEC3-mediated viral mutagenesis and
subsequent drug resistance can be modeled in this system. Human APOBEC3G transgenic mice infected
with murine retroviruses and treated with an antiretroviral drug allows examination of natural levels of
viral replication, APOBEC3 induced hypermutation, and potential viral escape.
Studies described herein explore mechanisms of APOBEC3-mediated restriction and drug resistance in
vivo. We show that endogenous APOBEC3 protein is efficiently packaged into viral cores, and this protein
maintains catalytic activity against artificial substrates. We recovered low levels of G-to-A mutations from
natural reverse transcription products, although approximately five to ten fold lower than that thought to
be necessary for efficient viral restriction. We show that inhibition of reverse transcription is the main
mechanism of restriction in vivo, and can be targeted through virion-packaged or cell-associated protein.
Transgenically-expressed human APOBEC3G is instead able to heavily deaminate viral DNA, although
frequently to sublethal levels. We assessed the effect of both murine APOBEC3 and APOBEC3G on viral
replication in the presence and absence of an antiretroviral drug, and examined viruses for drug
resistance mutations. APOBEC3G has a clear effect on the rate of viral mutagenesis in vivo, with the
potential to induce drug resistance mutations.
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ABSTRACT
INTERACTIONS BETWEEN APOBEC3 AND MURINE RETROVIRUSES: MECHANISMS OF
RESTRICTION AND DRUG RESISTANCE
Alyssa L. MacMillan
Susan R. Ross, Ph.D.
APOBEC3 proteins are important for antiretroviral defense in mammals. The activity of
these factors has been well characterized in vitro, identifying cytidine deamination as an active
source of viral restriction leading to hypermutation of viral DNA synthesized during reverse
transcription. These mutations can result in viral lethality via disruption of critical genes, but in
some cases is insufficient to completely obstruct viral replication.
mutagenesis could aid in viral evolution.

This sublethal level of

A cytidine deaminase-independent mechanism of

restriction has also been identified, as catalytically inactive proteins are still able to inhibit
infection in vitro. Murine retroviruses do not exhibit characteristics of hypermutation by mouse
APOBEC3 in vivo. However, human APOBEC3G protein expressed in transgenic mice maintains
antiviral restriction and actively deaminates viral genomes.

The mechanism by which

endogenous APOBEC3 proteins function is unclear.
The mouse provides a system amenable to studying the interaction of APOBEC3 and
retroviral targets in vivo. Virions packaging endogenous protein were isolated from mice for
analysis of APOBEC3 without a need for protein overexpression. Biochemical and molecular
studies are possible using endogenous protein and viral nucleic acids. Additionally, the effect of
APOBEC3-mediated viral mutagenesis and subsequent drug resistance can be modeled in this
system. Human APOBEC3G transgenic mice infected with murine retroviruses and treated with
an antiretroviral drug allows examination of natural levels of viral replication, APOBEC3 induced
hypermutation, and potential viral escape.
Studies described herein explore mechanisms of APOBEC3-mediated restriction and
drug resistance in vivo. We show that endogenous APOBEC3 protein is efficiently packaged into
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viral cores, and this protein maintains catalytic activity against artificial substrates. We recovered
low levels of G-to-A mutations from natural reverse transcription products, although
approximately five to ten fold lower than that thought to be necessary for efficient viral restriction.
We show that inhibition of reverse transcription is the main mechanism of restriction in vivo, and
can be targeted through virion-packaged or cell-associated protein.
Transgenically-expressed human APOBEC3G is instead able to heavily deaminate viral
DNA, although frequently to sublethal levels. We assessed the effect of both murine APOBEC3
and APOBEC3G on viral replication in the presence and absence of an antiretroviral drug, and
examined viruses for drug resistance mutations. APOBEC3G has a clear effect on the rate of
viral mutagenesis in vivo, with the potential to induce drug resistance mutations.
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Chapter 1- Introduction
1.1: Retroviruses
Retroviruses are a family of enveloped RNA viruses that are distinctive due to the
replication of their RNA genome into DNA, which is then incorporated into the host cell genome.
This integration event has occurred thousands of times over the course of mammalian evolution,
leading to a significant portion of mammalian genomes being comprised of endogenous viral
remnants.

Most of these proviruses no longer encode for an active, infectious virus, but

exogenous retroviruses still pose an important threat as human pathogens.
Retroviruses were first discovered in the early twentieth century, as investigators worked
to find causes for specific neoplasias in animals that could be transmitted from one animal to
another. Ellermann and Bang first showed that a form of chicken leukemia was transmissible, the
cause of which was eventually found to be avian leukosis virus (ALV) (Ellerman and Bang, 1908).
Soon after, Peyton Rous determined that sarcomas could be transferred between chickens by
injection of cell filtrates; this virus was termed Rous sarcoma virus (Rous, 1910). Virus-induced
tumors were then discovered in a number of other species, including mice, cats and cattle. The
first human retroviral pathogen was human T-cell leukemia virus (HTLV-1), found in leukemic
human T-cells after epidemiological studies suggested an infectious cause for a cluster of
aggressive leukemias in small islands off of Japan (Poiesz, 1980). The most devastating human
retrovirus was identified soon after, as epidemics of Acquired Immune Deficiency Syndrome
arose in several countries around the world (Barre-Sinoussi, 1983). Now known as human
immunodeficiency virus, HIV has been the most difficult challenge to the field of retrovirology
since its discovery.
Retroviruses have a condensed core of electron-dense material, and are 80-120 nm in
diameter (Coffin, 2002). An outer lipid envelope studded with viral glycoproteins surrounds these
viruses. The viral genome is a single-stranded, positive sense RNA of between 7-12 kb in size,
with each viral particle containing two copies (Coffin, 2002). This genome is transcribed into a
double-stranded DNA intermediate through a process known as reverse transcription, and this

	
  

2	
  
DNA is integrated into the host cell genome. The virus recruits host cell machinery to transcribe
and translate viral proteins and full genomic RNAs for new viral particles (Coffin, 1996). Both
introduction of highly expressed, virus-associated oncogenic genes or mutation of oncogenic host
genes through integration can lead to transduction of the host cell, eventually leading to
pathogenic neoplasias (Robinson, 1982).

1.2: The RNA Genome and Virus Structure
All retroviral genomes are organized around common core genes (see Figure 1.1). The
four major coding domains gag, pro, pol, and env produce proteins necessary for the basic
retroviral life cycle.
1.2.1 The viral gene gag
The gag gene contains the genetic information to produce internal structural proteins,
including matrix, capsid, and nucleocapsid. These proteins are all proteolytically cleaved from a
large polyprotein called Gag (Vogt and Eisenman, 1973). The amino-terminal portion of gag
encodes for matrix (MA, membrane-associated). Matrix drives the interaction between the virus
and the inner leaflet of cellular membranes during virion formation (Figure 1.2) (Hamard-Peron
and Muriaux, 2011). Matrix proteins have a myristate added co-translationally. This 14-carbon
fatty acid promotes association with membranes, and without it, viral assembly is blocked (Grand,
1989). Moving downstream of matrix on the gag gene, the next encoded protein is capsid. It is
typically a very large antigenic protein, and through multimerization, forms a shell within the virion
interior to encapsulate the genomic RNA and associated proteins. This capsid structure and its
contents are considered the viral core. The true function of this capsid-created shell is unknown,
but it likely serves to shield the genomic RNA until the virion is ready to undergo reverse
transcription after infection of a new cell (Roos, et al., 2007). Capsid also serves a number of
other functions, including recruitment of critical protein components into the assembling virion
(Smith, et al., 1993).
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Fig. 1.1. Basic structure of a retroviral genome. The retroviral genome encodes four major
coding domains shown in gray, confined between regulatory 5’ and 3’ LTR segments. Both the 5’
and the 3’ end contain an identical sequence, R, shown in red. R is necessary for correct strand
transfer during reverse transcription (see Chapter 1.3.2). U5 (orange) and U3 (green) are short
unique sequences, which contain regulatory elements. The primer binding site (PBS; yellow) is
an 18 bp segment complementary to the tRNA primer used by the virus to begin reverse
transcription. Figure credit: Matt MacMillan

Fig. 1.2. Basic structure of a retroviral virion. The main virion components are the lipid
envelope (dark green), RNA genome (orange), structural proteins (capsid, red; matrix, light green;
and envelope glycoproteins, green), and nonstructural proteins (protease, light blue, integrase,
dark blue; reverse transcriptase, brown). Figure credit: Matt MacMillan
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The final critical component created from gag is nucleocapsid, encoded at the 3’-terminus
of the gene.

This small protein is found within the viral core created by the capsid shell, and is

associated with the viral RNA (Davis and Rueckert, 1972; Meric, 1984). Nucleocapsid has a
number of roles important for the viral life cycle, including assisting in RNA dimerization,
promoting nucleic acid annealing, assisting with the early steps of reverse transcription, and
stabilizing the newly formed viral DNA before integration (Freed, 1998). However, perhaps the
most critical role is recruiting viral RNA into the virion through direct binding, using zinc-finger
motifs (South and Summers, 1993). In some retroviruses, gag also encodes for one or two
additional small proteins. These sequences can be located in between those encoding for the
three main Gag proteins, and vary between viruses.

Roles for these proteins are not well

understood, although they are typically necessary for a complete viral lifecycle. Investigations
continue to examine these additional factors, with recent work showing the murine leukemia virus
protein p12 is critical for both core stability and tethering of the viral DNA to host chromosomes
during integration (Wight, 2012; Elis, 2012).

1.2.2 The viral genes pro and pol
The genes pro and pol are adjacent to one another in the retroviral genome. Some
viruses transcribe these genes as a single open reading frame, with cleavage of the polyprotein
late in assembly (HIV), while others transcribe them from separate open reading frames (MMTV,
MPMV). Still others have overlapping open reading frames with gag (HTLV) or an even larger
polyprotein formed with Gag (MLV) (Coffin, 2002).

Regardless of the organization, all

retroviruses encode three important enzymes within pro and pol: protease, reverse transcriptase
(RT), and integrase. Regulation of transcription and translation leads to significantly less enzyme
production than Gag protein production (Coffin, 2002). Protease is required to cleave the large
polyproteins into mature individual proteins.

This activity occurs late in the viral lifecycle,

immediately after budding (Dougherty and Semler, 1993). Viruses that are deficient in protease
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will bud, but will not form infectious mature particles, thereby making protease a popular drug
target (Lee, 2012). Protease functions through two apposed aspartate residues, each provided
by two protease monomers, which together form a homodimer (Navia, 1989). This homodimer
targets specific stretches of amino acids that are thought to be linkers between different domains
of the larger polyprotein (Coffin, 2002).
Reverse transcriptase converts the viral ssRNA genome into dsDNA.

The paradigm

existing prior to studies of retroviral RT considered DNA the template for RNA, with the reverse
reaction impossible. This was known as the “central dogma,” coined by Francis Crick (Crick,
1970). The discovery of RT redefined this paradigm, and also helped shape modern molecular
biology (Baltimore, 1970; Temin and Mizutani, 1970).

RT exists as either a monomer or a

heterodimer in different retroviral families, but all have a similar three-dimensional structure
necessary to bind specifically to its nucleic acid substrate, and are homologous in the active site
region (Goff, 1990). RT is a complex enzyme, working not only as a DNA polymerase using both
RNA and DNA substrates, but also as a ribonuclease (Grandgenett, 1978).

This activity is

termed RNase H, based on its specificity for RNA in a RNA:DNA hybrid, and is necessary to
complete reverse transcription (Moelling, 1971).
The final protein product of pro and pol is integrase, which is responsible for integrating
viral DNA into the host genome. Integrase recognizes the ends of linear dsDNA after reverse
transcriptase is complete, and characteristically cleaves two or three nucleotides from the 3’ end
of each strand.

This exposes a CA dinucleotide end, which is covalently linked to the host

genome (Coffin, 2002). Some retroviruses integrate randomly throughout the genome, while
others preferentially integrate into actively transcribed genes (Mitchell, 2004). Integrase is also
often targeted by antiretroviral drugs.

1.2.3 The viral gene env
In order to achieve entry, retroviruses must display glycoproteins on the virion surface,
which pass through the lipid membrane and are exposed to target cell viral receptors. The main
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function of these proteins is to enable entry into a host cell. These proteins are encoded by env,
located at the 3’ end of the genome.

Unlike gag, pro, and pol, this gene is spliced from

subgenomic RNA. It is also unique to retroviral proteins, as it must be processed for transport to
the cell surface. These proteins are heavily glycosylated, primarily though N-linked glycosylation
but also by 0-linked glycosylation (Pinter and Honnen, 1988). The purpose for this glycosylation
includes increased protein stability, more efficient protein folding, and protection from host
enzymes and immune responses (Elder, 1986). Further processing is required as typically a
single Env polyprotein is produced which is then proteolytically cleaved into two distinct proteins,
termed SU (surface) and TM (transmembrane) (Coffin, 2002).

This typically requires a cellular

protease such as furin (Einfeld, 1996). SU contains the receptor binding domain, and helps
instigate conformational changes in TM which leads to the active fusion of virus and cell. After
cleavage, the two subunits continue to interact via disulfide or noncovalent bonds, depending on
the virus. Envelope heterodimers form multimers, consisting of three SU-TM proteins, which
provides a more rigid structure that appears as a spike by electron microscope (Coffin, 2002).
Each of the SU units is able to independently bind to a host cell receptor, and multiple
interactions may be necessary to facilitate entry (Layne, 1990). Structurally, the cytoplasmic tail
of TM interacts with internal Gag proteins. This interaction mediates incorporation of the viral
envelope proteins located on the cell surface with all the necessary internal viral components.

1.2.4. The long terminal repeats
The RNA genome of retroviruses is flanked by sequences required for replication,
integration, and transcriptional regulation post-integration. The 5’ end begins with an R sequence
followed by U5 (Unique 5’), while the 3’ end consists of a U3 (Unique 3’) sequence and ends with
an R sequence identical to that found at the amino-terminus. During reverse transcription, the
RNA genome is copied in such a way that both ends of the DNA are flanked by a U3-R-U5
sequence repeat, termed the long terminal repeat. These regions range in size from 200 bp to
over 1200 bp (Coffin, 2002). The 5’ LTR serves as an RNA pol II promoter, and contains a
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variety of regulatory sequences such as enhancers responsive to both viral and cellular activating
factors (Krebs, 2001). Although the 3’ LTR has an identical sequence to that of the 5’ LTR, its
location at the 3’ end of the genome provides it a different role. Instead of acting as a promoter,
the 3’ LTR signals for transcriptional termination and polyadenylation. In certain retroviruses, the
LTR also contains an open reading frame, which is transcribed via alternative splicing from the 5’
to the 3’ LTR (Korman, 1992).

1.2.5 Virus Structure
Retroviral particles consist of RNA, lipids, and proteins. Approximately 1-2% of the total
viral content is RNA, two-thirds of which are viral genomic RNA, and one-third of which is transfer
RNA (used to prime reverse transcription) and small host RNAs (Coffin, 2002). The lipid content
accounts for 35% of the virus, and comes from host cell lipid membranes. However, retroviral
lipid envelopes have a larger concentration of cholesterol and sphingomyelin. These components
aid in temperature stability and viral assembly (Slosberg and Montelaro, 1982). All of the virally
encoded proteins make up the bulk of the virion, with approximately 75% Gag-derivatives, 1520% envelope proteins, and 5-10% non-structural enzyme and accessory proteins. Together,
these produce a virion of approximately 80-120 nm in diameter. However, virion morphology
varies greatly, and is used to characterize and classify viruses (Table 1.1).
Mature virions have a condensed core, which can be round, slightly angular, cone
shaped or bar shaped (Coffin, 2002). The viral core contains two copies of the RNA genome,
which are non-covalently joined together through RNA dimerization (Paillart, 2004). This RNA is
coated with nucleocapsid proteins. Protease, reverse transcriptase, and integrase are also found
within the viral core, which is composed of tightly packed capsid proteins surrounding this RNAprotein complex. A spherical layer of matrix proteins surrounds the viral core, and serves as the
interior layer of the viral envelope, beneath the lipid bilayer envelope. Envelope glycoproteins
stud the viral surface (Coffin, 2002).
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Table 1.1 Retroviral Classification
Viral Group
Example
Avian sarcoma
Rous sarcoma
and leukosis
virus
B-type
mammalian
Murine
leukemia
viruses
HTLV & bovine
leukemia
D-type virus
Lentivirus
Spumavirus

Family Name
Alpharetrovirus

Morphology
Central, spherical
core (C particles)
Irregular,
spherical core
(B particles)

Genome
Simple

Mouse mammary
tumor virus

Betaretrovirus

Moloney MLV

Gammaretrovirus

Central, spherical
core

Human T-cell
leukemia virus
Mason-Pfizer
monkey virus
Human
immunodeficiency
virus

Deltaretrovirus

Central, spherical
core
Cylindrical core
“D particles”

Lentivirus

Cone shaped
core

Complex

Foamy virus

Spumavirus

Central, spherical
core

Complex

Betaretrovirus

Simple or
complex
Simple
Complex
Simple

Chapter 1.3 Viral Replication Cycle
1.3.1 Viral Entry
The first step of the viral infection cycle is binding of the virus to a target cell and entry
into the cytoplasm (Figure 1.3). Initial absorption onto the cell surface can be enhanced by
additional host proteins or molecules, such as heparin sulfate proteoglycans, that are distinct from
the viral receptor (Sharma, 2000). The surface envelope glycoproteins bind to specific host cell
membrane components (the viral receptor) through high affinity binding via the receptor binding
site.

Each virus uses a very specific receptor, which determines the tropism, or range of cell

types able to be infected with the virus. Binding of the receptor initiates a conformational change
in the envelope protein subunits, which brings the viral and cellular membranes into very close
proximity and mediates fusion of the two. The TM glycoprotein of each retrovirus contains the
fusogenic peptide required for fusion. This peptide is positioned next to a domain similar to a
leucine zipper that forms a coiled-coil structure.

Because the envelope is oligomerized, the

multiple coiled-coil domains form a stable structure that can insert the fusogenic peptide into the
host cell membrane (Bentz and Mittal, 2000).

Although the exact process is not clearly
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understood, a fusion pore is created, the lipid membranes mix, and the viral core is internalized
into the cell.

Fig. 1.3 Retroviral Lifecycle. MMTV completes a viral lifecycle similar to other retroviruses.
Virion binds to a target cell via cellular receptor, and enters the cell via membrane fusion. The
RNA genome is converted to dsDNA via reverse transcriptase, and targeted to cellular
chromosomes for integration into the host DNA. Integrated viral proviruses are templates for new
viral genomes, as well as for transcription of viral genes to produce new viral proteins. Viral
assembly occurs at different sites of the cell, depending on the specific virus, and eventually
produces new virions budding out of cellular membranes. Figure credit: Matt MacMillan
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Viral internalization occurs quickly after initial fusion, typically within five minutes. Most
retroviruses are thought to enter at the plasma membrane, while others appear to enter from an
intracellular compartment after endocytosis, with fusion occurring between the virus and the
endocytic vesicle (Nisole and Saib, 2004). Other retroviruses, including MMTV and amphotropic
MLV require a drop in pH to catalyze fusion and thus enter cells from an acidic compartment
(McClure, 1993; Ross, 2002). Some retroviruses, including HIV-1 and HTLV-1, may also enter a
new cell through cell-to-cell infection. There is some evidence that the mechanism of specific
virus entry may be cell-type dependent.

1.3.2. Reverse Transcription
After the core is released into the target cell cytoplasm, the RNA genome must be
reverse transcribed into dsDNA. This process is linked to the disassembly of the capsid core,
which exposes the reverse transcription complex (RTC) (Zhang, 2000). Disassembly and reverse
transcription may occur simultaneously, but the exact timing and connection are poorly defined.
However, disrupting reverse transcription slows capsid uncoating (Hulme, 2011). Some viruses
seem to completely disassemble, while others remain relatively intact (Fassati and Goff, 2001).
Some structure is necessary, as complete disassembly via detergent prevents DNA synthesis in
vitro (Haseltine, 1976). However, all of the components necessary for reverse transcription are
contained in the virion, as purified virions can still complete the process if dNTPs are supplied
(Baltimore, 1970; Temin and Mizutani, 1970). Reverse transcription involves a number of steps,
outlined below and in Figure 1.4.
1. tRNA is annealed to the primer binding site (PBS), an approximately 18 bp
complementary region (Mak and Kleiman, 1997). Annealing occurs prior to or
during virus assembly.
2. Minus strand DNA is synthesized from 5’ to 3’, ending at the 5’ end of the
genomic RNA. This new synthesized piece is called minus-strand strong-stop
DNA, and is about 100-150 bp long (Varmus, 1978).
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3. RT mediates RNase H degradation of RNA in duplex with strong-stop DNA, and
first-strand transfer delivers the DNA to the 3’ end of the genomic RNA, based on
matching sequences present on both ends (R) (Tanese, 1991).
4. Minus-strand DNA synthesis resumes, and RNase H degradation continues as
needed, skipping a short polypurine tract (PPT) upstream of U3.
5. The RNA left at the PPT serves as a primer for plus strand DNA synthesis to
begin, continuing this time to the 3’ end. This results in a second strong-stop
DNA, called plus-strand strong stop (Finston and Champoux, 1984).
6. The tRNA primer is displaced by plus-strand synthesis and second strand
transfer attaches the exposed plus-strand PBS to the minus strand PBS, creating
a circular template (Boone and Skalka, 1981).
7. Both strands then complete synthesis, using each other as a template.
The primer tRNA is a critical host-derived factor, which is bound to the genomic RNA during
viral assembly and maturation (Mak and Kleiman, 1997). Each retrovirus uses a specific tRNA,
which is captured by the virus in the cytoplasm during viral assembly (Kelly, 2003). For example,
Moloney murine leukemia virus uses tRNA

Pro

, while HIV uses tRNA

Lys,3

(Mak and Kleiman, 1997).

RT begins reverse transcription with the tRNA primer marking the PBS as the start site. Although
each viral particle contains two copies of the viral genome, only one dsDNA will go on to integrate
into the host genome (Coffin, 2002). During reverse transcription, template switching can occur
between the two strands, leading to increased viral diversity if differences in the two copies exist.
It is also important to note that RT does not have a proofreading function, and is therefore errorprone, which results in sequence variation amongst viral swarms. However, each RT has a
slightly different rate of error. Analysis of SIV variation by infecting monkeys with a molecular
-3

clone estimated variation to be 9 x 10 at single nucleotide bases, with most mutations resulting
in amino acid changes (Burns and Desrosiers, 1994). In vitro reactions using purified HIV-1
reverse transcriptase determined an error rate of 3 x 10

-5

per target base pair per replication
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-6

cycle, while the same assay using M-MLV reverse transcriptase only resulted in 2 x 10 (Mansky,
1996; Varela-Echavarria, 1992).

Fig. 1.4 Process of reverse transcription. Reverse transcription begins with DNA synthesis
from a tRNA primer bound to primer binding site (PBS) towards the 5’ end of the RNA genome.
First-strand transfer allows continued synthesis using the 3’ end of the RNA genome as a
template. RNA in RNA:DNA hybrids is degraded by RNaseH. Second-strand transfer joins PBS
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from the second strand to the complementary PBS on the first strand, allowing full extension of
both strands. Figure credit: Matt MacMillan
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1.3.3. Integration
The final product of correctly completed reverse transcription is a linear, blunt-ended
dsDNA. While this is now ready for integration in the host genome, two alternatives can occur
which prevent normal integration. First, integrase can mediate circularization of the complete
DNA, known as a 2-LTR circle, which is thought to be a dead-end product that is unable to
integrate into the genome. A separate circularization can also be caused by host ligases, similar
to homologous recombination, which forms circles with a single LTR (Kulkosky, 1990).
Integration into the host genome is a defining characteristic of retroviruses. This process
allows them to be stably maintained during division of cells, prevents degradation of the viral
genome, and allows the cell to use host transcriptional machinery as the provirus acts essentially
like a mammalian gene (Coffin, 2002). During reverse transcription, the viral nucleic acids and
associated proteins undergo a transformation, which readies them for integration. This complex
is called the pre-integration complex (PIC) (Delelis, 2010).

One or more of these proteins

typically helps hijack cellular machinery to actively transport the PIC to the nucleus (Naghavi and
Goff, 2007). Some retroviruses must then await nuclear membrane breakdown during mitosis in
order to access the viral genome.

These viruses, including MLV and MMTV, cannot infect

differentiated cells or cells in prolonged interphase. The PICs of HIV and other lentiviruses are
actively imported into the nucleus, thereby surpassing the requirement for mitosis in some cell
types, including macrophages (Bukrinsky, 1992).
Once the PIC is properly localized for integration at the chromatin, the enzymatic
activities of integrase are required. First, as previously mentioned, the exonuclease activity acts
on the 3’ ends, removing two or more bases. Integration into the host genome uses a strand
transfer process to simultaneously insert both ends of the linear DNA into host chromatin.
Integrase utilizes nucleophilic attack using the 3’-OH of the processed strand to insert the DNA,
removing 2-4 bases from the host DNA. Cellular factors then repair the dinucleotide overhang via
polymerization and ligation (Delelis, 2008). Different retroviral integrases create characteristic
duplications of host sequences at the insertion point, from 2-4 bp.
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Once integrated, the provirus will be replicated prior to mitosis and passed on to daughter
cells.

The process is also inherently mutagenic, as integration disrupts the region of the

chromatin it lies within. Insertion into a proto-oncogene can change the expression pattern of the
gene, causing transformation and eventually lead to tumorigenesis (Robinson, 1982).

1.3.4 Transcription and Translation
Integration is necessary for transcription of retroviruses, which differs from other viruses
that transcribe immediately from cytoplasmic viral RNA or DNA (Coffin, 2002). At this point in the
viral lifecycle, the virus requires host cellular machinery in order to transcribe the provirus into
RNA. RNA polymerase II and associated co-factors transcribe the provirus just as it would a
cellular gene, beginning directly upstream of the R region of the 5’ LTR. This region contains
appropriate promoter sequences, including a core promoter element TATA box, which helps
direct the cellular machinery (Laimins, 1984).

Each viral promoter has unique enhancer

sequences, thereby attracting different positive and negative regulators to the LTR. This can
change the pattern of expression in different cell types and in different cellular conditions (Coffin,
2002). The rate of transcription can also be dependent on the site of integration, with placement
near a cellular enhancer increasing transcription, or placement near an epigenetically silenced
region decreasing or silencing transcription (Niwa, 1983). Conversely, the viral enhancers can
influence the expression of cellular genes at the site of insertion.
Transcription terminates in the 3’ LTR, at or near the end of the 3’ R sequence, and is
coupled to 3’ end processing, which both cleaves and polyadenylates the transcript (Guntaka,
1993). These transcripts can also serve as templates for splice machinery, as splicing is required
for expression of some viral genes, including env. Simple retroviruses will only produce unspliced
and singly-spliced transcripts, but complex retroviruses can produce multiply spliced RNAs, as
well as use alternative splice sites to produce variations on the same product (Coffin, 2002). Any
spliced transcript will contain the same first exon, the U5 region of the 5’ LTR, as well as the
same sequence in the final exon, the U3 and R regions of the 3’ LTR (McNally, 2008). The
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unspliced transcript will either act as genomic RNAs for new virions, or as templates to translate
Gag and Pro-Pol proteins.
Translation of viral genes begins similarly to that of cellular genes, with transport out of
the nucleus. However, some viral proteins are translated from unspliced RNA, which is also
necessary to be used as genomic RNA. Retroviruses have evolved mechanisms to allow for
nuclear export of unspliced RNA. Simple retroviruses utilize cis-acting stem-loop structures called
constitutive transport elements (CTE), which are bound by nuclear export factors to mediate
export (Bray, 1994).

Complex retroviruses, including HIV-1, typically encode for trans-acting

protein factors that bind to viral RNA sequences and recruit other cellular export factors to
transport this RNA/protein complex (Fischer, 1995; Harris, 2000).
Membrane-associated envelope proteins are translated within the endoplasmic reticulum,
while other viral proteins such as Gag are translated within the cytoplasm. Viral RNAs, like
cellular RNAs, are capped at their 5’ end, which typically attracts translational machinery and
allows ribosomes to bind and begin translation.

However, it is hypothesized that some

retroviruses, including HIV-1, may be able to navigate translation independently of ribosome
scanning. The 5’ untranslated region shows a significant degree of secondary structure, and
AUG start codons downstream of the initial AUG codon are sometimes used (Yilmaz, 2006).
Internal ribosome entry site (IRES) elements have been found within ALV, F-MLV, and HIV-2
(Balvay, 2007).

Therefore, cap-dependent and cap-independent translation may both play

important roles for retroviruses.

1.3.5 Assembly and Budding
After translation of the required proteins, assembly of new virions can occur.

This

typically takes place at the plasma membrane, but for both type B and type D retroviruses, can
begin internally, with resulting immature virions assembling prior to associating with the plasma
membrane or an internal cellular membrane. Localization of viral assembly is driven through
association between core and membrane-associated envelope glycoproteins, and is dependent
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on several factors, including cell localization properties of both envelope and core proteins
(Sandrin and Cosset, 2006). For all retroviruses, a high concentration of Gag proteins must
accumulate together in order to drive self-assembly.

Gag-Gag interactions typically rely on

specific regions of the nucleocapsid portion of the Gag polyprotein (Gheysen, 1989). Cellular
factors also play an important role in mediating core assembly. For example, the ATPase ABCE1
is recruited to HIV-1 core assembly sites, and is required for HIV-1 assembly (Klein, 2007). Gag
in immature cores also interacts with Env proteins expressed on the cell surface, ensuring its
presence in the budding virion.

However, these interactions are not required for membrane

proteins to associate with viral particles, as envelope proteins from unrelated viruses can be used
to produce pseudotype viruses with retroviral cores in vitro (Sandrin and Cosset, 2006).
RNA is also required for particle assembly. While viral like particles can form in the
absence of specific viral RNA, the virus also selectively incorporates two copies of the full-length
RNA genome (Campbell and Vogt, 1997; Johnson and Telesnitsky, 2010).

As discussed

previously, membrane association relies on the matrix region of the Gag polyprotein (see Chapter
1.2.1).

Eventually, through exponential rates of recruitment and association, enough Gag

particles will connect with the membrane and with each other to form a lattice, which begins the
formation of a budding sphere (Carlson, 2010). While this lattice is important for creating the
structure of virion, it is in an immature form. An immature virion is non-infectious. Protease is
responsible for viral processing, cleavage of the polyproteins, and subsequent condensation of
the viral core, a process resulting in mature virions (Dunn, 2002).

Chapter 1.4 Mouse Mammary Tumor Virus
Mouse Mammary Tumor Virus (MMTV) was the first mammalian retrovirus characterized.
John Bittner first identified a milk-transmitted, microscopic agent as the cause of mammary
carcinomas in mice (Bittner, 1936). Its identification has led to decades of research, with focuses
on both virology and cancer, and the development of mouse models for breast cancer. It is
characterized as a betaretrovirus, which consists of virions with Type B or Type D morphology
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(see Table 1.1). Type B viruses are identified by an eccentric condensed core and prominent
surface spikes.

Unlike gammaretroviruses and lentiviruses, betaretroviruses are assembled

intracellularly, and then traffic to the plasma membrane for budding (Coffin, 2002). MMTV is a
complex retrovirus, encoding accessory genes as well as the basic genes required for retroviral
replication.

Accessory genes are non-structural, and typically help the virus evade the host

immune response in vivo. The genome is approximately 9 kB in length, with notably long LTRs
(approximately 1.3 kB compared to 400-800 bp of most other retrovirus) (Coffin, 2002).
Viral proteins are translated from five different transcripts. The full-length genomic RNA
encodes Gag and Pol proteins, and an additional non-structural protein dUTPase (Dut). The dut
gene is also carried by equine infectious anemia virus (EIAV), where it likely aids in replication in
nondividing cells which carry a surplus of UTP (Elder, 1992).

A 73 kD Env polyprotein is

translated from a singly spliced transcript. This is cleaved by furin into SU (52kD) and TM (36
kD), both of which are glycosylated. The Env subunits facilitate entry into acidic endosomes.
Unlike many retroviruses, MMTV entry is pH dependent (Ross, 2010).

Two additional viral

proteins are translated from additional splice variants. A double spliced mRNA encodes the
regulator of export of MMTV (Rem), which is similar to the HIV accessory protein Rev. These
proteins aid in transportation of unspliced viral RNA into the cytoplasm (Mullner, 2008). The other
is encoded by an ORF in the 3’LTR, discussed below.
The MMTV LTRs define several important characteristics of MMTV. First, the ORF in U3
encodes a gene termed sag, producing the accessory protein Superantigen (Sag). The inclusion
of this ORF contributes to the particularly long LTR, even though the R region of the LTR is the
shortest among all retroviruses at 15 nucleotides (Coffin, 2002). Sag is necessary in vivo to
boost early viral infection in target lymphocytes, resulting in increased viral spread (Held, 1993;
Golovkina, 1998). The LTR is also home to a number of MMTV-specific transcription factor
binding sites, which act within the 5’ LTR after proviral integration. The transcription factors
necessary are tissue-specific, allowing for expression in B and T cells, as well as mammary
epithelial cells (Reuss and Coffin, 2000). Hormones including glucocorticoid and progesterone
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regulate expression in the mammary gland because of hormone responsive elements in the LTR
(Payvar, 1983).
Exogenous MMTV infection is transmitted vertically via cell-free virus expressed into the
breast milk. The virus binds to transferrin receptor 1 (TfR1) on the cell surface of dendritic cells in
the Peyer’s patches of the intestine, and then spreads to T and B cells in this secondary lymphoid
organ (Ross, 2002; Ross, 2008). Infected dendritic cells and B cells present the viral Sag protein
on their surface major histocompatibility (MHC) class II proteins, and thereby activate T cell
receptors on specific CD4+ T cells. This stimulates activation of the T cells, which causes them
to proliferate locally, provide help to nearby B cells, and produce cytokines that attract additional
cells of the immune system to the area. This attraction then provides a large pool of new target
cells (Ross, 2010). Different strains of MMTV encode different Sag proteins, each of which binds
to a different T-cell receptor based on variability in the C-terminus of the protein (Ross, 2008).
This leads to strain-dependent activation of different subsets of CD4+ T cells, which can be
monitored through flow cytometry. Eventually, activation of the targeted subset will lead to almost
complete depletion (Ignatowicz, 1992).

Without Sag-mediated activation, the virus will not

replicate to levels necessary for viral spread to the mammary gland (Golovkina, 1998). This
depletion also alters the immune response profile of the mouse, causing an infected mouse to be
more or less susceptible to other pathogens (Ross, 2010).
The MMTV receptor, the murine transferrin transporter, TfR1, is highly expressed on
activated lymphocytes and dividing mammary epithelial cells (Schulman, 1989; Brekelmans,
1994). This expression pattern helps to determine the tropism of the virus. Infected lymphocytes
trafficking to the mammary gland deliver virus to this region. Mammary epithelial cells undergo
division during both puberty and pregnancy, at which time cells are susceptible to infection by
lymphocyte-derived virions. Because of cellular hormonal responses, viral transcription is highest
during pregnancy and lactation, producing a large quantity of new virions that are shed into milk
(Ross, 2008). Besides this virus expressed in milk, virus is completely cell-associated in vivo.
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Mammary tumors are typically formed when MMTV integrates near a cellular protooncogene, as tissue-specific, hormonally responsive transcription of the virus can upregulate
nearby genes (Ross, 2010). Time to tumor and tumor incidence mirrors overall viral load, as
increased viral replication leads to more integration sites and higher likelihood of integration near
an oncogene (Golovkina, 1993).

The majority of MMTV-induced tumors are caused by

integration near just a few families of genes, including Wnt, Int, Hst, and Fgf genes (Callahan and
Smith, 2008).
Mice can also acquire MMTV through endogenous proviruses. Almost all inbred mice
carry at least one endogenous Mtv, although more than 50 have been identified and some strains
of mice carry up to ten (Cohen and Varmus, 1979). These proviruses are named Mtv loci and
encode primarily defective viruses due to mutations acquired over the 20 million years they are
estimated to have been in the mouse genome (Ross, 2008).

However, the majority of

endogenous loci encode a functional Sag protein, which can lead to activation and depletion of
specific subsets of CD4+ T cells (Kappler, 1988). Endogenous viral transcripts can be packaged
into exogenous virions and cause the formation of infectious recombinant viruses. This can lead
to significant viral diversity, and cause increased viral spread due to activation of additional
subsets of T-cells by the endogenous Mtv Sag (Golovkina, 1994).

Chapter 1.5 Murine Leukemia Virus
Murine leukemia viruses, while similar to MMTV in terms of basic retroviral structure and
function, present a number of important differences. MLV was discovered over two decades after
MMTV, but through similar experiments that showed that leukemia could be transmitted to a
newborn mouse through a microscopic, filterable agent (Gross, 1957). It is characterized as a
gammaretrovirus, and displays Type C viral morphology, which is characterized by a central
spherical condensed inner core (See Table 1.1; Coffin, 2002). Unlike MMTV, MLV is a simple
retrovirus, which does not encode accessory proteins outside of Gag/Pol/Env. MLV does not
cause general pathogenic effects in infected cells, unless transformation occurs (Rein, 2011).
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However, immune responses to infected cells in the nervous system can cause motor disease
and encephalopathy (Zachary, 1992).
The gag gene of MLV has some important differences.

As stated previously, an

additional protein, p12, is produced from the Gag polyprotein. Additionally, some, but not all,
murine leukemia viruses produce a secondary form of Gag, called glyco-Gag or gPr80

gag

. This

protein begins from a start site upstream of the normal Gag AUG initiation codon, adding an
additional 264 bases onto the amino-terminus (Prats, 1989). Unlike the smaller, non-glycosylated
Gag protein, glyco-Gag undergoes Golgi-processing and is not incorporated into budding virions.
This form of Gag is dispensable in vitro, but is necessary to efficiently replicate in some strains of
mice (Corbin, 1994). Recent research has shown that this protein functions to counteract the
intrinsic immune factor, APOBEC3 (see Chapter 1.6.5) (Kolokithas, 2010).
MLV env is transcribed and translated into the Env polyprotein, which is glycosylated in
the Golgi apparatus and cleaved by a furin-like protease to form gp70 SU and the p15E
transmembrane TM. These proteins trimerize before relocating to the plasma membrane (Rein,
2011).

Viral maturation includes an additional processing step of Env, in which a small

cytoplasmic C-terminus portion of p15E is cleaved off. This cleavage is critical for fusion of the
virus to a target cell (Freed and Risser, 1987). MLVs are polymorphic in terms of their cellular
receptors. The receptor use determines host specificity or tropism, and is useful for classifying
MLV into four main groups: ecotropic, amphotropic, xenotropic, and polytropic. Ecotropic MLVs
are only able to infect mice, and do so using the mCAT-1 receptor, a cationic amino acid
transporter (Albritton, 1989; Kim, 1991). Amphotropic MLVs have a wider tropism, infecting both
mice and cells of many other species using Pit-2, a type III sodium phosphate cotransporter, as a
receptor (Hartley and Rowe, 1976; Miller, 1994). Xenotropic MLVs are unable to infect mice, but
can infect cells of other species, including human, cat, and rabbit cells. These viruses use XPR-1
as a receptor, which is a multiple-membrane-spanning protein with no identified function (Kozak,
2010). Finally, the polytropic MLVs have similarities to both amphotropic and xenotropic MLVs.
They are able to infect some mouse cells and some cells of other species, similar to amphotropic
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MLVs. However, they use XPR1 as their receptor, like xenotropic MLVs, but have a more limited
host range (Kozak, 2010). Viruses of each classification are found in the genomes of mice as
endogenous viruses. As with MMTV, transcripts of endogenous MLV can cause endogenousexogenous recombinants in infected cells.
Although murine leukemia viruses were first named based on their ability to cause
leukemias in mice, the retroviral group has been expanded to include many related mouse
gammaretroviruses. The most well characterized viruses include Friend MLV (F-MLV), Moloney
MLV (M-MLV), Rauscher MLV (R-MLV), and Abelson MLV (A-MLV). All of these cause slightly
different phenotypes of disease and are named after the primary investigator responsible for the
discovery (Coffin, 2002). Work described in subsequent chapters focuses on Moloney murine
leukemia virus, which causes T-cell lymphomas due to insertional activation of proto-oncogenes
(Dunn, 1961). Tissue tropism of the virus is carried in the 5’ LTR, which carries cis elements
including a direct-repeat enhancer responsible for promoting transcription and thus potential
pathogenesis (Li, 1987). Different mouse strains have diverse susceptibilities to MLV-induced
leukemia, ranging from 1-100%. Susceptible mice develop disease in 6 to 24 months (Shiff and
Oliff, 1986). Mice can become infected through horizontal and vertical routes: either by postnatal
exogenous infection or trans-uterine congenital exogenous infection. The majority of mother-topup transmission is thought to occur via breast milk (Duggan, 2006).

Chapter 1.6 Retroviral Restriction Factors
The host cells targeted by viruses have many means of defense. Both the innate and
adaptive immune responses recognize invasion by pathogens, and then actively work to clear
infection. The innate immune system is comprised both of cellular proteins and specific immune
cells.

Most cell types are able to recognize pattern-associated molecular patterns (PAMPs),

molecular signatures of invading pathogens, and mount a quick response. Other cells, including
leukocytes such as natural killer cells, mast cells, and eosinophils, as well as phagocytic cells
including macrophages, neutrophils, and dendritic cells are professional innate immune cells
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(Janeway, 2001). These cells recognize and bind common constituents of pathogens and will
lead to inflammation and assist with viral or bacterial clearance. The adaptive immune response
is induced secondarily, and requires highly specific pathogen recognition by T- and Blymphocytes via antigen-presenting cells. This pathway takes longer to mount during an initial
infection, but leads to a long-lasting defense generating immunological memory (Janeway, 2001).

Chapter 1.6.1 Overview of Retroviral Restriction Factors
Restriction factors are cellular proteins of the innate immune system that make up the
intrinsic immune system that serve to block infection. Many of these factors have been found to
specifically inhibit retroviruses.

A retroviral restriction factor is identified by several major

characteristics. First, it must directly cause a decrease in viral infectivity, and have a dominant
effect. Targeted retroviruses must show evolution of a counter-defense mechanism, which is
necessary for viral survival against a potent restriction factor. This defense and counter-defense
must continuously evolve according to the Red Queen hypothesis, which proposes that constant
adaptation and evolution is required for survival against changing opposing organisms (Van
Valen, 1973). Therefore, the restriction factor will show signatures of rapid evolution, typically in
an increased number of amino acid substitution mutations, often in regions of the protein that
specifically interact with the virus. Finally, the expression regulation of a restriction factor is tightly
controlled by the general anti-viral immune response of a cell, typically the interferon response
(Neil and Bieniasz, 2009).
Restriction factors of HIV-1 are best studied, and include APOBEC3, BST-2/tetherin, and
TRIM5. Genes responsible for conferring resistance to mouse retroviruses were discovered even
before the onset of the HIV epidemic. Friend virus models provided information about genetic
susceptibility to disease, with many of these genetic determinants encoding retrovirus-specific
restriction factors. Susceptibility to F-MLV is limited to certain strains of mice, with the two major
host ranges determined by a gene called Fv-1 (Pincus, 1971). Susceptibility to different strains of
MLV (either N- or B-tropic, named for their ability to infect NIH Swiss or Balb/c mice) depends on
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the allele of Fv-1 (either N- or B-type) encoded by a specific mouse strain. A third class of MLV
strains termed NB-tropic can infect mouse cells regardless of the Fv1 allele. Further research
showed that the viral determinants for tropism map to the capsid protein, and the protein encoded
by Fv1 is related to endogenous retroviral Gag proteins (Bieniasz, 2003). However, the exact
mechanism of restriction is unclear. Another genetic factor controlling F-MLV infection is Rfv-3.
Mice expressing the Rfv3 recessive allele fail to mount neutralizing antibodies, and cannot control
infection, while mice expressing the dominant allele recover from viremia (Chesebro and Wehrly,
1979). The molecular identity of Rfv3 was not discovered until after the HIV-1 restriction factor
APOBEC3 was identified in human cells, at which time Rfv3 was found to encode murine
APOBEC3 (Santiago, 2008).

Chapter 1.6.2 HIV-1 and the Discovery of APOBEC3
HIV-1 infectivity is inhibited by several restriction factors, which target different steps of
the viral life cycle. HIV-1 is a complex retrovirus, carrying genes for six additional non-structural
accessory proteins, one of which is named Vif (virion infectivity factor) (Fisher, 1987). Studies
using molecular clones of HIV with the Vif gene deleted (HIVΔvif) show markedly decreased
infectivity in some cell types, thus providing Vif its name (Gabuzda, 1992; Sova and Volsky,
1993; von Schwedler, 1993).

Restrictive cells are called non-permissive cells, and include

normal HIV targets such as CD4+ T cells and macrophages. However, pseudotyped HIVΔvif is
able to infect to wild-type levels in other cells, termed permissive cells, which include nonhematopoietic cells such as HeLa (human cervical carcinoma cells), 293T (immortalized human
kidney epithelial cells), and COS (immortalized monkey kidney fibroblasts) cells (Sova and
Volsky, 1993). The nonpermissive phenotype is dominant over permissive in heterokaryons,
which led to the hypothesis that nonpermissive cells expressed a restriction factor whose function
is overcome by Vif (Madani and Kabat, 1998).
Interestingly, infected nonpermissive cells are able to support a single round of
replication, producing high levels of virions comparable to permissive cells. The block to infection
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occurs in the second round of infection, early after viral entry (see Figure 1.5A vs. 1.5B). This
block is dependent on the producer cell type (nonpermissive vs. permissive), but independent of
the target cell type (see Figure 1.5C). Gene expression screens of nonpermissive and permissive
cells narrowed the list of potential candidates.

Genetically related cell lines were used in a

complementary DNA subtraction strategy using a nonpermissive T-cell line CEM and a
permissive subclone of this cell line, CEM-SS (Sheehy, 2002). This method removes all cDNAs
present in both cell types, and enriches sequences found solely in CEM cells. These cDNAs were
screened in further RNA hybridization screens of other permissive cell lines, and resulted in the
identification of a single gene, called CEM15 (Sheehy, 2002). When cloned and transfected into
new cells, CEM15 could convert permissive cells into nonpermissive cells, and was later
identified as a known member of the apolipoprotein B mRNA-editing, enzyme-catalytic,
polypeptide-like family and named human APOBEC3G (A3G). These studies also showed that
APOBEC3G was packaged into virions budding from non-permissive cells, which explained the
block in the subsequent round of infection (Sheehy, 2002; Fig. 1.5).
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Fig. 1.5. Wild-type HIV and HIVΔVif in Permissive and Nonpermissive Cells. (A) HIVΔVif
infection of APOBEC3-expressing cells is able to produce virions at wild-type levels. These
virions contain APOBEC3G, which acts to restrict reverse transcription and deaminate newly
formed viral DNA, preventing productive infection. (B) Cells infected with HIV containing Vif
suffer degradation of cytoplasmic APOBEC3G, preventing incorporation into virions. Subsequent
infection with these virions is not impeded. (C) Permissive cells do not contain APOBEC3,
allowing production of infectious virions regardless of Vif expression. Nonpermissive cells contain
APOBEC3, leading to production of noninfectious APOBEC3-containing HIVΔVif virions (shown in
gray). Figure credit: Matt MacMillan
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Chapter 1.6.3: APOBEC3 Evolution
Cytidine deaminases are found in a wide array of organisms, including yeast. However,
the AID/APOBEC gene family is found only in higher organisms. Genes are clustered into AID,
APOBEC1, APOBEC2, and APOBEC3 subfamilies based on nucleotide sequence surrounding
the active site. Homologs of AID and APOBEC2 are found in chicken, frog, and bony fish
(Conticello, 2005). Both of these loci are found in syntenic regions in chickens, mice, and
humans. However, APOBEC1 and APOBEC3 evolved later, likely derived from duplication of
AID, and are found only in mammals. APOBEC3 underwent further duplication early in primate
evolution, producing seven bona fide APOBEC3 genes, designated APOBEC3A to APOBEC3H,
all of which are clustered together on human chromosome 22 (Conticello, 2005). This cluster is
syntenic to a region of chromosome 15 in mice, although lack of expansion provides only a single
APOBEC3 gene in mice. Other mammalian species have varying numbers of APOBEC3 genes.
For example, pigs have two APOBEC3 genes, cats have four, and horses have six (LaRue,
2008).
APOBEC3 genes in both primates and rodents have undergone evolutionary changes
suggestive of positive selection, and it is hypothesized that host/virus interactions have been the
driving force for rapid expansion and evolution. In humans, five of the APOBEC3 genes display
some of the highest signals for positive selection in the entire genome, likely attributed to an
ancient battle between viruses and hosts (Sawyer, 2004). The evolution of this family provides
primates with a more varied antiviral response compared to mammals with fewer APOBEC3
genes.

The human APOBEC3 genes also have antiviral activity on other viruses, including

HTLV-1, Hepatitis B virus, and endogenous retroviruses, suggesting that many different viruses
may have helped shape this evolution (Chiu and Greene, 2008).

1.6.4 APOBEC3 Structure, Function, and Regulation
Human APOBEC3 belongs to a family of cytidine deaminases, enzymes that are able to
edit RNA and/or DNA (Teng, 1993; Harris, 2002). The most well characterized members of this
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family are activation-induced deaminase (AID) and APOBEC1. AID is expressed in B cells and
specifically edits the genome to promote somatic hypermutation and class switch hypermutation
(Muramatsu, 2000). APOBEC1 is expressed in the gastrointestinal tract and edits a single site of
apolipoprotein B mRNA to induce expression of a truncated version of the protein, which is
important for regulation of lipid metabolism (Mehta, 2000). All of the family members share a
similar domain structure. An alpha-helix is followed by a catalytic domain, a linker peptide, and a
pseudoactive domain (Jarmuz, 2002).
Some family members contain a duplication of this structure, with two catalytic domains.
Generally, a single domain is the active domain, while the other functions to bind substrate and
aid packaging into the virion (Goila-Gur and Strebel, 2008). Human APOBEC3G’s active domain
is the C-terminal domain, whereas mouse APOBEC3 has an active N-terminal domain (Hakata
and Landau, 2006). The catalytic domain is characterized by a conserved zinc-binding motif
(Cys/His)-Xaa-Glu-Xaa23-28-Pro-Cys-Xaa2-4-Cys. The His and Cys residues are responsible for
coordinating the Zn

2+

and the Glu plays a role in proton transfer during hydrolytic deamination of

a cytidine. This deamination occurs at the C4 position of the C base, which converts the cytidine
to a uracil (Chiu and Greene, 2008).
Although cytidine deaminases can edit DNA or RNA, APOBEC3 selectively targets
single-stranded DNA (Suspene, 2004). This is the direct means by which viral replication is
targeted. APOBEC3 is packaged into virions and is closely associated with the viral core, with
access to the reverse transcription complex during reverse transcription (Schafer, 2004).
Reverse transcription first creates an RNA:DNA hybrid, but the RNA is degraded by reverse
transcriptase (see Chapter 1.2.2). The RNA degradation is also critical for APOBEC3 activation,
as APOBEC3 bound to RNA is not enzymatically active (Soros, 2007). The minus-strand viral
DNA is thus the single stranded target of APOBEC3 (Yu, 2004).
Cytidine deamination of the minus-strand causes extensive dC-to-dU mutagenesis. DNA
containing uracils is typically targeted for degradation by DNA base repair enzymes, but it is
unclear whether this occurs in the viral context (Kaiser and Emerman, 2006). A dU in the minus
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strand causes dA to be incorporated into the coding plus-strand, resulting in G to A mutations.
Mutation rates vary, but can reach up to 10% of all dG residues (Chiu and Greene, 2008). The
volume of mutagenesis of different regions of the genome is directly related to the reverse
transcription process. DNA that is produced earlier is single stranded for a longer period of time,
therefore more susceptible to APOBEC3 editing. This results in a 5’ to 3’ increasing gradient of
mutation through the genome (Suspene, 2006). These mutations disrupt viral open reading
frames and can translate into stop codons.
Cytidine deaminases prefer to target a cytidine within a specific sequence context.
Examination of site targets can be used to distinguish the probable deaminase. This specificity
maps to a loop of 9-11 amino acids, which targets the enzyme to the specific sequence. The loop
is composed primarily of amino acids with basic, acidic, and aromatic side chains, which may
help mediate specific interactions (Kohli, 2009). For example, APOBEC3G prefers to target 5’CC-3’, resulting in a GG-to-AG pattern on the coding strand (Mangeat, 2003). However, certain
GG dinucleotides are “hotspots” for deamination over others, which is likely due to secondary
structure of the ssDNA (Holtz, 2013).
APOBEC3 proteins also exert cytidine deaminase-independent antiviral activity.

The

mechanisms are unclear, but include impeding tRNA-mediated reverse transcription initiation,
impairing plus-strand DNA transfer, and causing inefficient nuclear import and integration (Chiu
and Greene, 2008).

However, perhaps the most important deaminase-independent antiviral

activity comes from inhibition of reverse transcription post-initiation. APOBEC3 with impaired
active sites (via site directed targeting of necessary amino acids) are still packaged into virions,
and still exhibit a strong antiviral capacity in the absence of G to A mutations (Newman, 2005).
These mutant proteins can inhibit viral cDNA accumulation by stalling elongation of reverse
transcription products (Bishop, 2008). This inhibition may be mediated by interactions with viral
reverse transcriptase (Wang, 2012). The individual contributions of deamination and deaminaseindependent activity are unclear.
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APOBEC3 is interferon-inducible, and is a major component of this antiviral response for
targeted retroviruses (Peng, 2007; Okeoma, 2009). Different APOBEC3 family members are
differentially regulated, and this regulation leads to different expression levels in different cell
types. APOBEC3G protein is primarily expressed in peripheral blood mononuclear cells and
immune organs such as the spleen and thymus. APOBEC3A, APOBEC3C, and APOBEC3F are
also highly expressed in PBMCs. Stimulation of naïve T-cells leads to induction of all of the
APOBEC3 genes except for APOBEC3A. APOBEC3A is instead highly expressed in CD14+
cells, including macrophages and monocytes (Koning, 2009).

Expression of all APOBEC3

proteins is also generally high in the lung, the ovary, the cervix, and adipose tissue, and low in the
brain, esophagus, kidney, testes, and skeletal muscle in humans (Refsland, 2010). APOBEC3G
is also highly inducible in the liver (Bonvin, 2006).
In order to be packaged into budding virions, APOBEC3 must be expressed in the
cytoplasm.

Highly expressed cytoplasmic APOBEC3 can also protect a cell by restricting

incoming viruses, without specific packaging for activity in subsequent round of infection (Vetter
and D’Aquila, 2009). However, some members of the APOBEC family are expressed in the
nucleus (APOBEC3B), or pan-cellular (APOBEC3A).

These members have significantly less

activity against exogenous retroviruses (Chiu and Greene, 2008).

Chapter 1.6.5: Murine APOBEC3 and Murine Retroviruses
Multiple allelic variants of mouse APOBEC3 (mAPOBEC3) exist which differ in their
ability to restrict murine retroviruses. The two main alleles are represented by inbred strains
BALB/c and C57BL/6, and will be referred to as such (APOBEC3

BALB/C

and APOBEC3

C57BL/6

).

These two alleles differ in protein sequence, splicing pattern, and expression level, all of which
may contribute to differences in viral resistance (see Table 1.2).
There are also fifteen polymorphic amino acids between the two APOBEC3 alleles
(Figure 1.6). Genetic analysis from dozens of inbred and wild mouse species identified twenty
amino acids that are under positive selection, eleven of which are in this polymorphic group
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(Sanville, 2010). Several of these residues are found within two clusters in the active cytidine
deaminase domain, and are likely involved in long-term genetic conflict with pathogen targets.
These amino acids are directly involved in viral restriction, with the APOBEC3

C57BL/6

-encoded

residues creating a more restrictive enzyme. Genetic analysis also discovered a polymorphism in
a splice branch selection site, and an inserted sequence in the more virus restrictive
APOBEC3

C57BL/6

that acts as an enhancer (Okeoma, 2009). This insertion is a long terminal

repeat from a xenotropic mouse gammaretrovirus, and drives elevated mRNA expression levels
(Sanville,
APOBEC3
2012).

2010).
BALB/c

Additional

post-transcriptional

regulation

influences

translation

of

, as the inclusion of the fifth exon leads to decreased protein production (Li,

This leads to significantly more APOBEC3 protein produced in animals carrying the

APOBEC3

C57BL/6

allele, further contributing to increased viral restriction. Data included herein

support this differential expression as the primary influence on the difference in restriction (see
Chapter 2.4.5).

Table 1.2. Murine APOBEC3 Alleles
APOBEC3

C57BL/6

APOBEC3

BALB/c

Exons

8

9

Polymorphic Residues

15

15

Prototype Strains

C57BL/6, NZB/N, RF/J

mRNA Expression

High

BALB/c, C3H/He, AKR, NIH
Swiss
Low

Murine Retrovirus
Restriction

High

Low

The full length Apobec3 gene encodes nine potential exons.

Sequence variations

between the two alleles, specifically a difference in number of TCCT repeats in intron 4 and a
single nucleotide difference in exon 5, determine the inclusion or exclusion of exon 5.
APOBEC3

C57BL/6

excludes this exon, which translates into a slightly shorter protein of 49 kDa

compared to the 52 kDa APOBEC3

BALB/c

(Li, 2012). Mice carrying the allele for APOBEC3

BALB/c
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produce primarily the full-length transcript, but also produce a small proportion of transcripts
lacking exon 5. Transcripts have also been found that lack both exon 2 and 5, but are very rare
(Sanville, 2010; Okeoma, 2009; Takeda, 2008).

Figure 1.6 Murine APOBEC3 Alleles. Protein sequence alignment of the two allelic variants of
BALB
mouse APOBEC3. Alleles are labeled by the representative strain encoding each. APOBEC
C57BL/6
retains a fifth exon whereas APOBEC
does not due to a putative change in splice acceptor
site (Sanville, 2010). Polymorphic amino acids do not directly affect residues critical for catalysis
of cytidine deamination, but several amino acid differences in the substrate recognition loop
potentially alter the affinity for cytidines in different DNA sequence contexts (Kohli, 2009). Figure
credit: Rahul Kohli
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Mouse APOBEC3 shows a strong inhibitory phenotype against HIV in vitro.

This

inhibition is resistant to Vif, and is associated with heavy G-to-A mutagenesis of the viral genome,
at a rate of 1 mutation per 100 bp (Bishop, 2004; Hakata and Landau, 2006). These mutations
display a pattern of 5’-TT/CC-3’, giving mouse APOBEC3 a distinctive signature compared to
human APOBEC3 preferred targets; human APOBEC3G prefers to deaminate at 5’-CCC’-3’;
APOBEC3F prefers 5’-CTC-3’, and APOBEC3B prefers 5’-C/GTC-3’ (Bishop, 2004). The
beteretrovirus mouse mammary tumor virus is inhibited by both human and murine versions of
the protein, and served as the first model to demonstrate the antiviral activity of APOBEC3 in
vivo, using APOBEC3-deficient knockout animals (Okeoma, 2007).

Although MMTV is not

completely restricted by APOBEC3, mice lacking the gene have increased viral loads, faster viral
replication, and decreased time to mammary tumor formation. However, this restriction occurs in
the absence of G-to-A mutagenesis in vivo, contrary to that seen in an HIV vector restricted by
murine APOBEC3 in vitro (Okeoma, 2007). Mouse mammary tumor virus is also differentially
restricted by different APOBEC3 alleles, with an identical phenotype compared to Friend MLV
(Okeoma, 2009a). Mice expressing APOBEC3

C57BL/6

are thus more resistant to several classes of

murine retroviruses compared to those expressing APOBEC3

BALB/c

. This resistance appears to

be directly correlated to levels of APOBEC3 expression, as inducing expression in vivo increases
restriction in both APOBEC3

C57BL/6

- and APOBEC3

BALB/c

- expressing mice (Okeoma, 2009b).

Murine leukemia viruses are also inhibited by murine APOBEC3. This observation was
first made before the discovery of APOBEC3, as a genetic factor influencing recovery from FMLV (see Chapter 1.6.1). A single autosomal gene named Rfv3 (Recovery from Friend virus 3)
has long been known to influence neutralizing antibody responses and help control MLV viremia,
but the molecular identity was not known until after the discovery of APOBEC3 (Chesebro and
Wehrly, 1979). Mice are categorized as either resistant or susceptible to Friend virus, and this
pattern matches the expression of allelic variants, with those expressing APOBEC3

BALB/c

characterized as susceptible (Santiago, 2008; Takeda, 2008). For MLV, APOBEC3 acts as an
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intrinsic immune factor, but also affects the adaptive immune system. One theory suggests that
restriction by APOBEC3 reduces virus-induced immune dysfunction, thereby promoting
neutralizing antibody responses (Santiago, 2010).
APOBEC3’s role in viral restriction extends to other murine retroviruses as well, including
Moloney murine leukemia virus. Bone marrow-derived dendritic cells isolated from APOBEC3-/mice support higher levels of infection than those isolated from mice expressing APOBEC3. This
higher level of infection also leads to more rapid development of leukemia (Low, 2009). Another
gammaretrovirus, the endogenous AKV virus found specifically in AKR mice, is also restricted by
both alleles of APOBEC3 in vitro, under identical expression conditions. APOBEC3 proteins
expressed via transfection also caused low-level deamination of AKV genomes, at a rate of
approximately 2 mutations per kB (0.2%) (Langlois, 2009).
Evidence suggests that mouse APOBEC3 may have had mutagenic activity in the past,
as some clades of endogenous murine leukemia viruses show significant G-to-A mutations
consistent with the mouse APOBEC3 editing pattern (Jern, 2007). These mutations may have
helped inactivate the viruses as they integrated into the mouse germline. Retrotransposons,
particularly the IAPE element, are also potently restricted by mouse APOBEC3 ex vivo, and show
low-level mutagenesis (0.1-0.5%) (Esnault, 2008).

Mouse APOBEC3 does not deaminate

present day exogenous murine leukemia viruses, although the protein is packaged into budding
virions and causes inhibition of reverse transcription (Browne and Littman, 2008). Based on the
ability for mouse APOBEC3 to restrict and mutate HIV in vitro, it was hypothesized that murine
retroviruses have developed mechanisms to resist the mutagenic effects of their species-specific
APOBEC3 (Rulli, 2008).
Human APOBEC3G is an incredibly potent antiviral factor of HIVΔVif, but is unable to
restrict wild-type HIV. Murine APOBEC3 shows an intermediate phenotype in restricting murine
retroviruses such as MMTV and MLV. This inability to fully restrict these viruses suggests a
potential Vif-like factor. However, MLV does not encode for any accessory proteins, and the
accessory proteins of MMTV have other defined roles in the viral lifecycle. However, MLV does
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encode for an elongated form of Gag, known as glycosylated Gag (gGag) (see Chapter 1.5).
Without this factor, MLV replicates inefficiently in cells (and mice) expressing mouse APOBEC3,
but replicates to wild-type levels in APOBEC3-deficient cells (Kolokithas, 2010). This restriction
can be either virion- or cell-associated, and gGag does not prevent packaging of the protein into
the virion. However, viruses expressing gGag have more stable viral cores, which may protect
the viral reverse transcription complex from APOBEC3 (Stavrou, 2013). Reverse transcription
within these viruses proceeds unimpeded, while reverse transcription of gGag-mutant viruses is
reduced.

The mechanism by which gGag improves capsid stability and prevents APOBEC3

access is unknown.

Chapter 1.6.6: APOBEC3 and Drug Resistance
A defining feature of retroviruses is significant diversity and enormous evolutionary
potential based partly on error-prone reverse transcriptase enzymes (approximately one mutation
per genome per replication cycle) (Chiu and Greene, 2008). Other sources of viral mutation
come from cellular RNA polymerase (during transcription of the genome) and genomic
recombination, as reverse transcriptase can utilize both copies of the viral RNA packaged into the
viral core (Rambaut, 2004). This rapid evolution is a particular problem in the case of HIV-1.
This virus has a particularly high replication rate and maintains a large population size, which
together with an error prone polymerase, allow the virus to quickly evolve to evade immune
responses and develop resistance to antiviral drugs.

This variation also makes creating an

effective HIV vaccine more difficult. APOBEC3 is also a source of viral mutagenesis. The degree
to which APOBEC3 is responsible for viral evolution is unknown, but it was early noted that G-toA mutations account for a large percentage of drug-resistance mutations (Berkhout and de
Ronde, 2004).

Although APOBEC3 can cause lethal mutagenesis based on missense and

nonsense codon changes, if APOBEC3 is restricted by Vif-mediated degradation, limited
mutations may occur. Thus, APOBEC3 may not only serve as an antiretroviral factor, but also as
a potential proviral factor by aiding viral evolution.
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Several important experiments have provided evidence that APOBEC3-mediated
mutagenesis can in fact aid viral evolution and lead to drug resistance. The majority of these
experiments have utilized in vitro transfection and infection systems with human APOBEC3G.
Using a wide range of APOBEC3 expression levels in single round infections, Sadler and
colleagues found a number of integrated HIV proviruses with only a single APOBEC3 mutation (at
least within the viral gene examined). Although APOBEC3G levels affected virus infectivity, lowlevel, non-lethal mutagenesis occurred both in the presence and absence of Vif (Sadler, 2010).
In silico analysis also supports a role for APOBEC3G in HIV-1 evolution, through simulation of
multiple rounds of infection using prediction models to map mutations based on calculated
APOBEC3G target probabilities.

These models also assessed G-to-A nonsynonymous and

synonymous mutations in present-day HIV compared to ancestral genomes, and showed a higher
proportion of nonsynonymous mutations compared to random controls, implying some selection
for APOBEC3G-mediated mutations (Jern, 2009).
In vitro experiments have also directly tested the ability for APOBEC3G to cause drug
resistance through viral mutation.

The use of the nucleoside analog reverse transcriptase

inhibitor 3TC often leads to drug resistance in patients based on a single amino acid substitution
in the catalytic site of RT. This mutation is at position 184, changing the normally occurring
methionine in the conserved YMDD motif to isoleucine, valine, or threonine (Boucher, 1993).
Monotherapy with this drug leads to drug resistance within a few weeks in HIV-infected patients
(Sarafianos, 1999). The M184I mutation is specifically caused by mutation from AUG to AUA,
which also lies within the preferred editing context of APOBEC3G (5’-GG-3’). Wild-type virus
grown in vitro in the presence of IC90 levels of 3TC rapidly developed resistance via the M184I
mutation in cells engineered to express APOBEC3. The development of resistance did not occur
in cells lacking APOBEC3 during the timeframe assessed, nor did the mutation become fixed in
viral populations not grown with 3TC (Kim, 2010).
Natural variations in the Vif protein may largely affect APOBEC3 activity. A partially
active or inactive Vif could profoundly impact viral sequence evolution within virally infected
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individuals. Viruses isolated from HIV-infected patient samples show a large diversity in the vif
coding region, with variation of up to 8% from the consensus sequence (Simon, 2005). When
tested in vitro, these naturally occurring variants had variable activity against APOBEC3, with
selected mutants failing to effectively block these enzymes. For example, Vif harboring a K22E
mutation fails to restore HIV-1 infectivity in the presence of APOBEC3G (Simon, 2005).
Virus containing this mutant Vif was propagated in PBMCs in vitro for two weeks, and
resulting viruses had over thirty times more mutations compared to wild-type viruses undergoing
similar propagation.

These mutations were characterized by a strong bias toward G-to-A

mutations in the APOBEC3G editing context (Mulder, 2008). Over forty percent of recovered viral
sequences also harbored the G-to-A mediated M184I 3TC-resistance mutation, compared to
none in the wild-type viral population. However, all of the viruses harboring this drug resistance
mutation were contained within replication-defective proviruses, based on premature stop codons
also induced by APOBEC3. Infection with a viral quasi-species containing these resistancecontaining replication-defective viruses together with wild-type sequences eventually led to drugresistant, replication-competent viruses produced through viral recombination in vitro (Mulder,
2008).

These experiments provide essential evidence that APOBEC3 can result in drug

resistance, even in the complete absence of selective pressure by existing drug.
These experiments are corroborated by analysis of patient viral samples. A cohort of
HIV-1 infected individuals failing antiretroviral therapy was compared to a cohort of treatment
naive infected patients. The patients failing therapy typically have a higher rate of drug resistant
viruses (Sethi, 2003). Virus was isolated from plasma, and protease, reverse transcriptase and
Vif genes were amplified and sequenced. Mutation K22H in Vif was more frequently seen in
viruses isolated from the cohort failing treatment. Of viruses harboring this Vif mutation, 72% had
at least two drug-resistance-associated mutations in a GA or GG dinucleotide context, compared
to 42% of all viruses with a wild-type K22 Vif (Fourati, 2010). Thus, a partially effective Vif is
associated with APOBEC3-mediated drug resistance mutations in vivo.
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Chapter 1.7: Specific Aims and Significance of Dissertation
APOBEC3 is an important antiviral factor, which specifically targets retroviruses. Since
its discovery, APOBEC3 has been shown to restrict many different viruses, including important
human pathogens such as HIV-1. The overall aim of this study is to understand how APOBEC3
functions in vivo. We used a murine model to address three main questions that are poorly
understood to date.
Specific Aim 1: Determine the mechanism by which murine APOBEC3 restricts MMTV in vivo.
We hypothesize that murine APOBEC3 is unable to create G-to-A mutations in MMTV reverse
transcription products, but instead inhibits reverse transcription via cytidine deaminaseindependent mechanisms. We used biochemical approaches to test the ability of endogenous
murine APOBEC3 to catalyze cytidine deamination, and endogenous reverse transcription
assays to assess mutagenesis and inhibition of MMTV reverse transcription products.
Specific Aim 2: Establish important differences between murine APOBEC3 alleles that lead to
differences in viral restriction. We hypothesize that APOBEC3 expression level differences in
mice expressing APOBEC3
level of viral restriction.

BALB/c

or APOBEC3

C57BL/6

contribute to the associated difference in

Biochemical approaches were used to determine potential target

sequence specificity differences, and viruses isolated from heterozygous APOBEC3+/- mice
utilized for assessing a dose effect of APOBEC3 on inhibition of reverse transcription.
Specific Aim 3: Assess the effect of APOBEC3 on viral evolution and drug resistance in vivo. We
hypothesize that the mutagenic effect of APOBEC3 will increase the rate of nucleotide mutation,
thus decreasing time to development of drug resistance. We utilized two systems to address this:
MMTV-infected APOBEC3+/+ mice, as well as MLV-infected transgenic APOBEC3G-expressing
mice. We measured viral replication over time in AZT-treated vs. untreated mice, and sequenced
reverse transcriptase from MLV viruses at multiple time points post-infection. These sequences
were analyzed for nucleotide and amino acid mutations.
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Chapter 2: APOBEC3 inhibition of MMTV infection: the role of cytidine deamination versus
inhibition of reverse transcription
This work has been adapted from an original publication, Copyright © American Society of
Microbiology, Journal of Virology, 87(9), 2013, 4808-4817, doi: 10.1128/JVI.00112-13. Additional
authors include Rahul Kohli, University of Pennsylvania Department of Medicine, and Susan R.
Ross, University of Pennsylvania Department of Microbiology.
Chapter 2.1: Abstract
The apolipoprotein B editing complex 3 (APOBEC3) family of proteins is a group of
intrinsic anti-viral factors active against a number of retroviral pathogens including HIV in humans
and mouse mammary tumor virus (MMTV) in mice. APOBEC3 restricts its viral targets through
cytidine deamination of viral DNA during reverse transcription or via deaminase-independent
means. Here, we used virions from the mammary tissue of MMTV-infected inbred wild type mice
with different allelic APOBEC3 variants (APOBEC3

BALB

and APOBEC3

C57BL/6

) and knockout mice

to determine whether cytidine deamination was important for APOBEC3’s anti-MMTV activity.
First, using anti-murine APOBEC3 antisera, we showed that both APOBEC3 allelic variants are
packaged into the cores of milk-borne virions produced in vivo. Next, using an in vitro
deamination assay, we determined that virion-packaged APOBEC3 retains its deamination
activity and that allelic differences in APOBEC3 affect the sequence specificity. In spite of this in
vitro activity, cytidine deamination by virion-packaged APOBEC3 of MMTV early reverse
transcription DNA occurred only at low levels. Instead, the major means by which in vivo virionpackaged APOBEC3 restricted virus was through inhibition of early reverse transcription, both in
cell free virions and in vitro infection assays. Moreover, the different wild type alleles varied in
their ability to inhibit this step. Our data suggest that while APOBEC3-mediated cytidine
deamination of MMTV may occur, it is not the major means by which APOBEC3 restricts MMTV
infection in vivo. This may reflect the long term co-existence of MMTV and APOBEC3 in mice.

Chapter 2.2: Introduction
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Organisms adapt to infectious agents by developing protective responses and
conversely, infectious agents develop adaptive countermeasures to these responses.
Retroviruses are major causes of disease such as cancer and acquired immunodeficiency in
animals and humans and are likely one of the infectious agents that put selective pressure on
host evolution. Because of the frequent encounter of vertebrates with retroviruses, selection for
host anti-viral defense systems is likely and indeed, various host restriction factors have been
identified (Emerman and Malik, 2010).

These include the TRIM proteins, Bst2/tetherin and

APOBEC3 proteins (Malim and Bieniasz, 2012; see Chapter 1.6). Most of these anti-viral intrinsic
restriction factors were identified through the discovery of viral gene products that counteract their
actions.
Members of the APOBEC3 gene family encode DNA and RNA editing enzymes.
APOBEC3 proteins inhibit retroviral infection in target cells by deaminating deoxycytidine
residues on the DNA minus strand following reverse transcription, inducing hypermutation in
newly synthesized retroviral DNA. The various human APOBEC3 proteins have different
preferred target sequences; for example, APOBEC3G-mediated deamination occurs more
frequently at CCC residues, whereas APOBEC3F preferentially deaminates TCC sites (Bishop,
2004; Beale, 2004; Langlois, 2005). APOBEC3 proteins also inhibit replication by undefined
cytidine deaminase (CDA)-independent mechanisms (Newman, 2005). A number of in vitro
studies have suggested that APOBEC3 proteins in particles can inhibit binding of the tRNA

Lys3

primer to the viral RNA, RT-mediated elongation and accumulation of HIV-1 reverse transcription
products or integration into the host genome, at least in tissue culture cells (Bishop, 2006;
Iwatani, 2007; Li, 2007; Guo, 2007; Holmes, 2007a; Holmes, 2007b; Luo, 2007; Bishop, 2008).
Although several studies have argued that CDA-independent inhibition is an artifact of APOBEC3
over-expression (Schumacher, 2008; Miyagi, 2007), other studies have argued that it is
biologically relevant (Holmes, 2007; Bishop, 2008; Gillick, 2013) and recent work with mouse
retroviruses indicates that CDA-independent inhibition occurs in vivo (see Chapter 2.4).
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Clearly, viruses that persist in their hosts cannot be totally restricted by anti-viral host
mechanisms. In support of this, we have shown that mouse APOBEC3 contributes to resistance
to MMTV infection but does not totally restrict infection. MMTV is an endemic milk-borne
retrovirus that entered mice ~10 - 20 million years ago and causes mammary carcinomas in
female mice (Nandi and McGrath, 1973). Using APOBEC3 knockout mice, we provided the first
demonstration that APOBEC3 proteins function in vivo by showing that APOBEC3-/- mice were
more susceptible to MMTV infection compared to their wild type littermates; virus spread and
tumorigenesis were more rapid and extensive in the knockout mice (Okeoma, 2007). Moreover,
we found no evidence of cytidine deamination of the MMTV genome in wild type mice. Similarly,
several studies have shown that APOBEC3 inhibits Moloney (M-MLV) and Friend (F-MLV) murine
leukemia virus infection in vivo in the absence of mutations suggestive of cytidine deamination
(Rulli, 2007; Browne and Littman, 2008; Takeda, 2008; Low, 2009). However, mouse APOBEC3
retains deaminase activity on HIV substrates, with a preference for TCC targets (Bishop, 2004)
and has also been shown to have low activity on TTC residues in the endogenous murine
leukemia virus AKV (AKV-MLV) (Langlois, 2009).
Interestingly, there are allelic differences in mouse APOBEC3 among different inbred
mouse strains that encode proteins with the ability to restrict MMTV, as well as F-MLV, to
different extents (Takeda, 2008; Okeoma, 2009). In particular, C57BL/6 and BALB/c mice
express different APOBEC3 variants, with 15 polymorphic amino acids in the proteins encoded in
their genomes (Figure 1.6). Moreover, the BALB/c allele (APOBEC3
transcript and protein than that found in C57BL/6 mice (APOBEC3
fifth exon that is spliced out in the latter. Finally, APOBEC3

BALB

BALB

C57BL/6

) encodes a longer

) because it includes a

transcript and protein levels in

BALB/c mice are significantly lower in various tissues compared to APOBEC3

C57BL/6

in C57BL/6

mice (Takeda, 2008; Okeoma, 2009; Miyazawa, 2008; Sanville, 2010; Li, 2012). The
APOBEC3

C57BL/6

allele encodes a more effective in vivo restriction factor of murine retroviruses. It

is currently unclear as to whether the differential ability to restrict MLV or MMTV infection in vivo
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is due to the coding region changes that affect its anti-viral activity or to expression level
differences (Okeoma, 2009; Miyazawa, 2008; Li, 2012).
Here we show that APOBEC3 packaged into virions retains its deamination activity and
deaminates MMTV reverse transcripts at a low level. Interestingly, the APOBEC3
APOBEC3

BALB

C57BL/6

and

variants packaged in MMTV virions have altered substrate preferences for

deamination. In spite of the deamination activity, however, the major means by mouse APOBEC3
inhibits MMTV is by blocking early reverse transcription.

Chapter 2.3: Materials and Methods
Chapter 2.3.1 Plasmids, Cells, and Viruses
Plasmids expressing flag-tagged APOBEC3 (pFLAG-CMV vector) cloned from primary
DNA of C57BL/6 and BALB/c mice and HA-tagged catalytically inactive APOBEC3

C57BL/6

(E73Q/E253Q; pCMVpA vector) were acquired as a gift from Masaaki Miyazawa. Primary cDNA
samples were prepared from spleens, and full-length APOBEC3 was amplified using the
olionucleotide

primers

5’-

GGGGTACCGCCGCCACCATGGGACCATTCTGTCTGGGATGCAGCCATCGC-3’

AND

5’GGTCTAGACATCGGGGGTCCAAGCTGTAGGTTTCC-3’ (Takeda, 2008). The pFLAG-CMV2
vector (Sigma-Aldrich Corp., St.. Louis, MO.) was digested with SalI and EcoRI enzymes, and
the APOBEC3 cDNA was ligated into the vector. The catalytically inactive vector was created
through site directed mutagenesis using the pFLAG-CMV2-APOBEC3

C57BL/6

plasmid as the

template (Takeda, 2008).
293 cells stably expressing mouse transferrin receptor 1 were maintained in DMEM
supplemented with 10% FBS, 100 U/ml penicillin, 100 ug/ml streptomycin and 100 ug/ml
geneticin.

These cells were originally produced by cotransfecting 293 cells with a plasmid

containing the mouse transferrin receptor coding region in a CMV promoter-containing vector, as
well as a plasmid containing a neomycin resistance gene under SV40 promoter control (Zhang,
2003). Cells were selected in G418 (100 ug/mL) and FACS sorted for transferrin receptor 1
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expression. These cells were then stably transfected with APOBEC3 plasmids (described above)
and a plasmid containing a puromycin resistance gene, followed by selection in puromycin (1
ug/mL).

Expression was verified by SDS-PAGE and Western Blotting using anti-murine

APOBEC3 (Okeoma, 2010), anti-Flag (Cell Signaling) and anti-HA (Abcam) antibodies.
MMTV virions were isolated from mammary tumors or breast milk of MMTV-infected
mice. All steps of purification were performed on ice. First, tumors were cut into small pieces
and homogenized via Dounce homogenizer in buffer with 10 mM Tris pH 8.0, 0.1M NaCl, and 1
mM EDTA. The homogenate was centrifuged at 66g for 5 minutes at 4°C, and the supernatant
removed to a fresh 50 mL centrifuge tube (pellet discarded).
centrifuged at 12,400g for 10 minutes at 4°C.

The supernatant was further

Further purification of the supernatant was

achieved via ultracentrifugation at 21,000 rpm for 1 hour at 4°C. The pellet was dissolved in 2 mL
PBS, which was layered over 0-60% sucrose gradient (sucrose dissolved in PBS), or over a 30%
sucrose cushion, and then ultracentrifuged for 1 hour at 32,000rpm at 4°C.

Pellets were

resuspended in PBS (100 ul per gram of tumor tissue), and stored in aliquots at -80°C. Virions
from breast milk were isolated with minor modifications. Stomachs were removed from 1-3 day
old mouse pups of APOBEC3+/+ or APOBEC3-/- MMTV RIII-infected mothers. At least ten
stomachs of the same genotype were combined, and purified as above starting with Dounce
homogenization. Milk fat was skimmed from the top of the supernatant after the first two spins
and discarded.
RNA was purified from these virions using the QIAGEN RNeasy Mini Kit (QIAGEN,
Germantown, MD). Eight uL of virus was combined with 95 ul of PBS and 95 uL of RNAlater
RNA Stabilization Reagent (QIAGEN), then instructions per kit manual followed. RNA was eluted
into 30 uL of RNase free water, and reverse transcribed using SuperScript III First-Strand
Synthesis SuperMix, based on a modified M-MLV RT (Invitrogen Corp., Carlsbad, CA). Viral
cDNA was then measured by quantitative PCR for normalization, using primers specific for the
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MMTV

RIII

LTR

(Forward:

5’-CGTGAAAGACTCGCCAGAGCTA-3’;

Reverse:

5’-

GAAGATCTTCAAGGGCAATGCCTTAA-3’).
Viral cores were isolated by ultracentrifugation of purified virions through 10% sucrose
with 5% Triton-X on a 30% sucrose cushion, at 32,000rpm for 1 hour at 4°C. Pellets were
resuspended directly in 4x SDS-PAGE protein loading buffer (200 mM Tris pH 6.8, 400 mM DTT,
8% SDS, 0.4% bromophenol blue, 40% glycerol).

Chapter 2.3.2 Mice
MMTV(RIII)-infected APOBEC-/- mice and APOBEC+/+ mice were used for virus and
organ harvesting.

APOBEC3-/- mice were generated by gene trapping of intron 4 of the

APOBEC3 gene (Okeoma, 2007). This trapping would theoretically create a fusion protein of the
first four APOBEC3 exons and B-galactosidase, but no fusion protein was detected in tissues
from these mice (Okeoma, 2007). APOBEC-/- and APOBEC+/+ mice were crossed onto the
C57BL/6 background and thus wild type mice encode the APOBEC3

C57BL/6

allele. For genetic

consistency, experiments used the two matched strains; however, wild type animals are referred
to as C57BL/6 in the text to reflect their APOBEC3 allele. Mice were housed according to the
policies of the Institutional Animal Care and Use Committee of the University of Pennsylvania.
Heterozygous F1 mice were created by crossing APOBEC-/- males with MMTV(RIII)-infected
C57BL/6 or BALB/c females. The MMTV-infected female F1 mice were then bred and virus was
isolated from milk collected from their 1-3 day old pups, as described above.

Chapter 2.3.3 In vitro deamination
FAM-labelled 50mer oligonucleotide substrates with a TTC target site were incubated
with serial (ten-fold) dilutions of tumor-derived virions. Virus was first lysed in buffer containing 10
ug/ml RNase A, 50 mM Tris pH 8.0, 40 mM KCl, 50 mM NaCl, 5 mM EDTA and 0.1% TritonX100. Virus was then incubated with 1x UDG Buffer (NEB), 2.5 u UDG (NEB), 5 mM EDTA, and
100 nM substrate at 30°C for 4 hours. Samples were heated to 95°C for 20 minutes before

	
  

45	
  
addition of formamide load buffer and 0.1 M NaOH to cleave abasic sites. Separation of products
on a 20% acrylamide/TBE/Urea gel was imaged via direct fluorescence on a Typhoon 9410
Molecular Imager. Control deamination reactions were carried out with purified mouse APOBEC1
or APOBEC3, received from Rahul Kohli. These proteins are produced in and purified from
BL21(DE3)-Star E. coli (Novagen), from pET41 vectors encoding the APOBEC3

BALB/C

gene

downstream of an N-terminal maltose-binding protein (Nabel, 2012).
For targeting preference experiments, 60mer oligonucleotide substrates were labeled
with ddUTP-FAM at their 3’ end using Terminal dNTP Tranferase (NEB). Ten units of terminal
transferase is combined with 0.5 mM ddUTP-FAM, 200 ng of substrate DNA, and 1.25 mM
CoCl2, and incubated for 30 minutes at 37°C. The reaction is stopped by heating to 70°C for 10
minutes, and labeled substrate was purified using the QIAquick Nucleotide Removal Kit (QIAGEN
Corp.). Substrate sequences are shown in Table 2.1. Determination of targeting preferences
was then carried out by a two-step calculation (Kohli, 2009). Percent product formation was
calculated for each sample, and values averaged for all sequences that contain the same
nucleotide at either the -1 or -2 position. Then, the percent deamination of each nucleotide at the
-1 or -2 position was calculated compared to the other nucleotide variants, for example for A at
the -2, (ATC/(AmCC + AAC + AGC)) x 100 (Kohli, 2009).
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Table 2.1 Oligomer substrate sequences for in vitro deamination assay.
Target substrates used for cytidine deamination targeting assay (1-17) (Fig. 2.2) contained 60
nucleotides and differed solely in the two nucleotides directly upstream of the single cytosine.
Fluorescent ddUTP was added after synthesis. Substrates used for initial in vitro deamination
assay (Fig. 2.2) contained 50 nucleotides and were fluorescently labeled upon synthesis. F:
Enzo Life Sciences ddUTP-FAM

Target

Sequence

Template

GTGGTGTGGT TTGATGGTAT
TTGTTTTATTF	
  
GTGGTGTGGT TTGATGGTAT
TTGTTTTATTF	
  
GTGGTGTGGT TTGATGGTAT
ATTGTTTTATTF	
  
GTGGTGTGGT TTGATGGTAT
TTGTTTTATTF
GTGGTGTGGT TTGATGGTAT
TTGTTTTATTF	
  
GTGGTGTGGT TTGATGGTAT
ATTGTTTTATTF	
  
GTGGTGTGGT TTGATGGTAT
AATTGTTTTATTF	
  
GTGGTGTGGT TTGATGGTAT
ATTGTTTTATTF	
  
GTGGTGTGGT TTGATGGTAT
ATTGTTTTATTF	
  
GTGGTGTGGT TTGATGGTAT
TTGTTTTATTF	
  
GTGGTGTGGT TTGATGGTAT
ATTGTTTTATTF	
  
GTGGTGTGGT TTGATGGTAT
TTGTTTTATTF	
  
GTGGTGTGGT TTGATGGTAT
TTGTTTTATTF	
  
GTGGTGTGGT TTGATGGTAT
TTGTTTTATTF
GTGGTGTGGT TTGATGGTAT
ATTGTTTTATTF
GTGGTGTGGT TTGATGGTAT
TTGTTTTATTF
GTGGTGTGGT TTGATGGTAT
TTGTTTTATTF
GTGGTGTGGT TTGATGGTAT
TTGTTTTATTF
ATTATTATTA TTTTCATTTA
GGTGTGGTT/36-FAM/
ATTATTATTA TTTTUATTTA
GGTGTGGTT/36-FAM/

AAC
AmCC
AGC
ATC
mCAC
mCmCC
mCGC
mCTC
GAC
GmCC
GGC
GTC
TAC
TmCC
TGC
TTC
TTU
S50TTC
S50TTU

GXXCTTGGTG TGGTTGATAG TTGTGATGAA
GAACTTGGTG TGGTTGATAG TTGTGATGAA
GAmCCTTGGT GTGGTTGATA GTTGTGATGA
GAGCTTGGTG TGGTTGATAG TTGTGATGAA
GATCTTGGTG TGGTTGATAG TTGTGATGAA
GmCACTTGGT GTGGTTGATA GTTGTGATGA
GmCmCCTTGG TGTGGTTGAT AGTTGTGATG
GmCGCTTGGT GTGGTTGATA GTTGTGATGA
GmCTCTTGGT GTGGTTGATA GTTGTGATGA
GGACTTGGTG TGGTTGATAG TTGTGATGAA
GGmCCTTGGT GTGGTTGATA GTTGTGATGA
GGGCTTGGTG TGGTTGATAG TTGTGATGAA
GGTCTTGGTG TGGTTGATAG TTGTGATGAA
GTACTTGGTG TGGTTGATAG TTGTGATGAA
GTmCCTTGGT GTGGTTGATA GTTGTGATGA
GTGCTTGGTG TGGTTGATAG TTGTGATGAA
GTTCTTGGTG TGGTTGATAG TTGTGATGAA
GTTUTTGGTG TGGTTGATAG TTGTGATGAA
TTTATTTATT TATGGTGTTT
TTTATTTATT TATGGTGTTT
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Chapter 2.3.4: In vitro reverse transcription
Virions isolated as described above were normalized to equal RNA levels, and incubated
with PBS, 2.5 mM MgCl2, 0.01% NP-40 and 1 mM dNTPs at 37°C.

Reverse transcription

products were taken from the reaction in aliquots at the specified time points, added to equal
volumes of PBS with 40 ug/mL salmon sperm DNA (Stratagene) and frozen at -80°C (Bishop,
2008). Control reactions were incubated without dNTPs and in the presence of 2.5 mM EDTA.
DNA was isolated from the samples using the DNeasy Blood & Tissue Kit (QIAGEN Corp.).
Intracellular reverse transcription products were produced by infecting 293T-mTrf1 cells
with tumor-derived virions in the presence of 8 ug/ml polybrene. At the designated time points,
media and virus were removed, cells were washed with PBS and cells were removed from the
plate.

Total DNA was purified using the DNeasy Blood & Tissue Kit (QIAGEN Corp.).

To

measure the effect of intracellular APOBEC3, the same protocol was followed using the 293TmTrf1 cells stably transfected with APOBEC3
expression vectors.

C57BL/6

, APOBEC3

BALB/c

or mutant (E73Q/E253Q)

Viral DNA was then quantified (see Chapter 2.3.5) or assessed for

mutagenesis (see Chapter 2.3.6).

Chapter 2.3.5: Polymerase Chain Reaction
PCR reactions to amplify edited reverse transcription products were performed using a
gradient cycler. Equal volumes of viral DNA were added to GoTaq DNA Polymerase (Promega),
and either a 200 bp region of env or a 400 bp region of the 3’ LTR was amplified with following
primers. Env_Forward: 5’-GCCTCGAGCTAAGTAACACAG-3’, Env_Reverse:

5’-

TCAGGGGCCAATACAAAACTGGT-3’, LTR_Forward: 5’-CGTGAAAGACTCGCCAGAGCTA-3’,
LTR_Reverse: 5’-GAAGATCTTCAAGGGCAATGCCTTAA-3’. A temperature gradient of 81-95°C
was applied during an initial 5 min denaturing step, as well as the 1 min denaturing step of each
subsequent cycle (35 total), followed by 1 min at 55°C and 1 min at 72°C. DNA was purified from
a 1% agarose gel using QIAGEN QiaQuick Gel Extraction Kit (QIAGEN Corp.).
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Quantitative PCR for strong stop DNA was performed in triplicate, using primers
StrongStop_Forward:

5’-CGTGTGTTTGTGTCTGTTCG-3’

GACCCTCTGGAAAGTGAAAGTCAAGG-3’.

and

StrongStop_Reverse:

5’-

These primers amplify 90bp product from the

MMTV RIII U5 region. Equal volumes of viral DNA was combined with Power SYBR Green PCR
Master mix and amplified under standard conditions on an ABI Prism Model 7900HT.

Chapter 2.3.6: Sequencing and Statistical Analysis
Following PCR and DNA isolation, the env and LTR fragments were cloned into pCR2.1TOPO vector, as directed (Invitrogen, Inc.). The cloning product was used to transform OneShot
TOP10 chemically competent E. coli (Invitrogen, Inc.), and bacteria plated on LB plates
containing 100 ug/mL ampicillin for selection. Individual colonies were picked and grown in LB +
ampicillin culture shaking overnight at 37°C. Plasmid DNA was isolated from cultured bacteria
using QIAprep Spin MiniPrep Kit (QIAGEN Corp.).

The MMTV fragment within the isolated

plasmids were then sequenced using a BigDye Terminator v3.1 Cycle Sequencing Kit from
Applied Biosystems. Sequences were aligned using the ClustalW program, and G to A mutations
were annotated by Hypermut (www.hiv.lanl.gov/content/sequence/HYPERMUT/hypermut.html).
Statistical analysis was performed using the GraphPad/PRIZM software.

Chapter 2.4: Results
Chapter 2.4.1: Both murine APOBEC3 variants are packaged into virion cores
We first considered the possibility that APOBEC3 allelic variants could differ in the levels
of protein incorporated into virus particles or in their localization within virions. Most APOBEC3
proteins are incorporated into virus particles during virion assembly in infected producer cells.
Indeed, APOBEC3G binds to the HIV NC (Zheng, 2004) and mouse APOBEC3 to the MMTV NC
(Okeoma, 2007), as well as viral RNA, suggesting that upon viral maturation, the restriction factor
is concentrated within the viral core. However, APOBEC3A is packaged into virions, yet remains
outside the viral core, preventing it from restricting HIV infection (Aguiar, 2008). If APOBEC3 was
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excluded from the MMTV cores, this could result in an inability to access the reverse transcription
complex and cause cytidine deamination. Moreover, the changes in protein sequence could
differentially alter packaging of the full-length APOBEC3

BALB

, thereby diminishing its ability to

restrict infection.
To test this, we isolated virions from the mammary glands of MMTV-infected C57BL/6,
APOBEC3 knockout (APOBEC3-/-), and BALB/c mice. We used reverse transcribed real-time
quantitative PCR primers specific to viral RNA to normalize virion levels in the three different
virion preparations. In addition, Western blot analysis for both MMTV and APOBEC3 proteins
were performed to confirm equal protein loading, and to determine the relative level of packaged
APOBEC3. APOBEC3 was detected in virions isolated from C57BL/6 and BALB/c but not the
APOBEC3-/- mice (Figure 2.1). The presence or absence of the fifth exon was visible by a 4 kDa
size difference. BALB/c-produced virions packaged primarily the full-length version of the protein,
but also packaged a small quantity of the shorter version.

C57BL/6-isolated virions solely

packaged the isotype lacking exon 5 and contained a significantly higher level of packaged
protein as compared to BALB/c virions. The level of virion-packaged protein reflected the
intracellular levels of APOBEC3 mRNA in C57BL/6 and BALB/c mouse tissues, as previously
described (Okeoma, 2010).
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A.

B.

Figure 2.1 APOBEC3 is packaged within MMTV viral cores in vivo. (A) Virions were isolated
from the mammary tissue of MMTV-infected C57BL/6, BALB, and APOBEC3-/- mice. Virus
levels were normalized to viral RNA via RT-qPCR and equal amounts subjected to Western blot
analysis using rabbit anti-mouse APOBEC3 antisera. The immunoblot was stripped and
reprobed with goat anti-Env (gp52) antisera. C57BL/6 mice solely express and package a shorter
form of the protein lacking a fifth exon. BALB mice express predominantly a protein including all
exons (4 kD larger), but also express a small amount of protein lacking this exon. The antiAPOBEC3 antisera also detects a cross-reacting protein (non-specific, NS) of approximately
50kD that is present in some but not all virion preparations, as previously reported (Okeoma,
2010). (B) Core fractions and whole virus were assessed for APOBEC3 as described above, and
the immunoblot was serially stripped and reprobed for MMTV Env and p27 as controls for
removal of envelope and retention of viral cores. The p27 blot was exposed for five seconds and
one minute to visualize protein in both cores and whole virus.
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We next isolated viral cores by centrifugation of purified virus through 10% sucrose
containing 5% Triton-X over 30% sucrose cushions. The detergent treatment removes the viral
envelope and contaminating cellular membrane compartments, including exosomes, and allows
viral cores to pellet.
APOBEC3

C57BL/6

Purified viral cores were then used for Western blotting. Both the

and APOBEC3

substantially more APOBEC3

BALB

C57BL/6

were incorporated within viral cores. Importantly, there was

than APOBEC3

overall higher levels of APOBEC3

C57BL/6

BALB

in cores (Figure 2.1), suggesting that the

in virions are not associated with mislocalized

APOBEC3.
Chapter 2.4.2: Allelic differences in substrate specificity
A second possible explanation for the lack of cytidine deamination was that the
APOBEC3 packaged into MMTV virions is rendered enzymatically inactive, perhaps by a viral
protein. To determine if MMTV-packaged APOBEC3 retains its deaminase activity, we isolated
virions from the mammary glands of MMTV-infected C57BL/6, APOBEC3 knockout, and BALB/c
mice and examined the purified viral lysates for in vitro deaminase activity against a fluorescently
tagged oligonucleotide substrate bearing the reported mouse APOBEC3 consensus target
sequence (5’TTC3’) (Langlois, 2009). Although C57BL/6-isolated virions packaged substantially
more APOBEC3 than BALB/c virions (Figure 2.1), the protein packaged in BALB/c virions had
equivalent activity to that packaged in BL/6 virions (Figure 2.2). Densitometry analysis measuring
packaged APOBEC3 protein (Figure 2.1) and deamination on this substrate (Figure 2.2) revealed
a 1.9 fold increase in activity of APOBEC3

BALB/c

compared to APOBEC3

C57BL/6

when normalized to

protein content. In contrast, very little deamination activity was detected in particles isolated from
knockout mice: the small amount of deamination (<5% of virions containing APOBEC3
APOBEC3

BALB/c

C57BL/6

or

) may be attributed to cellular contamination with other known mouse cytidine

deaminases such as APOBEC1 (Petit, 2009). The deaminase activity required RNaseA
treatment, demonstrating that like human APOBEC3G, mouse APOBEC3 is not enzymatically
active when bound to RNA within the virion (Figure 2.2). These data suggested that both
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APOBEC3

C57BL/6

and APOBEC3

BALB/c

are functional deaminases that retain enzymatic activity in

virions.
A.

B.

Figure 2.2 In vivo packaged APOBEC3 variants are enzymatically active and target
different substrates. (A) Ten-fold increasing concentrations of virions isolated from C57BL/6,
BALB, and APOBEC3-/- mice were lysed with 0.1% Triton-X in the presence or absence of
RNase A and incubated with a 50mer single-stranded oligonucleotide (S50) containing a single
cytosine and uracil DNA glycosylase, followed by cleavage with NaOH (see substrate sequences,
Table 2.1). An oligonucleotide containing a uracil confirmed complete cleavage of uracilated
products and acted as a size standard (uncleaved substrate at S50, cleavage product at S35).
C57BL/6 virions were also lysed in the absence of RNaseA and subjected to otherwise identical
conditions. (B) Representation of the two murine APOBEC3 variants. *= active site residue,
vertical lines= location of amino acid differences, green= differences within substrate recognition
BALB
loop, dotted line= deletion of exon 5. Numbering is relative to APOBEC3
variant. (C) Virions
isolated from C57BL/6 and BALB mice were incubated with 16 different substrates containing a
single cytosine with variations of nucleotides in the -1 and -2 position to include each possible
combination of A, G, T, or mC. Product to substrate ratios were calculated for 3 to 4 replicate
experiments. Blue= A, Red= mC, Green = G, Purple= T. T-tests were used to verify significant
BALB
differences between the APOBEC variants preference for G (higher preference by APOBEC3
,
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C57BL/6

p<0.05) and T (higher preference by APOBEC3
, p=0.05) at the -2 position and T at the -1
BALB
position (higher preference by APOBEC3
, p<0.05).
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Different cellular cytidine deaminases can be distinguished from one another by their
preferred editing contexts, based on the nucleotides surrounding the targeted cytosine. This
preference has been mapped to a recognition loop of 9-11 amino acids that interacts with
nucleotides upstream of the target site (Kohli, 2009). The two APOBEC3 isoforms differ in the
presence of exon 5 and in addition have several amino acid differences in their other exons
(Figure 2.2), including three polymorphisms in the putative substrate recognition loop which could
influence the editing context. We thus examined if the nucleotide context of cytidine deaminase
activity differed between each isoform. The in vitro deaminase assay was carried out with
fluorescently labeled substrates bearing each of the sixteen possible 5’-XXC-3’ combinations. To
make the assay specific for deamination at the target cytosine, 5-methylcytosine (mC) was used
in place of cytosine at the two upstream positions (Nabel, 2012). The assay was performed with
APOBEC3 isolated from virions as described above, and substrate to product ratios measured
(Figure 2.2).

While APOBEC3

C57BL/6

canonical TTC substrate, APOBEC3

exhibited a higher selectivity at the -2 position for the

BALB/c

had stronger preferences at the -1 position, with ATC

as a favored substrate. These results imply a difference in activity that is likely due to a change in
substrate recognition based on the allelic amino acid differences, not simply based on different
levels of packaged protein.

Chapter 2.4.3: APOBEC3 deamination of natural MMTV transcripts is low
Although the results of the preceding sections demonstrate that APOBEC3 packaged into
MMTV virions retained functional deaminase activity, we previously showed that integrated
MMTV proviruses found in wild type mice showed no mutagenic hallmarks of cytidine
deamination compared to knockout mice (Okeoma, 2007). However, uracil-containing reversetranscribed DNA could be degraded in cells prior to integration into the host genome or prevented
from integration (Russell, 2009), which would account for the absence of G to A mutations in
integrated MMTV proviruses. We thus next tested whether ex vivo reverse-transcribed MMTV
DNA made from viruses containing packaged APOBEC3 underwent cytidine deamination.
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Purified virions from wild type, knockout and BALB/c mice were used in endogenous reverse
transcription assays (EnRT) and DNA produced by these particles was subjected to differential
DNA deamination 3DPCR using primers to two different regions of MMTV (3’ long terminal repeat
(LTR) and envelope (env) (Figure 2.3). PCR was performed using a gradient range of denaturing
temperatures from 81-95°C. Amplification of products from all three types of virions was similar
at melting temperatures from 85-95°C (3’LTR amplification shown in Figure 2.3). When the PCR
was carried out at higher stringency (≤ 83°C melting temperature for 3’ LTR, ≤ 85°C for env),
reverse transcribed DNA from either BALB/c or BL/6 virions was more highly amplified than that
from APOBEC3-/- virions, indicating a higher AT content in reverse transcribed DNA produced in
the presence of either allele of APOBEC3.
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A.

B.

C.

D.

	
  

57	
  
FIG. 2.3. Packaged APOBEC3 edits MMTV reverse transcription products. (A) 3DPCR
amplification of MMTV viral DNA isolated from EnRT reactions using virions from C57BL/6,
BALB, and APOBEC3-/- mice. A ~200 bp region from the 3’LTR was amplified using an
increasing denaturing temperate gradient (Td) from 81° to 95°. Densitometry was performed, and
density of each band normalized to 95° (labeled as 100%). (B) 3DPCR amplification of MMTV
viral DNA isolated 6 hours after infection of 293T-mTfR1 cells with virions isolated from C57BL/6,
BALB, and APOBEC-/- mice. A 480 bp region of env was amplified using an increasing
denaturing gradient from 83° to 95°. (C) 3’ LTR DNA isolated from low and high denaturation
temperature PCR reactions shown in (A) were cloned and sequenced. These sequences were
aligned and G to A mutations were annotated using HyperMut as compared to a reference MMTV
RIII NCBI GenBank sequence (AF136898). A representative portion of these sequences is
displayed. (D) All G to A mutations found in clonal sequences isolated from 3’LTR sequences (A)
and env sequences (B) were analyzed for sequence context at the -1 and -2 nucleotide positions
for the minus strand targeted cytosine.
To confirm these results in infection, we performed a similar experiment in 293T-mTfR1
cells (293T cells expressing the MMTV entry receptor transferrin receptor 1). The cells were
infected with viruses isolated from the three strains of mice, and total cellular and viral DNA was
isolated 6 hours after infection, at which time pre-integration reverse transcription products will
predominate. This DNA was then amplified using 3DPCR.

Similar to the in vitro reverse

transcribed DNA, MMTV reverse transcription products produced in the presence of either
APOBEC3

BALB/c

or APOBEC3

C57BL/6

was amplified using highly stringent (low denaturation

temperature) conditions, whereas APOBEC3-/- reverse transcribed DNA was not amplified under
these conditions (env amplification shown in Figure 2.3).
The PCR products generated in both cell-free and tissue culture infection conditions were
cloned and sequenced. When the PCR was carried out at high stringency (95°C melting
temperature), there were few G to A mutations in any of the viruses and there was no statistical
difference in the rate of G to A mutations found in reverse transcription products of viral particles
or in infected cells with or without packaged APOBEC3 (Table 2.2, p=0.17). However, low levels
of cytidine deamination were detected in the APOBEC3

C57BL/6

and APOBEC3

BALB/c

reverse

transcribed DNA produced in both the in vitro EnRT and the tissue culture infection, when
amplified at low stringency (Figure 2.3; Table 2.2). This rate of deamination was statistically
higher than that seen in products amplified at 95°C (p<0.05). Even in the less stringent
conditions, which should enhance detection of G to A transversions, the overall rate of G to A
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mutation (0.47% for APOBEC3

C57BL/6

, 0.41% for APOBEC3

BALB/c

) was significantly lower than that

seen in viruses known to be disabled by APOBEC3 editing, such as HIV, which averages 7-8% G
to A mutations in vivo (Armitage, 2012). There was no difference in the frequency of mutations
seen in reverse transcription products isolated from APOBEC3

BALB/c

- or APOBEC3

C57BL/6

-

containing particles (p=0.67). This further supports our hypothesis that hypermutation is not a
significant source of viral restriction, as the more restrictive APOBEC3

C57BL/6

variant did not show

higher rates of mutagenesis. Some G to A mutations were detected from DNA isolated from
reactions using APOBEC3-/- viral particles at both low and high stringency PCR, but the very low
number can be attributed to RT error (not statistically different from no G to A mutations; p=0.42).

Table 2.2 Mutation analysis of MMTV reverse transcription products. Sequences cloned
from 3DPCR amplification products in (Figure 2.3) were aligned to their respective reference
sequence. G to A versus all other mutations were recorded. Sequences from C57BL6-isolated
viral DNA isolated using a low denaturing temperature contained significantly more mutations
than APOBEC3-/- isolated DNA (p<0.05), but not significantly more mutations than BALB-isolated
viral DNA (p=0.67). Deamination levels in viral DNA isolated from all three genotypes using a
regular denaturing temperature were not statistically significantly different from one another.
Virus/Temperature
(°C)

G to A

C57BL/6 95°

28

C57BL/6 81-83°

73

BALB/c 95°C

2

BALB/c 81-83°

52

APOBEC3-/- 95°

2

APOBEC3-/- 81-83°

7

Other

# of
Clones

Total (bp)

G to A
Frequency

20

50

13236

0.21

24

44

15652

0.47

2

18

4050

0.05

15

34

12690

0.41

7

17

4726

0.04

30

9720

0.07

9

When the target nucleotide context was analyzed, a majority, but not all mutations were
found in the mouse APOBEC3-preferred TXC context (92% for APOBEC3
APOBEC3

BALB/c

C57BL/6

and 67% for

) (Figure 2.3). As seen in the in vitro targeting assay APOBEC3

BALB/c

had a

stronger preference for ATC, with 24% of all mutations falling within this context, compared to 2%
for APOBEC3

C57BL/6

. APOBEC3

C57BL/6

maintained a stronger preference that APOBEC3

BALB/c

for
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T at the -2 position, further supporting our in vitro data (Figure 2.2). Within the env and LTR
fragments sequenced, 22.9% of all cytosines were found in the preferred TXC context (2.6%
TGC, 3.9% TAC, 9.2% TTC, 7.2% TCC). The most highly favored TTC (APOBEC3
ATC (APOBEC3

BALB/c

C57BL/6

) and

) target sequences were present 14 and 15 times, respectively, in these

genomic regions (of 152 total cytosines); thus, the low levels of deamination are not due to a lack
of preferred substrate.

Chapter 2.4.4: APOBEC3 inhibits MMTV reverse transcription
These results suggested that while APOBEC3 packaged into MMTV virions retains its
deaminase activity, this is unlikely to be the major mode of restriction since it occurs only at low
levels. To determine if APOBEC3 restricts virus infection by other means, we next tested if the
mouse protein restricted MMTV at an early step of reverse transcription. We utilized the DNA
produced by EnRT reactions with virions isolated from C57BL/6, APOBEC3-/- and BALB/c mice,
and performed RT-qPCR using primers specific to MMTV strong-stop DNA. We found that
synthesis of this early reverse transcription product was strongly inhibited when the reaction was
carried out with APOBEC3
APOBEC3

BALB

C57BL/6

-containing virions in comparison to APOBEC3-/- virions, while

virions showed an intermediate phenotype (Figure 2.4).
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A.

B.

FIG. 2.4. Packaged APOBEC3 restricts MMTV reverse transcription. (A) Equivalent amounts
of MMTV virions isolated from C57BL/6, BALB, and APOBEC3-/- mice were subjected to EnRT
reactions. DNA was harvested at the indicated time points and strong stop DNA was quantified
via qRT-PCR. Shown is the average of three independent experiments. (B) 293T-mTfR1 target
cells were infected with MMTV virions isolated from C57BL6, BALB, and APOBEC3-/- mice.
Total DNA was isolated from cells at the indicated times after infection, and strong stop DNA was
quantified relative to the housekeeping gene GAPDH using qRT-PCR. Triplicates were
performed for each time point and averaged; shown is a representative from three independent
experiments.
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To determine if reverse transcription was also inhibited during virus infection, the virions
were used to infect 293T-mTfR1 cells. DNA was isolated at various time points after infection and
subjected to RT-qPCR. Similar to what was seen in the in vitro EnRT reactions, strong-stop DNA
synthesis was greatly reduced in cells infected with APOBEC3-containing virions compared to
cells infected with knockout virions, particularly at later time points. Infection with APOBEC3

BALB/c

virions again showed an intermediate phenotype, suggesting that these virions are restricted
compared to those produced in the absence of APOBEC3 but to a lesser extent than those
produced in C57BL/6 mice (Figure 2.4). These data suggest that inhibition of early reverse
transcription is the major means by which virion-packaged APOBEC3 inhibits MMTV infection.

Chapter 2.4.5: Restriction of reverse transcription is correlated to level of packaged APOBEC3
The differential ability of APOBEC3

C57BL/6

and APOBEC3

BALB

to restrict MMTV infection

could be due to the level of packaging or to the differences in the proteins. We used a genetic
approach to determine if the level of restriction was affected by the level of packaged APOBEC3.
We crossed MMTV-infected APOBEC3-/- females and C57BL/6 or BALB/c males, and generated
F1 heterozygotes; these heterozygotes acquired the virus from their infected mothers (Figure
2.5). Virus was then isolated from the milk of the heterozygotes at their first pregnancy. Virions
derived from both APOBEC3

C57BL/6

/- and APOBEC3

BALB/c

/- F1 mice packaged an intermediate

amount of APOBEC3 compared to virions isolated from the parental homozygous strains of mice
(Figure 2.5).

	
  

62	
  
A.

B.

C.

FIG. 2.5. Restriction of reverse transcription correlates with the amount of packaged
APOBEC3. (A) MMTV-infected heterozygous F1 mice were obtained by mating APOBEC3-/male mice to MMTV-infected wild-type C57BL/6 or BALB females. The female F1 mice were
bred and MMTV was isolated from milk as described in Materials and Methods. (B) Virions
obtained from homozygous, heterozygous, and APOBEC3-/- milk were subjected to Western
blotting after normalization by RT-qPCR. Immunoblots were serially probed with rabbit antimouse APOBEC3 antisera and goat anti-gp52 antisera as a loading control. (C) Virions isolated
from milk of the indicated mouse genotypes were used in endogenous reverse transcription
reactions. Strong stop DNA was quantified from total viral DNA harvested at the indicated time
points. Three independent reactions were averaged.
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Virions isolated from both heterozygous crosses were then used in EnRT assays, and the
level of strong-stop DNA was compared to that produced by virus isolated from homozygous
C57BL/6, BALB, and APOBEC3-/- mice; the level of virus in each reaction was normalized by
RNA and viral protein levels.

Virions isolated from homozygous C57BL/6 mice showed the

strongest effects of APOBEC3, reflected by low levels of viral transcripts, and homozygous
APOBEC3-/- virions produced the highest level of strong-stop DNA (Figure 2.5). Virions from
heterozygous animals produced an intermediate level of strong stop DNA between that seen with
virus isolated from the parental strain and knockout animals (Figure 2.5). In addition, the amount
of strong-stop DNA produced by the APOBEC3
APOBEC3

C57BL/6

BALB

/- virions was higher than that seen with the

/- virions and was not statistically different than that seen with virions from

APOBEC3-/- mice (Figure 2.5). This suggests that while alteration in the protein sequences in
APOBEC3

C57BL/6

and APOBEC3

BALB

affect the substrate specificity, the differential restriction by

these proteins is largely due to the level of packaged protein.

Chapter 2.4.6: Target cell expression of either APOBEC3 allele leads to virus restriction
Virion-packaging of APOBEC3 is thought to be critical for viral restriction. However,
intracellular cytoplasmic APOBEC3 is also believed to restrict incoming HIV virions (Gillick, 2013,
Vetter, 2009; Berger, 2011; Koning, 2011). We also previously showed that cells transfected with
APOBEC3 can restrict incoming MMTV viral particles and that APOBEC3 expression in target
dendritic cells limits infection in vivo (Okeoma, 2009). To determine the intracellular effect of both
natural variants of APOBEC3 on incoming in vivo produced virions, 293T-mTfR1 cells were stably
transfected with Flag epitope-tagged BL/6 or BALB/c variants of APOBEC3 (Rulli, 2008). Western
blot analysis using anti-Flag and anti-APOBEC3 antibodies demonstrated that the two variants
were expressed at similar levels in each cell line (Figure 2.6).
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A.

B.

FIG. 2.6. Target cell APOBEC3 can restrict reverse transcription of incoming virions and is
independent of cytidine deamination. (A) 293T-TfR1 cells were stably transfected with
BL6
BALB
mutant
plasmids encoding APOBEC3 , APOBEC3
, APOBEC3
, or an empty vector (no
APOBEC3). Top panel: protein extracts were assessed for APOBEC3 content using their
BL6
BALB
respective epitope tags (anti-FLAG for APOBEC3
and APOBEC3
; anti-HA for
mutant
APOBEC3
). Blots were stripped and reprobed for β-actin as a loading control. Bottom
panel: cell lysates were also probed using anti-APOBEC3 antisera. A cross-reactive protein (NS)
seen in all lysates is indicated. (B) Stably transfected cells were infected with MMTV isolated from
APOBEC3-/- mice. Total cellular DNA was harvested at indicated time points after infection, and
strong stop DNA was quantified in relation to GAPDH. Data representative of three independent
experiments.
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Virions produced from APOBEC-/- mice were used to infect each of the cell lines, total
cellular DNA was collected at various time points after infection and early reverse transcription
products were measured by quantitative PCR. Cells expressing either variant were similarly able
to restrict early reverse transcription, with approximately five to ten fold less DNA produced in
comparison to cells lacking APOBEC3 (Figure 2.6). The intermediate phenotype typical of virions
packaging APOBEC3

BALB

expressing APOBEC3

C57BL/6

was attenuated in cells expressing this variant compared to cells
, suggesting that the two natural variants may share similar restriction

capacity when expressed at similar levels.
To further test the importance of cytidine deamination in restriction of MMTV, we
performed a similar experiment using cells stably transfected with an HA-tagged APOBEC3

C57BL/6

cytidine deaminase mutant (E73Q/E253Q) (Figure 2.6). Cells expressing this variant were able
to restrict reverse transcription of incoming MMTV equally well as the WT APOBEC3

C57BL/6

(Figure 2.6). Restriction of reverse transcription is thereby independent of cytidine deamination,
and these data further support this mechanism as the main method of APOBEC3 mediated
MMTV restriction in mice.

Chapter 2.5: Discussion
It is now well-established that mouse APOBEC3 limits the pathogenesis of a number of
murine retroviruses in vivo, including F-MLV, M-MLV and MMTV (Okeoma, 2007; Takeda, 2008;
Low, 2009; Santiago, 2008). Indeed, these studies, which compared infection and pathogenesis
in wild type and APOBEC3 knockout mice, provided the ultimate proof that APOBEC3 proteins
functioned as in vivo restriction factors. APOBEC3 restriction of murine viruses in vivo has also
provided a model for understanding the natural selection of host restriction factors, as the two
natural allelic variants of murine APOBEC3 show differential restriction against a number of
viruses which also affects their pathogenicity in different inbred mouse strains (Takeda, 2008;
Okeoma, 2009; Santiago, 2008).
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However, the mechanism of APOBEC3-mediated restriction in vivo has been less well
defined. The ability to deaminate cytidines within newly transcribed viral DNA certainly contributes
to the effect of APOBEC3 against viruses such as HIV, creating an array of G to A mutations that
can lead to missense and nonsense mutations thereby preventing productive infection. Moreover,
HIV DNA isolated from patients bears characteristic signatures of APOBEC3-mediated
deamination (Janini, 2001; Kieffer, 2005; Pace, 2006). In contrast, while in vitro transduced
mouse APOBEC3 generates a high rate of G to A mutations on HIV in the presence or absence
of Vif, in vivo, neither M-MLV nor MMTV show evidence of APOBEC3 mediated mutations,
although viral restriction still occurs (Okeoma, 2007; Takeda, 2008).
Here, we show that murine APOBEC3 packaged within MMTV virions is enzymatically
active and is able to catalyze cytidine deamination. Moreover, although there is abundant
evidence that APOBEC3

BALB

is less restrictive than APOBEC3

C57BL/6

in vivo, this is not due to

diminished catalytic activity. We show that both allelic forms of the protein, produced and
packaged in vivo, were capable of catalyzing this potentially antiviral reaction. In fact,
APOBEC3

BALB

showed an increase in activity on the 5’TTC3’ substrate when normalized to

protein input. However, when tested against a full array of deaminase substrates, APOBEC3
did not show an increase in activity on all substrates.

BALB

Notably, while both variants showed

relatively promiscuous targeting when compared to APOBEC3G, the two alleles showed different
patterns of preferred target sequences (Beale, 2004). Until this study, the mouse APOBEC3
preferred editing site was not well defined, as previous efforts have been inconsistent in
APOBEC3 plasmid, allelic variant, and target substrate (Bishop, 2004; Langlois, 2009; Renard,
2010).
A difference in targeting between the allelic variants could be attributable to the presence
of several polymorphisms localized to the substrate recognition loop that we have previously
identified in the APOBEC enzyme family (Kohli, 2009). However, as with HIV where altering the
targeting preference of APOBEC3G did not impact retroviral restriction, we did not find evidence
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that the altered sequence preference contributed to differences in MMTV restriction in our efforts
to sequence reverse transcript products (Kohli, 2010).
Indeed, while native APOBEC3 is able to catalyze cytidine deamination, further
investigation of early reverse transcription products showed very low levels of G to A mutation,
similar to what has been seen in integrated proviruses in vivo (Okeoma, 2007). Utilization of
3DPCR, a technique that maximizes detection and amplification of DNA with increased A/T
content, allowed us to uncover reverse transcription products with slightly more G to A mutations.
However, even under these highly selective conditions, rates of mutation remained a fraction of
that seen in HIV, which can vary from 7 to 8% total G to A mutations in vivo (Armitage, 2012;
Gandhi, 2008; Land, 2008).
Others have suggested that murine viruses may be able to block APOBEC3 deaminase
activity.

Browne and Littman showed that F-MLV was restricted by both forms of murine

APOBEC3 in vitro, but had only 1 G to A mutation per kb of genome. In comparison, both
APOBEC3 alleles were also able to restrict HIV, but produced 16 G to A mutations per kb of HIV
genome (Browne, 2008). However, Petit et al. utilized 3DPCR to uncover a significantly higher
rate of G to A mutations from F-MLV both in vitro and in vivo (Petit, 2009). Our MMTV data
closely matches the F-MLV data from these two groups, suggesting similarities between the two
murine viruses. Both show G to A mutation at a very low level, and may share a mechanism to
block APOBEC3-induced deamination. Our data also showed that reverse transcription
amplicons recovered from virions isolated from BALB/c or C57BL/6 mice had similar levels of
editing. The large majority of the G to A mutations was found in the preferred deamination site 5’GXA-3’, with preference for GG and GA dinucleotides within those parameters. Our analysis
further supports a difference in target sequence preference between the two APOBEC3 alleles,
as targeting patterns between APOBEC3

C57BL/6

and APOBEC3

BALB

mirrored what was seen in the

in vitro assay. However, if deamination were a critical component of restriction, we would expect
these two alleles to show different levels of editing, to mirror their different levels of overall
restriction.
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Since restriction of MMTV is clearly mediated by mouse APOBEC3, we also assessed
whether reverse transcription was inhibited in the presence of the enzyme. This block to reverse
transcription has been described in several systems, although primarily in viruses produced in
vitro (Bishop, 2006; Iwatani, 2007; Holmes, 2007; Bishop, 2008). However, other studies suggest
that this is an artifact of high levels of transfected protein and maintain that deamination is
necessary for restriction (Miyagi, 2007).

Our analysis of virions isolated in vivo allows an

understanding of the activity of native protein packaged at endogenous levels. Our results clearly
show that both alleles of APOBEC3 are able to prevent early reverse transcription when
packaged within virions. The alleles show distinct differences in their ability to restrict in this
manner, with packaged APOBEC3

BALB

showing less restriction than the APOBEC3

C57BL/6

counterpart. We have also shown that APOBEC3 expressed within target cells is able to restrict
reverse transcription of incoming MMTV virions that do not contain packaged APOBEC3. This
suggests a possible dual role for APOBEC3- both within the virion and within target cells. It also
provides evidence that the MMTV core and the RT complex is accessible to intracellular factors
during reverse transcription, supporting recent studies showing that uncoating and reverse
transcription are linked (Hulme, 2011; Roa, 2012). However, unlike with the in vivo packaged
APOBEC3, we did not see as distinct a difference between the two allelic variants, which is likely
due do the similar levels of expression within our transfected cells. An APOBEC3 mutant that is
unable to catalyze reverse transcription was also able to efficiently prevent reverse transcription,
confirming that this arm of restriction is truly independent of deamination. Taken together, our
data suggest that the mechanism by which APOBEC3 restricts infection by MMTV, namely
blocking reverse transcription, is the same when packaged or present in the target cell.
The two major APOBEC3 alleles differ in both sequence and level of expression in vivo
and it has been suggested that positive selection by murine retroviruses may have played a role
in their acquisition. While we showed that the two alleles show altered sequence substrate
specificity, our data support the idea that it is the levels of packaged APOBEC3 rather than
polymorphic amino acid differences in the APOBEC3

C57BL/6

and APOBEC3

BALB

alleles that affect
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the degree of reverse transcriptase inhibition. By creating heterozygous mice that express
intermediate levels of APOBEC3 we generated MMTV virions that package half the parental
levels of protein and showed that the amount of reverse transcription products seen correlated
with level of packaged protein. While several in vitro studies have suggested that coding
sequence differences between the two alleles contribute to the more restrictive phenotype of the
APOBEC3

C57BL/6

allele, in vivo studies using C57BL/6 X BALB/c crosses have led to conflicting

results (Takeda, 2008; Santiago, 2008; Li, 2012; Abudu, 2006; Santiago, 2010). Additionally,
several studies suggested that a single copy of the APOBEC3

C57BL/6

allele is sufficient to confer

full resistance to MLV infection in vivo, since there was no difference in F-MLV or AKV infection of
APOBEC3+/+ and APOBEC3+/- mice (Takeda, 2008; Langlois, 2009). These studies may be
confounded by multiple genes in the different genetic backgrounds that affect both infectivity and
immune response (e.g. levels of neutralizing antibodies) in whole animal studies. Moreover, these
studies examined late stages in infection, by which time restriction by the single copy of
APOBEC3 in APOBEC3+/- mice may be dominant after many rounds of infection. Indeed, our
studies with M-MLV indicated that at early times after infection, APOBEC+/- mice were
intermediate in infection levels between knockouts and wild type mice, but succumbed to disease
with the same kinetics as the knockouts (Low, 2009). Our studies here, which used virions to
infect the same target cells lacking APOBEC3 proteins (293T-mTfR1) in single round infections,
may more accurately reflect the direct effects of APOBEC3 on infection.
In sum, our data show that MMTV is susceptible to reverse transcriptase inhibition by
APOBEC3, and is sensitive to levels of protein expressed and packaged within virions. Future
work is required to determine the mechanism by which MMTV and other murine viruses avoid
APOBEC3 mediated G to A mutations, as well as the mechanism by which all APOBEC3 proteins
are able to prevent reverse transcription.

Chapter 3: The effect of APOBEC3 on antiretroviral drug resistance in vivo
Chapter 3.1: Abstract

	
  

71	
  
The high rate of retroviral reverse transcription errors can result in rapid viral evolution.
This is particularly important in pathogenic viruses, as mutations can lead to drug resistance or
immune system evasion. Mutations can also arise via cellular factors, including APOBEC3. This
antiviral family of proteins creates G-to-A mutations in retroviral DNA leading to replicationdefective viruses. However, at a low level, these mutations could lead to increased viral evolution
without affecting viral infectivity, potentially decreasing time to drug resistance. We have shown
that mouse APOBEC3 generates a very low level of G-to-A mutations in the murine retrovirus
MMTV. We assessed whether these mutations can lead to increased viral evolution in the
presence of a strong evolutionary pressure. Treatment of MMTV infected animals with the
antiretroviral AZT began early in infection. We tracked viral loads via PBMC infection levels in
APOBEC3+/+ and APOBEC3-/- mice with or without treatment over a course of ten weeks. On
average, virus in APOBEC3+/+ mice responded better at the beginning of treatment but these
mice showed a rise in viral load over time, while virus in APOBEC3-/- mice responded only
slightly, but maintained steady viral loads over time. These data suggest that APOBEC3 plays a
role in viral evolution in response to drug treatment.
Additional experiments, including in-depth sequencing analysis and functional assays to
confirm viral mutation and drug resistance, were not easily addressed with the MMTV-infected
wild type and knockout mice. We thus next assessed similar questions using human APOBEC3G
transgenic mice infected with M-MLV, with APOBEC3-/- mice used as controls. Animals were
treated with AZT, and both integrated viral DNA and plasma virus RNA were isolated and
measured at various time points over six weeks of infection. APOBEC3G-expressing mice had
an increased response to AZT compared to their APOBEC3-/- littermates.

A region of pol

corresponding to the active site region of reverse transcriptase was isolated and sequenced from
mice at two and six weeks post infection, and viral diversity was assessed within each group. We
found that APOBEC3G led to increased viral diversity in the presence or absence of the drug.
These data support a role for APOBEC3G in viral evolution and potential drug resistance.
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Chapter 3.2: Introduction
APOBEC3 acts as an intrinsic immune factor against retroviral infection. This family of
proteins is capable of a two-pronged antiviral attack, through inhibition of viral reverse
transcription (see Chapter 2.4.4), as well as via cytidine deamination. APOBEC3 deaminates C
residues on the minus strand of retroviral DNA during reverse transcription, resulting in G-to-A
transitions on the coding strand. The effect of different human APOBEC3 proteins on HIV is
highly variable, as the accessory protein Vif blocks APOBEC3 variants to different levels. Vif
targets the APOBEC3 family for ubiquitination and proteosomal degradation by bringing
APOBEC3 and an Elongin-BC-dependent ubiquitin ligase complex together (Yu, 2003).
Degradation of APOBEC3 prevents its incorporation into budding virions, thus preventing any
antiviral activity at the subsequent round of infection.

Vif is able to neutralize APOBEC3D,

APOBEC3F, and APOBEC3G, but not APOBEC3A and APOBEC3B. Also, APOBEC3F may be
slightly less sensitive to Vif than APOBEC3G (Chiu and Greene, 2008). Of note, the low
expression of APOBEC3B in HIV-infected cell types eliminates it as a threat to the virus.
APOBEC3H may or may not be susceptible to Vif, depending on the haplotype of APOBEC3H
encoded. This enzyme is highly polymorphic, with each haplotype possessing a variable level of
anti-HIV activity, which is at least in part dependent on interactions with Vif (Ooms, 2013).
Normal variation in Vif can also cause different levels of anti-APOBEC3 activity. Vif
variants isolated from HIV infected patients showed 3-9% divergence from a prototype vif
sequence at the nucleotide level (Simon, 2005). Much of this nucleotide diversity results in amino
acid changes, which can cause truncated proteins, folding defects, or mislocalization (Simon,
1999). These changes can also affect binding capacity to APOBEC3, or interactions with key
mediators of Vif regulation and APOBEC3 degradation, including core-binding factor-beta (CBFβ)
and Elongin B/C (Zhou, 2012).

This disruption of regular Vif function prevents complete

inactivation of APOBEC3.
If Vif fully blocks APOBEC3 from accessing the viral genome, no APOBEC3-mediated
mutations will occur. However, if Vif is unable to cause complete degradation of APOBEC3, viral
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packaging can occur, potentially resulting in significant levels of G-to-A mutations.

These

mutations are typically deleterious to the virus, preventing productive infection. However, HIV
viruses with G-to-A mutations have been found in human plasma, suggesting that these
mutations are not always lethal. These viruses may be the result of an incomplete block of
APOBEC3 by different natural Vif variants (Simon, 2005).

Thus, partial neutralization of

APOBEC3 could result in sublethal mutagenesis, thereby promoting viral sequence diversity.
There is also evidence that even lethal levels of APOBEC3-mediated mutagenesis can
affect viral evolution, through recombination of mutant virus and replication competent virus.
Retroviruses package two copies of viral RNA into virions, and recombination of both copies
commonly occurs during reverse transcription (Rambout, 2004). In a cell dually infected with a
lethally mutated virus and a functional provirus, progeny viruses may carry one copy of each.
Mutations that benefit the virus may be transferred from the mutant copy to the functional one,
working as an additional factor to promote viral evolution. Several studies have shown that G-toA mutations in HIV can result in drug resistance to many first line therapeutics.

These

APOBEC3-mediated drug resistance mutations have been transferred to drug-susceptible viruses
via this recombination method in in vitro infection models (Mulder, 2008).
potentially pro-viral role of APOBEC3 is not well understood.

However, this

Furthermore, the effect of

APOBEC3 on long-term viral evolution has not been studied in vivo.
G-to-A induced drug resistance mutations may stem from sublethal APOBEC3
mutagenesis, as viruses with defective Vif proteins are more likely to contain these drug
resistance mutations (Fourati, 2010). It has been estimated that approximately 20% of all known
drug-resistance mutations are the result of G-to-A substitutions, with A-to-G transitions also
common at approximately similar levels (Berkhout and de Ronde, 2004).

This pattern of

mutations reflects the general mutational bias seen in HIV-1 (Berkhout, 2001). The proportion of
these mutations stemming from APOBEC3, error-prone reverse transcriptase, or RNA
transcription machinery is difficult to estimate, and is highly dependent on variantions in Vif and
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reverse transcriptase. Thus, the specific contribution of APOBEC3 to the development of HIV
drug resistance in vivo has been difficult to ascertain.
Mice have a single APOBEC3 gene, and the natural murine pathogen, Mouse Mammary Tumor
Virus, has no known Vif-like factor. Murine APOBEC3 is able to restrict MMTV, but does not
induce significant G-to-A mutations in vivo (Okeoma, 2007; Chapter 2.4.3). However, both HIV
and MMTV share a similar bias in their nucleotide composition, with high percentage A content.
Interestingly, despite the rapid evolution of HIV throughout its relatively short lifespan in humans,
this nucleotide composition has remained stable (van der Kuyl and Berkhout, 2012). This high A
content is a general property of the lentiviral family to which HIV belongs, but is not consistent in
all other retroviruses; for example, the deltaretrovirus HTLV-1 has relatively low A content (Table
3.1). The adenine-enriched HIV and MMTV genomes could be the result of long-term selective
pressure by APOBEC3. This selective pressure may also continue to shape viral genomes,
aiding the virus in overcoming evolutionary pressures such as antiretroviral drugs.

Table 3.1 Retroviral Genome Composition
The genomes of both the human retrovirus HIV and mouse retrovirus MMTV are not constructed
from equal amounts of each of the four nucleotides. These genomes are enriched in adenine,
and depleted of cytosine. This skewing of nucleotide content is specific to these viruses, as the
human retrovirus HTLV-1 and the murine retrovirus M-MLV have their own unique nucleotide
content patterns (van der Kuyl and Berkhout, 2012).
Virus

%A

%G

%T/U

%C

HIV

36

24

22

18

MMTV

31

22

27

21

HTLV-1

24

18

23

35

M-MLV

26

24

21

29

Our goal is to determine the effect of APOBEC3 on the evolution of murine retroviruses,
and better understand the effect of APOBEC3 on anti-retroviral drug resistance in vivo. Little is
known about the activity of antiretroviral drugs against murine retroviruses. These drugs were
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designed for HIV-specific use. However, retroviruses share significant functional homology, and
thus some anti-HIV therapeutics have previously been shown to inhibit MMTV and M-MLV (Held,
1994; Paprotka, 2010; Sakuma, 2010). Other drugs that are able to inhibit HIV have no activity
against these viruses.

For example, lamivudine (3TC) effectively impedes HIV reverse

transcription, yet has insignificant activity against MLV.

This inability to affect MLV reverse

transcriptase is thought to be based on a residue within the YMDD sequence motif, which when
mutated in HIV-1 RT is known to cause drug resistance (M184V). M-MLV RT naturally contains a
valine within this motif (Ndongwe, 2011). Further studies of XMRV, which shares 95% homology
with M-MLV, engineered the known AZT resistance mutation of HIV-1 RT, Q151M, into the XMRV
RT (Q190M). When expressed as recombinant protein, the mutant protein was five-fold less
susceptible to AZT in vitro, indicating that homologous drug resistance mutations can occur in
multiple retroviral genomes (Ndongwe, 2011). This is helpful in constructing an understanding of
potential drug resistance mutations within murine retroviruses, as so little is specifically known.
Treatment of these murine retroviruses with antiretrovirals designed for HIV-1 could then serve as
a selective evolutionary pressure for viral genomes in vivo.

Chapter 3.3: Materials and Methods
Chapter 3.3.1: Cells and Viruses
MMTV virions were isolated from mammary tumors or breast milk of MMTV-infected mice
(see Chapter 2.3.1 for protocol details). Viral RNA was isolated using the QIAGEN RNeasy Mini
Kit (QIAGEN, Germantown, MD) and reverse transcribed using SuperScript III First-Strand
Synthesis SuperMix, based on a modified M-MLV RT (Invitrogen Corp., Carlsbad, CA) (see
Chapter 2.3.1). For in vivo studies, newborn pups were naturally infected with MMTV RIII virus
from their infected mothers.
293 cells stably expressing mouse transferrin receptor 1 were maintained in DMEM
supplemented with 10% FBS, 100 U/ml penicillin, 100 ug/ml streptomycin, 2mM L-glutamine and
100 ug/ml geneticin (see Chapter 2.3.1). NIH3T3 murine fibroblast cells were obtained from
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ATCC, and cultured in Dulbecco-modified Eagle’s Medium (DMEM) supplemented with 10% fetal
bovine serum, 100 U/ml penicillin, 100 ug/ml streptomycin, and 2 mM L-glutamine. 43-D cells are
modified NIH3T3 fibroblasts that are stably infected with wild type M-MLV; these cells were
cultured in an identical manner. This cell line was used for M-MLV virus production. Cells were
grown to 50% confluence in multiple 100 mm culture dishes, at which time the media was
changed and reduced to half of the normal volume (5 mL per 100 mm plate). After an additional
24 hours of growth, supernatant from all plates was combined and centrifuged at 500g for 10
minutes at 4°C to remove cells and cellular debris. Further purification of the supernatant was
attained by syringe filtration through 0.45 µm filters. The resulting virus-containing media was
treated with 20u/mL of recombinant DNase I (Roche, Mannheim, Germany), and incubated for 30
minutes at 37°C. Virus was aliquoted and stored at -80°C.
4

The virus was titered on NIH3T3 cells, plated at 7 x 10 cells/well in 6-well culture dishes
one day before infection. Serial ten-fold dilutions were made in 500 µL of culture media (see
above), and 8 ug/mL polybrene added before initiating infection at 37°C. After 2 hours, viruscontaining media was removed from cells and replaced with 3 mL/well of fresh media. Four days
post-infection, media was removed and cells were washed with PBS. MLV Env expressing cells
were detected by staining with the mouse 538 env monoclonal antibody for one hour rocking at
4°C. Cells were then washed with PBS with 2% fetal bovine serum, and then incubated with a
secondary antibody, Alexa Fluor-conjugated goat anti-mouse IgG (H+L) (Invitrogen, Carlsbad,
CA), diluted 1:200 in PBS + 2% FBS, 40 minutes rocking at 4°C. Cells were washed and green
fluorescent colonies were counted on a microscope under UV light. Colonies were counted in a
well that provided between 5-50 colonies, and viral titer was calculated considering the dilution
factor specific to that well (in plaque forming units/mL of virus).

Chapter 3.3.2: In vitro infection and drug optimization
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293T-TrFR1 cells employed for MMTV infections, using virions isolated from APOBEC3-/mammary tumors. Cells were pre-treated for two hours with the reverse transcriptase inhibitor
AZT (zidovudine), the integrase inhibitor raltegravir, or the reverse transcriptase inhibitor
lamivudine, all of which were obtained from the NIH AIDS Research and Reference Reagent
Collection. Virus was then added in the presence of drug and 8 ug/ml polybrene, and media with
drug was replaced after four hours. Cells were harvested 24 hours after infection, washed with
PBS, and total cellular DNA extracted using QIAGEN DNeasy Blood & Tissue Kit (QIAGEN,
Germantown, MD).
3T3 cells were used for M-MLV infections. To test for drug susceptibility in vitro, cells
4

were plated at 3 x 10 cells/well in a 12-well tissue culture dish one day prior to infection. Cell
confluency of 60-70% was obtained for optimum infection conditions.

Two hours prior to

infection, cells were treated with three different antiretroviral drugs, at varying concentrations. All
drugs were obtained from the NIH AIDS Research and Reference Reagent Collection, and
solubilized in ethanol or water. The protease inhibitor ritonavir was used at 1 µM, 10 µM, and 100
µM, raltegravir was used at 10 nM, 100 nM, and 1 mM, and AZT (zidovudine) was used at 5 µM,
50 µM, and 500 µM. Cells were infected at an MOI of 100, in a volume of 200 µL, with drug
added to the appropriate concentration. Two hours after infection, virus was removed and fresh
media with drug was applied. Forty-eight hours after infection, cells were washed with PBS, and
then removed from the plate in 200 µL of PBS. Isolation of total cellular DNA was completed
using the QIAGEN DNeasy Blood & Tissue Kit. Similar analysis was performed using a wider
range of concentrations of AZT to determine optimum dose and create a dose curve in vitro, with
drug concentration ranging from 1 nM to 10 µM.

Chapter 3.3.3: Mice and Sample Collection
APOBEC3-/- and APOBEC3+/+ mice were used in MMTV infection studies.
APOBEC3+/+ mice encode the wild-type mouse APOBEC3

C57BL/6

, while APOBEC3-/- contain a
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gene trap vector in intron 4 of the APOBEC3 gene, and have been backcrossed to the C57BL/6
background (see Chapter 2.3.2).
APOBEC3-/- and transgenic mice expressing human APOBEC3G were used in MLV
infection studies. The transgenic mice were created by injecting a pCAG vector encoding the
gene into C57BL/6 blastocysts.

The gene is under control of the chicken β-actin promoter,

allowing for universal expression, and transcription terminates after addition of the rabbit β-globin
poly(A) tail. Resulting pups were screened for the transgene via PCR for human APOBEC3G.
Transgenic founders were crossed with APOBEC3-/- mice to obtain heterozygous APOBEC3G
mice not expressing mouse APOBEC3-/-. All mice were housed according to the policies of the
Institutional Animal Care and Use Committee of the University of Pennsylvania.
Mice infected with MMTV were screened for level of infection at various time points.
Blood was drawn by retro-orbital collection into 10% RPMI in PBS with heparin (500 USP
units/mL) (Sigma Aldrich Corp., St. Louis, MO). PBMCs were isolated using Gey’s solution (150
mM NH4Cl, 10mM KHCO3, 1mM EDTA, pH 7.3). Whole blood was added to 1 mL of Gey’s,
shaken for one minute, and centrifuged at 5000g for 5 minutes at 4°C. After removal of the
supernatant, this process was repeated once to produce PBMCs in the relative absence of red
blood cells. The pellet was resuspended in PBS, and total cellular DNA extracted using the
QIAGEN DNeasy Blood & Tissue Kit (QIAGEN, Germantown, MD).
Blood was also collected via retro-orbital bleed from mice used in MLV studies. Here,
blood samples were not incubated on ice upon collection. Samples were spun at 16,000g for 10
minutes at room temperature to remove all cellular debris from plasma, which was then removed
and stored at -80°C. PBMC DNA was isolated following steps detailed above. When necessary,
splenic DNA was also isolated. Spleens were removed after sacrifice and added to PBS on ice.
A single cell suspension was created by mechanical disruption through fine mesh to remove fat
and the splenic capsule. Red blood cells were lysed once with Gey’s solution, with a five-minute
incubation on ice prior to addition of equal volume DMEM supplemented with 10%FBS. Cells
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were spun at 5000g for 5 minutes at 4°C, and DNA was extracted from the cell pellet using the
QIAGEN DNeasy Blood & Tissue Kit.

Chapter 3.3.4: In vivo infection and drug treatment
MMTV-infected mice were treated with AZT upon weaning at four weeks of age. Males
and females were separated to prevent pregnancy, and mice housed together were either not
treated or provided with AZT. Upon weaning, treated mice were injected intraperitoneally with 2
mg AZT reconstituted and diluted in water (approximately 100 mg/kg assuming weight of
approximately 12-13 g/mouse). Water bottles containing reconstituted diluted AZT were then
provided to these animals until the end of the experiment. Water contained 0.25 mg/mL AZT,
providing an oral dose of approximately 40-50 mg/kg (40-50 µg/g) per day assuming water intake
of 3 mL/day.
Mice used for MLV studies were infected between 24-48 hours after birth, via
4

intraperitoneal injection with 3.7 x 10 plaque forming units of M-MLV in 100 µL total volume.
Upon infection, tissue samples were acquired for genotyping.

DNA was isolated using the

QIAGEN DNeasy Blood & Tissue Kit, and used for genotyping PCR using the following primers.
A3GFor: 5’-GGG ACC CAG ATT ACC AGG AG-3’; A3GRev: 5’-GCA GAT TAT TCC AAG GCT
CAA-3’. PCR products were analyzed via agarose gel electrophoresis to distinguish APOBEC3G
transgenic mice from APOBEC3-/- mice. Approximately half of all mice were begun on AZT
(Zidovudine syrup, 10 mg/mL, Aurobindo Pharma Limited, Dayton, NJ).

Dosing experiments

were performed in APOBEC3+/+ mice, and AZT doses ranged from 0.01 mg/g to 0.1 mg/g. For
viral evolution studies, 0.05 mg/g was administered daily. All mice were weighed daily to ensure
proper dosage.

Chapter 3.3.5: Polymerase Chain Reaction
Tumor and milk-derived MMTV-RIII viral cDNA was used for PCR amplification of viral
genes, including env and the 3’ LTR. Primers used included MMTVSagFor: 5’- TCC CGA GAG
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TGT CCT ACA CCT AG-3’; MMTVSagRev: 5’-GAA GAT CTT CAA GGG CAA TGC CTT AAT
ACT A-3’; MMTVEnvFor: 5’-GAA AGT TAT TGG GCT TAC C-3’; MMTVEnvRev: 5’-AAG TAA
CAC AGG CAG ATG TAG G-3’. For in vitro infection studies, integrated MMTV was measured
by quantitative PCR for strong stop DNA using primers against MMTV 3’LTR: LTRFor: 5’-CGT
GAA AGA CTC GCC AGA GCT A-3’ and LTRRev: 5’-GAA GAT CTT CAA GGG CAA TGC CTT
AAT ACT A-3’. These primers amplify 90bp product from the MMTV RIII U5 region. Equal
volumes of cellular DNA was combined with Power SYBR Green PCR Master mix and amplified
under standard conditions on an ABI Prism Model 7900HT.
Integrated virus in total PBMC DNA isolated from MMTV-infected mice was assessed via
quantitative PCR.

The concentration of DNA was measured using a NanoDrop 2000

Spectrophotometer (Thermo Scientific, Waltham, MA), and equal quantities used for a first-round
PCR reaction, using primers specific for MMTV RIII, spanning from pol to sag, MMTVPolFor: 5’ACC AGA TGA TTC ACA GG-3’; MMTVSagRev: 5’-GAA GAT CTT CAA GGG CAA TGC CTT
AAT ACT A-3’. This first-round PCR included 35 cycles at 1 minute 95°C, 1 minute 55°C, and 3
minutes at 72°C using GoTaq DNA Polymerase MasterMix (Promega). An equal volume of the
first-round product was transferred to a 386 well plate in triplicate for nested quantitative PCR
using the same reverse primer, and a sag-specific forward primer LTRFor: 5’-CGT GAA AGA
CTC GCC AGA GCT A-3’. Power SYBR Green PCR Master mix (Life Technologies, Carlsbad,
CA) was added to the DNA and primers, and samples were amplified under standard conditions
on an ABI Prism Model 7900HT.
For both in vitro and in vivo infection experiments, integrated MLV was also measured by
quantitative PCR, using primers specific to MLV env: SUMLV2F: 5’-CCT ACT ACG AAG GGG
TTG CC -3’ and SUMULV2R: 5’-CAC ATG GTA CCT GTA GGG GC -3’. Three µL of PBMC DNA
was added to Power SYBR Green PCR Master mix, and amplified under standard conditions as
above.
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Chapter 3.3.6: Titering of Plasma Viremia
Plasma MLV levels were measured in a similar manner as described in Chapter 3.3.1.
Briefly, 3T3 cells were plated in a 6-well cell culture dish 24 hours prior to infection. Plasma was
added to fresh DMEM media and two dilutions were produced per sample. The first dilution
contained 2.5 µL of plasma, and was used to produce a single 10-fold dilution (0.25 µL total
plasma) in a total volume of 500 µL with polybrene. This was added to the plated 3T3 cells and
incubated for two hours. Virus was then removed and fresh media added. Four days after
infection, cells were analyzed for MLV infection foci as described in Chapter 3.3.1.

Chapter 3.3.7: Sequencing and Statistics
MLV plasma virions were used for sequencing of MLV pol. RNA was isolated from 50 µL
of plasma using the PicoPure RNA Isolation Kit (Life Technologies, Carlsbad, CA). Plasma was
added to 120 µL Extraction Buffer and incubated at 42°C for 30 minutes. The samples were then
centrifuged at 3,000g for 2 minutes, and the supernatant was applied to the included column.
Samples were then treated as directed by manufacturers protocol. Viral RNA was eluted in 12 µL
volume (included Elution Buffer).

Total RNA was reverse transcribed using the QIAGEN

QuantiTect Reverse Transcription Kit (QIAGEN Corp., Germantown, MD). gDNA Wipeout Buffer
was added to remove any cellular or viral DNA contaminants prior to reverse transcription. The
reverse transcription reaction was carried out in a total volume of 16 µL, and cDNA was stored at
-20°C. MLV pol was amplified from viral cDNA using the following primers specific for Moloney
virus: MLVRTFor: 5’-TGC CAG TCC CCC CTG GAA CAC G-3’ and MLVRTRev: 5’-GGG CAG
TTA GAA GAG CTT GC-3’. Phusion High-Fidelity PCR Master Mix (NEB, Ipswich, MA) was used
in a 25 µL reaction, with 40 total cycles including 1 minute at 95°C, 1 minute at 55°C, and 1
minute at 72°C.
PCR products were run on a 0.8% agarose gel for product confirmation. DNA bands
corresponding to the correct fragment size were cut out of the gel and isolated using QIAGEN
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QiaQuick Gel Extraction Kit (QIAGEN Corp., Germantown, MD). The manufacturers protocol was
followed, with some modifications for increased DNA purity. The column was incubated with
Wash Buffer at 37°C before centrifugation, and this step was repeated for an additional wash.
Elution Buffer was heated to 72°C prior to addition to the column, and once applied, was
incubated on columns at 37°C for 5 minutes prior to elution.
Purified DNA fragments were cloned into the pCR2.1-TOPO vector, as directed
(Invitrogen, Inc.).

The resulting plasmids were transformed into OneShot TOP10 chemically

competent E. coli (Invitrogen, Inc.), and bacteria were plated on LB plates containing 100 µg/mL
ampicillin for selection. Following overnight growth at 37°C, colonies were picked and placed into
30 µL ddH2O for direct in vitro plasmid amplification using TempliPhi Amplification Kit according
to manufacturers directions (GE Healthcare, Piscataway, NJ). Samples were amplified during an
18-hour incubation to maximize template DNA. Samples were diluted in an additional 40 µL
ddH2O and one strand was sequenced on an ABI 3730XL automated cycle sequencer with ABI
BigDye Taq FS Terminator V 3.1 (Applied Biosystems, Foster City, CA) at the University of
Pennsylvania DNA Sequencing Facility.
Sequences from each mouse were aligned using ClustalW, and each nucleotide change
annotated. Sequences with nucleotide changes were translated into amino acid sequence using
ExPASy Translate Tool, and each amino acid change annotated. Mice with multiple viruses
harboring the same amino acid sequence change were also recorded.
Statistical analysis was performed using the GraphPad/PRIZM software, with the
exception of t-tests, which were performed in Microsoft Excel.

Chapter 3.4: Results
Chapter 3.4.1: Potential long term effects of mAPOBEC3 on MMTV
The primary means by which APOBEC3 inhibits MMTV infection is by blocking reverse
transcription (see Chapter 2.4.4). However, G-to-A mutation does occur at a low level in an
APOBEC3-dependent manner (<0.5% mutation rate; see Figure 2.2). Thus, we considered the
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possibility that over many rounds of replication, this mutation rate may influence the retroviral
genome. As described previously, the MMTV genome is similar to HIV in that it has a high
prevalence of genomic adenine, suggestive of an evolutionary pressure to maintain this skewed
content.

Murine leukemia viruses are also inhibited by murine APOBEC3 in a cytidine

deaminase-independent manner (Santiago, 2008; Low, 2009).

However, studies of recently

integrated endogenous MLV sequences suggest that mouse APOBEC3 has caused significant
mutation in these viruses, as viruses show an increase in A corresponding to a decrease in G,
with the majority of mutations occurring in the mouse APOBEC3

C57BL/6

preferred 5’-TTC-3’

context. Although modern ecotropic MLV is not edited by murine APOBEC3, the editing of these
endogenous viruses is hypothesized to have occurred directly prior to integration, and to have
played a role in its inactivation (Jern, 2007).

This provides further evidence that murine

APOBEC3 could have a potential important mutagenic effect.
We thus examined MMTV sequences isolated from APOBEC3+/+ and APOBEC3-/mice. Both genotypes of mice were infected with identical MMTV RIII and the virus was then
passed vertically through milk in multiple generations of mice (approximately 40-50 generations).
Viruses were isolated both from tumor tissue and from breast milk, and viral RNA was isolated for
sequencing analysis.

A 2400 bp segment of genome corresponding to env and the 3’LTR

(including sag) was amplified and sequenced from each sample. We found ten locations at which
an A-to-G or T-to-C nucleotide changes occurred in viruses isolated from APOBEC3-/- mice but
did not occur in wild type mice (Fig. 3.1). These changes were independent of viral tissue source
(tumor or breast milk). This is consistent with the hypothesis that APOBEC3 plays a role in
maintaining the high AT content, with lack of this pressure leading to a reversion to higher GC
content. However, of the ten changes, two did not fit a model of AT to GC reversion, and could
be compensatory mutations to retain infectivity.
Seven of the 10 changes altered the amino acid codon (Fig. 3.1). Several of these
nonsynonymous mutations were located near the receptor binding domain, potentially altering
viral entry. Most of these amino acid changes cluster in close proximity, further suggestive that
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these mutations are not random but instead important for the viral lifecycle. Other nucleotide
mutations found in env or the 3'LTR were not genotype specific, as they were only seen in single
isolates.	
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A.
Nucleotide (position and
consensus)
763; T
842; A
843; A
845; A
859; T
870; A
876; A
991; C*
1018; C*
1020; T

APOBEC3+/+ Viral Isolates
(9 total)
T: 4/9 (45%)
A: 7/9 (78%)
A: 7/9 (78%)
A: 6/9 (67%)
T: 8/9 (89%)
A: 8/9 (89%)
A: 9/9 (100%)
C: 7/9 (78%)
C: 8/9 (89%)
T: 9/9 (100%)

APOBEC3-/- Viral Isolates
(6 total)
C: 5/6 (83%)
G: 6/6 (100%)
G: 6/6 (100%)
G: 6/6 (100%)
C: 6/6 (100%)
G: 6/6 (100%)
G: 6/6 (100%)
T: 4/6 (67%)
C: 4/6 (67%)
C: 4/6 (67%)

B.

Fig. 3.1. MMTV passaged in APOBEC3-/- mice differs from virus passed in APOBEC3+/+
mice. (A) MMTV RIII was isolated from both mammary tumor tissue and breast milk from
APOBEC3-/- and APOBEC+/+ mice, and a 2400 bp region of env and 3’ LTR was sequenced.
Isolate number refers to the number of unique source samples from different mice. Specific
nucleotides were found to vary between viruses dependent on the source genotype. The number
and fraction of the nucleotide found at these specific env locations are listed for viruses from both
genotypes of mice. Nucleotide position is indicated based on GenBank accession number
DQ767968.1 (Mouse mammary tumor virus envelope glycoprotein Pr73 and superantigen
genes). Statistical association of APOBEC3-/- isolated viruses with total A-to-G changes
(compared to all other mutations) was confirmed by Fisher’s Exact Test (p<0.01). Starred
nucleotides indicate mutations which do not fit a model of AT to GC reversion, but are notable as
they are located within this region and seen in multiple viral isolates. (B) The nucleotide changes
found in viruses from APOBEC3-/- mice resulted in amino acid changes clustered together near
the receptor binding domain region. These changes are highlighted in red.
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Although the viruses isolated from all APOBEC3-/- samples were not identical, most of
the nucleotide changes leading to amino acid differences were present simultaneously in
individual viruses.

This suggests that in addition to the genetic changes that occur in the

presence or absence of APOBEC3, there are functional constraints to maintain infectivity that
limit the extent of these changes.

These data suggest that while mAPOBEC3 does not

significantly deaminate MMTV, it does provide pressure for the virus to maintain a high AT
content, which may have a detrimental effect on viral fitness. However, verification that these
mutations lead to increased fitness would require infection using tissue-isolated MMTV virions,
and analyzing replication kinetics over several rounds of replication. MMTV is quite sensitive to
small variations in in vitro conditions, and in my experience, difficult to maintain in culture for
multiple replication cycles (Fine, et al., 1976). Thus, these experiments were not performed.

Chapter 3.4.2: MMTV is restricted by therapeutic antiretrovirals in vitro
Sequence analysis of HIV genomes isolated from patients who have failed anti-viral drug
therapy suggests that human APOBEC3-mediated G-to-A transitions could play a role in the
development of drug-resistant virus. To directly test if such selection occurs in vivo, we wanted to
test the effect of antiretroviral drugs to MMTV-infected APOBEC3+/+ and APOBEC3-/- mice. We
tested several drugs that are used to treat HIV-infected patients to determine their efficacy
against MMTV in vitro. Virus isolated from APOBEC3-/- mammary tumors was used to infect
293T-mTfR1 cells (expressing the MMTV receptor, mouse transferrin receptor 1) in the presence
or absence of several different antiretroviral drugs. Infection levels were measured after 24 hours
using quantitative PCR to measure total integrated exogenous MMTV. At the concentrations
selected, the thymidine analog AZT was most effective, reducing viral integration approximately
100-fold (Fig. 3.2). Raltegravir was also very effective, while lamivudine was able to reduce
infection but with the lowest efficacy of those tested. Our results confirm previous studies that
support AZT as active against MMTV infection in a variety of cell types in vitro (Indik, 2007;
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Okeoma, 2009), and provide evidence for additional antivirals that are efficacious for
betaretroviruses. This information led us to select AZT for in vivo viral evolution studies, as it is
clearly potently antiviral.
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Fig.3.2. Antiretrovirals effectively block MMTV in vitro. 293T-mTfR1 cells were infected with
MMTV RIII in the presence or absence of antiretroviral drug. Total integrated exogenous MMTV
was measured via qPCR one day post-infection. Infection levels are normalized to total cellular
DNA using GAPDH as an internal control. Infection was performed in duplicate wells and results
averaged; results are representative of two replicates.
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Chapter 3.4.3: Selection of antiretroviral drug and dosing for studies of in vivo viral evolution
An effective agent for in vivo viral evolution studies should have several characteristics.
First, it should be highly effective in preventing viral replication. When using an antiretroviral as a
selective pressure against the virus, one measurable outcome is viral replication. Without viral
evolution and escape, viral replication remains low. However, if virus is able to evolve resistance
to the drug, replication will increase even in the presence of drug. It is more difficult to draw clear
conclusions using viral replication as a measure if using an ineffective drug that allows continuous
viral replication.
Dozens of mutations in HIV are known to cause resistance against the activity of AZT.
These mutations are collectively known as “thymidine analog mutations” or TAMs. TAMs are
unique sets of mutations within the gene encoding the viral reverse transcriptase, which cause
the RT to avoid the effect of the drug, at a potential fitness cost to the virus. TAMs typically occur
in sets, with initial mutations that decrease drug susceptibility selected first, and followed by
additional compensatory mutations that reduce any deleterious effect of the resistance mutations
(Garcia-Lerma, 2005). In measuring APOBEC3-mediated viral evolution, drugs that require a
“multiple hit” mechanism, needing several mutations to fully develop resistance, is potentially
beneficial over drugs that require a single mutation. APOBEC3 creates only G-to-A mutations,
but can cause several G-to-A changes in a single virus. Thus, it is useful to have a variety of
targets that could potentially cause drug resistance. One potential downfall is that resistance may
take longer and require more rounds of replication to arise. Furthermore, it is possible that some
TAMs are comprised solely of amino acids mutations that do not require G-to-A mutations at the
nucleotide level. In the presence of drug, these TAMs could arise with or without any additional
APOBEC3 mutations, creating a potential source of false positive or false negative results.
Dosing of the chosen drug is also critical for optimizing the possibility of obtaining clear
results. As stated previously, too low of a drug dose may allow continued viral replication. This
creates an ineffective system, as the virus has little selective pressure to evolve resistance
mutations. Further, if resistance mutations do occur, our measure of viral replication to detect
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these may fail. Observing an increased rate of viral replication of a drug resistant virus is more
difficult to distinguish if viral replication is significant even in the absence of drug. However,
suboptimal doses of drug are known to cause more rapid evolution of antiviral drug resistance
(Lucas, 2005). HIV-infected patients with non-perfect drug adherence are significantly more likely
to acquire drug resistant virus (Harrigan, 2005). Optimal drug doses in patients cause complete
cessation of viral replication, and prevents the opportunity for the virus to acquire resistance
mutations, through APOBEC3-mediated cytidine deamination, reverse transcriptase errors, or
RNA polymerase errors. Thus, in our system, drug should be administered at approximately 9095% the maximal inhibitory concentration, to establish and maintain a low level of viral replication
(to enable mutations to occur) but allow approximately a 10-fold difference between treated and
untreated mice (to increase ability to observe rapid changes in viral kinetics). We anticipate that
this would decrease time to development of drug resistance.
The IC90 value for AZT to treat HIV is approximately 5 µM.

However, current

recommended dosage of the drug in humans is 600 mg (approximately 8.8 mg/kg assuming 150
lb individual) daily. Further assuming complete bioavailability, serum concentrations with these
doses could reach 450 µM, significantly higher than the necessary dose. In MMTV studies, 10
µM was sufficient to completely inhibit viral replication in vitro (Indik, 2007).

In vivo, adult

C57BL/6 mice injected with 25 mg/kg of AZT achieved serum concentrations of approximately 50
µM, although levels dropped to 5 µM by 90 minutes after injection (Chow, 1998). In female
B6C3F1 mice, doses of 15, 30, and 60 mg/kg given orally led to maximum serum concentrations
of 34, 67, and 187 µM respectively (Trang, 1993). The half-life of the drug is also relatively short,
ranging from 16-46 minutes (Trang, 1993). However, dosage experiments for inhibiting MMTV
have not been performed in vivo.

Considering the high bioavailability but low half-life, we

provided drinking water with 0.25 mg/mL AZT to obtain relatively consistent plasma levels.
Assuming average weight of 20 g and consumption of 3 mL of drinking water per mouse per day,
the average dose was approximately 40 mg/kg per day.
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Chapter 3.4.4: The effects of antiretroviral treatment and APOBEC3 on MMTV replication
MMTV-infected APOBEC3+/+ and APOBEC3-/- mice were treated orally with 40 mg/kg
(40 µg/g) of AZT beginning at four weeks after birth, after a single initial dose of 100 mg/kg
delivered via intraperitoneal injection. The oral route of drug administration prevented treatment
immediately after MMTV infection, which occurs shortly after birth once the pup begins to
consume virus-containing breast milk. Thus, drug treatment began once mice were weaned and
began consuming solely water. Untreated mice were housed in separate cage and provided
drug-free water to serve as controls.

However, as infection began considerably earlier than

treatment, all mice began with significant initial viral loads. To control for this, we extracted blood
and isolated PBMCs upon weaning (at the start of treatment) to establish a baseline level of
infection for each mouse. This was measured via level of integrated virus within this target cell
population. MMTV does not produce plasma viremia, so cell-associated virus is an appropriate
measure of infection (Finke, 2001). Drug treatment continued for 10 weeks, and mice were bled
every 3-4 weeks (0, 3, 6, and 10 weeks).

After the final bleed, mice were sacrificed and

splenocytes harvested for viral integration analysis on this distinct target cell population.
At each time point, PBMCs were isolated from whole blood, and total DNA harvested for
PCR analysis.

Measuring integrated exogenous virus proved difficult.

Single-round PCR or

quantitative PCR was not sufficient to amplify measurable quantities of viral DNA from PBMCs.
Thus, we utilized a nested PCR-qPCR system to measure comparative levels of integrated virus.
Equal concentrations of DNA were first used to amplify a 3 kB region corresponding to the 3’ end
of the genome, using one MMTV-RIII specific primer to ensure endogenous viruses were not
amplified. Equal volumes of the PCR products were then used in a nested quantitative PCR
reaction, using the same MMTV-RIII specific primer to again ensure specificity and prevent
amplification of endogenous virus from carryover DNA. Multiple dilutions of several test samples
were run to ensure amplification was in linear range (not shown).
At the first time point, prior to AZT treatment for any group, average integrated MMTV
levels differed based on mouse genotype.

APOBEC3+/+ mice displayed a wide range of
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infection levels, which may reflect differences in initial infection based on nursing habits and
mother-to-mother disparities (Fig. 3.3). APOBEC3-/- mice maintained significantly higher viral
loads, approximately 10-fold higher than APOBEC+/+ mice on average (t-test, p<0.01). Viral
loads in these mice had less variability, perhaps an indicator of viral loads beginning to plateau
(Fig. 3.3).

Both the difference in viral levels in APOBEC3+/+ vs APOBEC3-/- mice and the

potential plateau in APOBEC3-/- mice is consistent with previous results (Okeoma, 2007).
However, these studies did not examine PBMCs directly.
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Fig. 3.3. The dual effect of APOBEC3 and AZT on MMTV replication in vivo. MMTV-infected
APOBEC3+/+ and APOBEC3-/- were treated with the antiretroviral AZT beginning at 4 weeks
post-infection. Blood was collected at various time points post-treatment, including a 0 week
timepoint to establish baseline MMTV infection. Viral load was measured by nested qPCR of
PBMC DNA using primers specific for MMTV RIII. T-tests were performed to determine statistical
differences between indicated groups. Each data point represents a single animal. The two
outlier data points at Week 10 may have been the result of an inefficient DNA isolation, as low
levels of amplification were seen in multiple PCR reactions.
Green dots: AZT-treated
APOBEC3+/+ mice; Red triangles: untreated APOBEC3+/+ mice; Blue triangles: AZT-treated
APOBEC3-/- mice; Black triangles: untreated APOBEC3-/- mice.
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After 6 weeks of AZT treatment, APOBEC3+/+ mice maintained a high level of variability
in viral loads. Several mice were able to control virus to levels similar to their respective baseline
(Fig. 3.3). Untreated APOBEC3+/+ mice showed a significant rise in viral load, although not
reaching statistical significance over treated mice. This rise is consistent with the hypothesis that
APOBEC3 controls MMTV early in infection, but is unable to completely prevent viral replication.
The early kinetics of viral replication were slower than that in APOBEC3-/- mice. However, AZTtreated APOBEC3-/- showed no discernable change in viral load from 3 weeks post-infection to 9
weeks post-infection (Fig. 3.3; comparing Week 0 to Week 6). This could indicate either an
efficacious antiretroviral treatment, or a viral load that has plateaued. However, viral loads in
untreated APOBEC3-/- mice continued to rise, becoming significantly higher than in treated
counterparts (p<0.05).
After an additional four weeks of infection and treatment, viral loads in all four groups
reached similar levels. Untreated APOBEC3+/+ mice and both groups of APOBEC3-/- mice
showed no significant change in viral load from the previous timepoint. Interestingly, the group
that differed the most from the experimental midpoint to endpoint was AZT-treated APOBEC3+/+
mice, which saw a marked increase in almost every single member of the group (Fig. 3.3). These
results again could be interpreted in two different manners. First, the AZT dose may have been
ineffective in controlling MMTV, which provided a second mechanism of slowing replication
together with APOBEC3. This control would slow the progression of viral integration events, but
eventually viral loads would reach the same putative plateau as APOBEC3-/- and untreated mice.
An alternative explanation suggests that AZT in fact was very effective (particularly bearing in
mind Week 0 to Week 6 similarities in AZT-treated APOBEC3+/+ mice), but viruses within these
mice evolved resistance to the drug. This drug resistance would allow increased replication even
in the continued presence of AZT, raising viral loads to similar levels as other experimental
groups. This would reflect a potential role for APOBEC3 in promoting retroviral drug resistance in
vivo.
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Chapter 3.4.5: Barriers to secondary analysis of exogenous MMTV variants
If APOBEC3 did cause drug resistant variants to arise in AZT-treated mice, we would
expect a higher level of integrated virus with G-to-A mutations within the reverse transcriptase
gene.

Follow up studies included an attempt to amplify and sequence regions of pol that

correspond to reverse transcriptase. However, multiple factors prevented effective analysis of
integrated exogenous virus. First, as stated previously, amplification of integrated exogenous
virus required consecutive rounds of nested PCR. Endogenous and exogenous MMTV differ in
very few regions of their genomes, with the most variation occurring in the 3’ LTR. No region of
pol has significant differences in RIII versus all of the endogenous MMTVs found in C57BL/6 mice
(Mtv-8, Mtv-9, and Mtv-17, {Peterson, 1985}), although there are a number of single nucleotide
differences. This prevents the design of pol primers that amplify exogenous RIII over these
endogenous viruses. Thus, while we could use an RIII-specific primer for the first round of PCR,
second round amplification of the shorter pol fragment used primers that could amplify all species
of MMTV present. Even with dilution of the first round products, a small amount of second round
product was formed even in control samples using uninfected PBMC DNA. This suggests that in
our infected experimental samples, contamination with endogenous sequence may exist.
Infection of all mice continued for four weeks prior to beginning AZT treatment. Our
quantitative data show that a high baseline infection was established in all groups at this point,
although there was a significant difference between APOBEC3-/- and APOBEC3+/+ mice. Unlike
in HIV, MMTV infection of target cells within the PBMC population does not cause rapid cell
death. A large fraction of cells infected during this initial untreated infection period are thus still
present in the samples drawn at later time points. Even if amplification of viral pol was completely
specific for exogenous MMTV, a significant portion of the amplified virus would be pre-treatment
virus, which may or may not carry any APOBEC3-mediated G-to-A mutations. This would make
classification of individual viral clone sequences as drug-susceptible or drug-resistant very
difficult, particularly without high throughput deep sequencing and computational analysis.
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Further complicating factors include the ability for exogenous MMTV to create
recombinant viruses with endogenous viruses. Although these endogenous viruses cannot form
functional infectious virions, they can be expressed at the RNA level and packaged into virions
alongside infectious exogenous viral RNA genomes.

Upon infection of a new cell, reverse

transcriptase can switch between the two templates to create a recombinant virus that may or
may not be infectious (Golovkina, 1994). During initial attempts to sequence exogenous RIII from
our PBMC samples, many samples appeared to contain a large percentage of recombinant
viruses. This recombination alone could result in drug-resistant viruses, which while noteworthy in
its own right, would be an APOBEC3-independent event and potentially confound the search for
any novel APOBEC3-mediated drug resistance mutations.

Chapter 3.4.6: MLV is restricted by therapeutic antiretrovirals in vitro and in vivo
Many of the difficulties we experienced in our MMTV studies could be ameliorated using
a different murine retrovirus, Moloney MLV. Mice are naturally infected with MLV through breast
milk similar to MMTV, but neonates can also be infected to high titer by intraperitoneal injection
with purified virus. This purified MLV is produced in vitro, and virus can be titered to ensure mice
are infected with the same number of infectious virus particles. MLV causes plasma viremia,
which is an easier measure of infectious virus load than total integrated viral DNA, since unlike
integrated proviral DNA, it reflects the actively replicating virus pool at any given time.
Additionally, plasma-isolated virions can be tested for infectivity in vitro. Laboratory and wild mice
do contain endogenous MLV viruses similar to M-MLV, and recombinant viruses produced
between the two can be infectious. However, there are more regions of dissimilarity between the
endogenous viruses and M-MLV than between endogenous and exogenous MMTV. These
differences allow specific primer design for easier amplification of exogenous virus without
amplifying endogenous viruses from genomic DNA.
M-MLV reverse transcriptase is a well-studied enzyme, with a known crystal structure.
This structure shows significant structural homology to HIV-1 RT, although they share only 25%
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sequence identity on the amino acid level (Das and Georgiadis, 2004). Main differences between
the structures include regions of the thumb, connection, and RNase domains. Some of this
structural difference is attributed to the fact that MLV RT is a 75 kDa monomer and HIV-1 RT is a
heterodimer consisting of p66 and p51 subunits. The palm and finger regions, which include the
polymerase active site and many catalytically essential residues, have more significant structural
and sequence similarities (Das and Georgiadis, 2004). These regions are also important for
nucleic acid binding, and in HIV-1 RT, contain the majority of mutations known to induce
resistance to reverse transcriptase inhibitors such as AZT (Rhee, 2003). Our analysis focused on
this region of MLV pol.
Because of the dissimilarities between MLV and HIV-1 reverse transcriptase, we first
tested whether AZT inhibits MLV in vitro. In order to maintain a similar model to the system we
used for MMTV, our goal was to use this drug as a selective agent to induce viral evolution. We
simultaneously tested other antiretrovirals for their potential use as well. We tested the integrase
inhibitor integrase and the protease inhibitor ritonavir.

All three drugs inhibited MLV at

concentrations within similar range to those used to treat HIV in humans (ritonavir: 30µM,
raltegravir: 3000 nM, AZT: 50 µM [van der Lugt, 2009; Sandkovsky, 2012; Bergshoeff, 2004)
(Fig. 3.4).
Because all concentrations of AZT tested were able to prevent infection, we tested
susceptibility to a greater range of the drug to determine more exact IC50 and IC90 concentrations
in vitro. We found that MLV was susceptible to much lower doses than previously tested, with
IC50 approximately 0.03-0.04 µM (Fig. 3.4). We believe this sensitivity to AZT, which is within a
similar range as the IC50 for HIV, makes AZT an appropriate choice for in vivo MLV studies, as we
are easily able to reach these inhibitory concentrations in vivo.

We also chose to continue

experiments with AZT because large amounts were available at low cost, an important factor in
designing long-term experiments involving many animals.
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A.

B.

Fig. 3.4. M-MLV is susceptible to antiretroviral drugs in vitro. (A) Increasing concentrations
of the protease inhibitor ritonavir, the integrase inhibitor raltegravir and the reverse transcriptase
inhibitor AZT were added to 3T3 cultures during infection with M-MLV. Infection levels were
measured by quantitative PCR of total cellular DNA 24 hours after infection, and normalized to
GAPDH. Values were set as proportion of infection in cells not treated with any drug. Each
experimental condition was performed in duplicate, and the average value is shown. (B) A wider
range of AZT concentrations were used in similar MLV infections to generate an in vitro dose
curve. Each concentration was applied in triplicate, and levels of infection averaged and
normalized to no drug controls.
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We next tested viral susceptibility to AZT in vivo. As stated previously, drug dosage is
critical when used as an evolutionary pressure. To avoid high baseline infection rates seen in
MMTV studies, we allowed infection to proceed for only 48 hours before beginning treatment.
Mice were also treated using a different mode of delivery, via daily intraperitoneal injection with
liquid AZT instead of adding lyophilized AZT to drinking water. Mice were given three different
concentrations, which were in approximately the same range (in mg/kg) as that given in the
MMTV experiments. Total integrated MLV in PBMCs and splenocytes and infectious plasma
viremia were measured to assess viral load. A dose-response effect was seen in this range,
confirming that the range chosen was appropriate (Fig. 3.5). Mice treated with 0.05 mg/g AZT
had a level of infection that was approximately 1-5% of untreated mice. This suggests a low level
of replication, which is necessary for the viral population to obtain and maintain diversity.
However, the difference in infection level between this treatment group and untreated mice is
sufficient to easily discern, which is important for determining a change in viral load within a single
mouse.
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A.

B.

Fig. 3.5. M-MLV is susceptible to AZT in vivo. C57BL/6 mice were infected with M-MLV 24-48
hours after birth. Daily intraperitoneal injections of the indicated dose of AZT were given
beginning two days post-infection. (A) Two weeks post-infection, mice were bled and total MLV
DNA was measured by quantitative PCR from isolated PBMCs and normalized to GAPDH levels.
Three weeks post-infection, mice were sacrificed and splenocytes were isolated for similar
quantitative analysis. Infection levels are normalized to untreated mice, which are set as 100%.
Each group contained three animals, and data are presented as averages with standard error.
ANOVA analysis indicates a significant difference between each group (p<0.01). (B) Plasma
viremia was calculated at both two weeks and three weeks post-infection. Plasma virus was
serially diluted and used to infect 3T3 cells. Four days post-infection, cells were stained with an
anti-MLV env antibody and fluorescent plaques counted. Average plaque forming units per mL of
serum per treatment group are shown. ANOVA analysis indicates a significant difference in viral
inhibition between each dose at Bleed 1 and Bleed 2 (p<0.01).
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Chapter 3.4.7: MLV is restricted and hypermutated in human APOBEC3G-expressing mice
Spiros Stavrou, a postdoctoral fellow in the lab, has recently created transgenic mice that
express human APOBEC3G in the absence of murine APOBEC3.

These mice express

APOBEC3G under a chicken ß-actin promoter, which supports universal expression.
APOBEC3G RNA and protein can be detected in M-MLV target tissues (PBMCs, spleen, and
thymus), as well as other tissues. APOBEC3G transgene expression by murine PBMCs was
about 10-fold lower than that found in human PBMCs. This level was sufficient to affect MLV
replication in vivo, with transgenic mice carrying approximately 7-8 fold less infectious plasma
virus than APOBEC3-/- mice two weeks post-infection (Stavrou, et al., in preparation).

The

human protein dramatically inhibits infection, and compared to endogenous mAPOBEC3, also
causes substantial G-to-A mutations of the env region of the M-MLV genome (Stavrou, et al., in
preparation). This corroborates previous experiments, which showed that human APOBEC3 is
an efficient anti-MLV factor in vitro (Mariani, 2003).

Because these human APOBEC3G

transgenic mice showed higher levels of deamination of the M-MLV genome without completely
inhibiting replication, we chose to examine whether human APOBEC3G is capable of generating
AZT-resistant M-MLV.
We first tested whether the pol gene of MLV was targeted for cytidine deamination by
transgenic APOBEC3G. A region of pol corresponding to reverse transcriptase was amplified
from splenic DNA and from plasma RNA of MLV-infected APOBEC3-/-, APOBEC3+/+, and
APOBEC3G-expressing mice, and the DNA was clonally sequenced and assessed for mutations.
Virus recovered from transgenic mice showed significantly higher levels of G-to-A mutations than
virus isolated from either other genotypes (Table 3.2A). Integrated viral DNA has been shown to
harbor more mutations than viral genomes packaged into newly formed virions (Russell, 2009;
Sato, 2010). We thus also sought to determine the rate of G-to-A mutations in packaged MLV
genomes isolated from cell-free virions.

Although we also saw a decrease in mutation rate

compared to integrated proviruses, cell-free virions from mice expressing the human APOBEC3G
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transgene had significantly more mutations within their genomes than those from APOBEC3+/+
or APOBEC3-/- mice (Table 3.2B). Mutation analysis of regions of env and gag also show higher
rates of G-to-A mutation in APOBEC3G-expressing mice, with an apparent gradient that
increases 5’ to 3’ (Table 3.2C). This is consistent with previous reports that indicate a gradient of
mutation that reflects the time the minus-strand DNA remains single stranded (Suspene, 2006;
Jern, 2007).
Table 3.2. Human APOBEC3G deaminates M-MLV in vivo. APOBEC3-/-, APOBEC3+/+, and
transgenic APOBEC3G-expressing mice were infected with MLV 1-2 days after birth.
Splenocytes were harvested 16 days post-infection. (A) Total DNA was extracted from a portion
of the splenocyte population, and used to amplify a region of pol corresponding to integrated MMLV reverse transcriptase. These amplicons were clonally sequenced and assessed for G-to-A
mutations. (B) A separate fraction of splenocytes was cultured for 48 hours in vitro, and virus
purified from the resulting supernatant. Similar amplification and sequencing analysis was
performed on RNA isolated from these viruses. ANOVA tests were performed to assess
statistical differences; *= p<0.05. (C) Two other regions of the MLV genome were analyzed via
clonal sequencing of integrated proviruses within MLV-infected splenocytes two weeks postinfection. G-to-A mutations falling within the APOBEC3G-preferred editing site 5’-GG-3’ were
calculated for each of three regions of the genome. Figure credit: Spiros Stavrou.
A.
Genotype

G-to-A mutations
2

Total bp
Analyzed
16050

Clones
Analyzed
21

Mutations
per kB
0.12

APOBEC3-/APOBEC3+/+

1

24480

31

0.04

APOBEC3G

9

16050

21

0.56*

Genotype

G-to-A mutations

APOBEC3-/-

2

Total bp
Analyzed
16830

Clones
Analyzed
22

Mutations
per kB
0.12

APOBEC3+/+

2

17610

23

0.11

APOBEC3G

5

11670

15

0.42*

B.

C.
Mutation frequency (G to A/total GGs sequenced)
gag

pol

env

APOBEC3G

.00063

.0041

.0157

APOBEC3-/-

0

0

.0005

APOBEC3+/+

0

0

0
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Chapter 3.4.8: Antiretroviral treatment is more effective in APOBEC3G-expressing mice
To study the role of APOBEC3 and viral evolution in the presence of antiretroviral drugs,
we infected APOBEC3-/- and APOBEC3G-expressing mice with M-MLV and began treatment
with the chosen sub-optimal dose of AZT two days post-infection. During the course of infection,
we periodically measured viral loads to determine any large changes in viral load within individual
mice.

A large increase in infection within an AZT-treated mouse previously able to control

infection could indicate the emergence of a drug-resistant virus. At two, four, and six weeks postinfection, blood was collected and both whole plasma and total PBMC DNA was collected.
Plasma viral levels were measured by titration on 3T3 cells, and PBMC DNA was analyzed for
levels of integrated MLV by quantitative PCR. At two weeks post-infection, significant differences
were seen in plasma viremia based on AZT treatment within each genotype (Fig. 3.6A). ANOVA
analysis also confirmed statistical differences between each of the four groups at all three time
points, confirming that both AZT treatment and genotype both have a significant effect on viral
load. Statistical differences were less apparent at the level of integrated provirus, as APOBEC3G
mice, but not APOBEC3-/- mice, showed a significant decrease in integration when treated with
AZT (Fig. 3.6B). This could be due to the more sensitive nature of the quantitative PCR assay,
as it is better able to detect minor variability. However, general trends remain consistent with
plasma viremia data, in which mice receiving AZT treatment or expressing APOBEC3G seem to
have lower levels of integration. Interestingly, AZT treatment seemed to have a greater effect in
mice expressing APOBEC3G, as fold change in plasma viremia between APOBEC3G treated
and untreated animals were significantly higher than that seen in APOBEC3-/- treated vs
untreated animals. This could indicate a potentially synergistic effect of the restriction factor and
the antiretroviral drug.

Fig. 3.6. The antiviral effects of APOBEC3G and AZT are distinct early in infection, but
become less apparent over time. APOBEC3-/- and APOBEC3G-expressing mice were
infected with MLV 48 hours after birth. At specified time points, blood was collected and both
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plasma and total PBMC DNA isolated. (A) Plasma viremia was measured by titration of plasma
on 3T3 cells. Four days post-infection, cells were stained with anti-MLV env antibodies, and
infectious plaques counted. Infectious plaque forming units per mL of plasma were calculated,
and plotted per individual mouse. Group averages per time point are shown. T-tests were
performed to determine statistical differences between treated and untreated mice within each
genotype, at each time point; *= p<0.01. The number above each treated vs. untreated group
indicates the fold change between the average viremia levels, Untreated/Treated. (B) Total
integrated M-MLV was measured by quantitative PCR using primers specific to MLV env, and
normalized to GAPDH. Statistical analysis was performed as above. (C) Plasma viremia levels
for individual mice were plotted chronologically for each experimental group.
A.

B.
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C.

At later time points, infection levels in all groups of mice began to reach comparable
levels. This is similar to the effect we saw in MMTV-infected mice (Fig. 3.3). On average,
infection levels in untreated mice continued to gradually increase over time as expected, but
levels in treated mice also increased on average. As drug was provided at a sub-optimal level,
this increase is not unexpected, as the dose may not have completely inhibited viral replication. If
drug-resistant virus arose, we might expect a larger rise in viral load over that in other similarly
treated mice. Although on average, viral loads increased in all groups, AZT-treated APOBEC3G
expressing mice showed the greatest fold increase in viral load between the first and last bleed,
which was influenced by virus in three specific mice (Figure 3.6C). Two mice in our APOBEC3-/treated group also showed over two-fold increase in viral load between the first and the last
bleed, while mice in both untreated groups showed less substantial increases. This suggests that
the pressure exerted by AZT may be sufficient to induce evolution of drug resistance.

Chapter 3.4.9: Human APOBEC3G affects MLV diversity in vivo
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We next assessed the effect of both APOBEC3G expression, as well as AZT-treatment
induced selection, on viral pol nucleotide sequences. Plasma virus cDNA was isolated from a
few selected samples at two weeks post-infection. Reverse transcriptase was amplified and
clonally sequenced to assess G-to-A mutation levels. In those samples assessed, pol sequences
from APOBEC3G-expressing mice did not show significantly increased mutagenesis compared to
APOBEC3-/- viral sequences at this early time point (Table 3.3A). This may have been a result of
our small sample size of mice for this analysis, as our APOBEC3-/- mice showed higher levels of
G-to-A mutation than expected, and our APOBEC3G-expressing mice showed lower levels than
expected. Viruses circulating in blood are representative of the pool of infectious M-MLV and
highly mutated viruses would not be found in this pool. To examine the overall extent of
deamination in the AZT-treated mice, we also assessed integrated viral DNA from selected
samples at two weeks post-infection.

Integrated proviruses isolated from AZT-treated or

untreated APOBEC3G-expressing mice contained slightly less G-to-A mutations as those
previously sequenced (Table 3.3B; compare to Table 3.2). However, these viruses did maintain
significantly higher levels of G-to-A mutations than integrated proviruses sequenced from
APOBEC3-/- littermates.
Plasma virions collected at six weeks post-infection were next evaluated for nucleotide
changes in pol. At this later time point, there were more G-to-A mutations apparent in circulating
plasma virus of APOBEC3G-expressing mice (Table 3.3C).

Although mutation rate had

considerable differences between mice, overall G-to-A mutations on average were significantly
higher on in APOBEC3G-expressing mice than APOBEC3-/- mice, irrespective of treatment
status (t-test, p<0.05). This is indicative of significant mutagenesis, and implies that APOBEC3G
is able to influence the viral genome in a relatively short time. G-to-A mutagenesis was not
significantly different between AZT-treated and untreated APOBEC3G-expressing mice (t-test,
p=0.15). Total rates of mutation (including G-to-A) were also not different between AZT-treated
and untreated mice, regardless of genotype, suggesting that at least in the region of pol
assessed, AZT was not sufficient to influence statistically significantly higher levels of total viral
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nucleotide diversity within this region. However, in many cases, multiple viruses cloned from an
individual mouse carried the same nucleotide change, which could indicate a selective advantage
provided by these mutations (see Figure 3.8).
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Table 3.3. APOBEC3G affects MLV genomic evolution in vivo. APOBEC3G-expressing and
APOBEC3-/- mice were infected with MLV and treated with sub-optimal doses of AZT to stimulate
development of drug resistant variants. Virus was isolated from either PBMCs (integrated
proviruses) or plasma (genomic RNA) at multiple time points as indicated, and pol fragments
clonally sequenced. (A) Plasma virus was isolated from selected mice at two weeks postinfection, and viral RNA isolated and reverse transcribed for pol sequence analysis. No AZTtreated APOBEC3-/- mice were analyzed at this time point. (B) Integrated proviruses were
amplified and sequenced from selected mice at two weeks post-infection. The number of all
mutations was recorded, and G to A mutations were normalized to total kB sequenced. Mutation
levels of mice of the same genotype were combined as shown in red, and a t-test was performed
to determine statistical differences. (C) Similar analysis was performed for plasma virions isolated
at six weeks post-infection. Multiple mice from each group were assessed at this time point. A ttest was again performed as described above.
A. Circulating plasma virus RNA, 2 weeks post-infection
Genotype/
# of G to
Other
# of
Total
Treatment
Mice
A
Mutations Clones
bp
APOBEC3-/No AZT
APOBEC3G
+AZT
APOBEC3G
No AZT

1

5

18

38

29130

G to A
mutations
per kB
0.17

3

14

35

114

89780

0.16

1

1

10

26

20800

0.05

B. Integrated proviral DNA, 2 weeks post-infection

C. Circulating plasma virus RNA, 6 weeks post-infection
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We next considered the effect of G-to-A mutations on MLV reverse transcriptase protein
in APOBEC3G-expressing mice.

The region sequenced represents about 200 amino acids,

comprising about 40% of the total RT structure. This region contains the active site regions of the
protein, which is known to be a region targeted for RT inhibitor resistance. It excludes the RNase
portion of the enzyme, which has fewer known drug resistance mutations.

The portion

sequenced also has the highest level of homology with HIV-1 RT (Das and Georgiadis, 2004).
Many nucleotide changes do not affect the resulting protein product, as codons maintain
redundancy, particularly at the third position. Thus, to fully appreciate the consequence of any
nucleotide mutation, amino acid sequence changes were assessed.

Although we were

particularly interested in G-to-A changes, viral diversity can arise from other factors, including
reverse transcriptase errors.

To determine the additional effect of APOBEC3G-mediated

mutagenesis, we examined amino acid changes resulting from any nucleotide change. Almost all
viral clones sequenced were evaluated for amino acid mutations, with the exception of a small
fraction that did not translate in frame (likely due to sequencing errors at the 5’ end of the
amplicon). The number of sequences analyzed at the amino acid level is shown in Table 3.4.

Table 3.4. Viral clones assessed for amino acid mutations.
Genotype/Treatment
# of Viral Clones Assessed for Amino
Acid Changes/All Clones Sequenced
APOBEC3-/- AZT200/207
treated
APOBEC3-/260/267
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Untreated
APOBEC3G AZTtreated
APOBEC3G
Untreated

208/218
213/221

The goal was to determine the frequency and location of amino acid changes, using our
sample of viruses as representative of the viral swarm of each individual mouse. Although it
would be expected that mice with more nucleotide changes would result in higher levels of amino
acid mutations, we did not see a statistically significant difference in total amino acid mutations
between APOBEC3G and APOBEC3-/- isolated virions as we did at the nucleotide level.
However, there were significantly more G-to-A mediated amino acid mutations within virions
isolated from APOBEC3G mice (Fig. 3.7).

The highest level was seen in AZT-treated

APOBEC3G mice, suggesting that this selective pressure may lead the virus to maintain
increased APOBEC3G-mediated genetic diversity within the targeted gene product.
To determine whether APOBEC3G resulted in an increase in stop codons within the viral
population, we assessed the total number of stop codons found per group within the sequenced
region. We found few bonafide stop codon-producing mutations, with the untreated APOBEC3-/group actually showing the largest number (6 stop mutations in 184,300 bp). This is somewhat
surprising, considering that a mutation of 5’-TGG-3’ to 5’-TGA-3’, a potential target for APOBEC3,
would result in formation of a stop codon.

It is possible that viral genomes containing stop

codons are transcribed and packaged into budding virions at a significantly lower rate than intact
genomes (Russell, 2009).
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Fig. 3.7. APOBEC3G affects level of viral amino acid diversity in vivo. Viruses isolated from
APOBEC3G and APOBEC3-/- mice were assessed for G-to-A nucleotide changes compared to
the initial viral stock consensus sequence. Viral sequences with G-to-A nucleotide changes were
translated to determine the effect on amino acid residues. Total number of G-to-A mediated
amino acid changes in all viral clones analyzed per experimental group are shown. A t-test was
performed to determine a significant difference between APOBEC3-/- and APOBEC3G-isolated
viruses.
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We next examined the location of amino acid changes within reverse transcriptase. The
region sequenced corresponds to the active site region of the DNA polymerase, including a
number of residues with known involvement in nucleic acid binding.

Although APOBEC3G-

expressing mice did not have an overall increased level of amino acid changes compared to
APOBEC3-/- mice, APOBEC3G-induced G-to-A mutations may select for specific mutations in
regions more likely to cause drug resistance. All amino acid changes were plotted onto a linear
map of the amino acids assessed. Similar regions of the gene were targeted in mice from all four
groups (Fig. 3.8).
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Fig. 3.8. MLV reverse transcriptase amino acid mutations in virions recovered from
APOBEC3-/- and APOBEC3G-expressing mice. Plasma virus was isolated from MLV infected
mice at 6 weeks post-infection. A portion of pol was amplified and clonally sequenced.
Nucleotide mutations were annotated, and clones containing mutations were translated.
Mutations that led to an amino acid change were recorded, and mapped onto a linear chart of the
sequenced region. Each line represents a mutation at the indicated position, and the height of the
line indicates how many viruses with this change were found within the experimental group
specified. Red lines indicate amino acid changes resulting from G-to-A mutations, and blue lines
indicate a change resulting from all other mutations. An APOBEC3G hotspot was targeted in
multiple mice, and results in a GàR amino acid change as indicated. * specifies residues known
to interact with nucleic acids.
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Interestingly, a stretch of amino acids (S180-L217) in viruses isolated from all mice
showed very few mutations, potentially indicating a critical region for reverse transcriptase
function.

This region was also relatively unaffected by mutations at the nucleotide level.

Interestingly, this region also contained only a single APOBEC3G residue target (amino acids
with 5’-GG-3’ within the first two positions of the codon). Although APOBEC3G is able to mutate
within other nucleotide contexts other than this preferred target, this perhaps helps explain the
lack of mutations in this region in virions isolated from APOBEC3G-expressing mice. Specific
residues targeted within AZT-treated and untreated animals were assessed for this APOBEC3G
preferred deamination context. One major hotspot was at G178, which contains a G within the
following sequence context: 5’-TGGGA-3’. This reflects the preferred editing site of APOBEC3G,
and leads to a glycine to arginine mutation. However, this mutation was found at similar levels in
both AZT-treated and untreated animals, signifying a lack of selective evolution for this mutation
in the presence of drug.

This amino acid analysis did not show any mutations found in

significantly high levels in any individual mouse or group of mice, nor did it show a region of the
gene more heavily targeted by APOBEC3G or in the presence of AZT.

However, it does

demonstrate the rapid diversification of retroviruses in vivo, and provides evidence that this can
be augmented by APOBEC3G-mediated deamination.

Chapter 3.5: Discussion
APOBEC3 has been well characterized as an intrinsic antiretroviral factor. Its enzymatic
cytidine deaminase activity causes a crippling level of mutagenesis during reverse transcription,
preventing establishment of productive infection (Mangeat, 2003; Zhang, 2003; Harris, 2003). In
HIV-infected individuals, circulating plasma virus with evident APOBEC3-mediated G-to-A
mutations can be found. This presumably sublethal mutagenesis is related to the activity of the
HIV accessory protein, Vif.

Viruses containing specific Vif mutations that decrease anti-

APOBEC3 activity undergo increased APOBEC3 editing (Simon, 2005; De Maio, 2012).
However, in vitro studies have shown that even with a fully functional Vif, low levels of G-to-A
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mutation can be seen in fully infectious virus (Sadler, 2010). Furthermore, in humanized mice
infected with wild-type HIV, integrated proviruses with significant G-to-A hypermutation were
found (Sato, 2010). In these studies, mutations often led to the formation of errant stop codons;
genomes within circulating virions showed significantly fewer mutations, suggesting selection for
viral genomes not containing mutations leading to truncated proteins.
Mutagenesis increases viral variability, which helps a viral swarm adapt to new pressures
such as antibody mediated immunity or antiviral drugs. APOBEC3-mediated mutagenesis could
thus serve the virus as a source of mutagenesis and variability.

The presence of G-to-A

mutations that do not destroy or significantly diminish infectivity provides principle evidence that
APOBEC3 mutations could benefit the virus. Antiretroviral drug resistance is a major problem in
HIV treatment. Although drug resistance has significantly declined since the advent of triple
therapy, drug non-adherence can still lead to resistance (Clavel and Hance, 2004).

Drug

resistance develops by viral mutagenesis of specific amino acids necessary for drug efficacy.
Some evidence suggests that APOBEC3 could aid the development of drug resistant virus (see
Chapter 1.6.6). The absolute contribution of APOBEC3 to viral evolution and consequently drug
resistance has not been determined in vivo.
We utilized two different models to test the effect of APOBEC3 on viral evolution and
drug resistance in vivo. Initial studies examined the effect of murine APOBEC3
mice on MMTV.

C57BL/6

-expressing

Previous work showed that murine APOBEC3 induces very low levels of

mutation during single rounds of reverse transcription (see Chapter 2.4.3). However, the MMTV
genome has a high A content, which could indicate long term mutagenic pressure from
APOBEC3. This mutagenesis may have arisen during the ostensible thousands of years of coevolution between MMTV and murine APOBEC3. We examined viruses replicating in the longterm absence of APOBEC3, and showed significant sequence reversion to a higher G/C content.
Almost all of the viruses with this reversion showed selection for multiple A-to-G mediated amino
acid changes within the same region of viral Env, which suggests that this reversion may support
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a virus with increased fitness.

This also supports present day maintenance of APOBEC3

mutagenic pressure.
To determine the effect of APOBEC3 on viral evolution during a shorter term, we
monitored infection levels in MMTV-infected AZT-treated vs. untreated APOBEC3+/+ and
APOBEC3-/- mice over a ten-week time course. We showed that AZT treatment was able to
block viral replication in mice of both genotypes. This block was maintained in APOBEC3-/- mice
over the course of the ten-week treatment. However, in APOBEC3+/+ mice receiving identical
doses of drug, viral replication levels significantly increased on average during this time. This
suggests that AZT lost efficacy, which may be the result of APOBEC3 mutagenesis and drug
resistance. An alternative explanation is that APOBEC3-/- mice reached maximum viral loads by
the first time point assessed, and that sub-optimal AZT treatment in APOBEC3+/+ mice allowed
for continued viral replication in these mice, allowing overall viral loads to eventually become
equal to untreated mice by the last time point assessed. Additional follow up analysis of viral
reverse transcriptase changes between endpoint untreated APOBEC3+/+ and AZT-treated
APOBEC3+/+ samples, as well as baseline and endpoint viruses from AZT-treated animals would
have helped elucidate a role for APOBEC3-mediated mutagenesis on these outcomes.
To overcome some of the experimental challenges of the MMTV system, we next
assessed a similar effect of APOBEC3 on retroviral evolution in vivo with two important
modifications. First, we used Moloney murine leukemia virus. Interestingly, unlike HIV-1 and
MMTV, M-MLV does not have a high genomic adenine content, which should make it more
susceptible to the editing effects of a cytidine deaminase. Like MMTV, it is restricted by murine
APOBEC3 in vivo in the absence of viral mutagenesis (Brown and Littman, 2008). However, MMLV encodes a Gag isoform with a glycosylated N-terminus extension called gGag, which is able
to counteract APOBEC3 (see Chapter 1.6.5). The anti-APOBEC3 activity of gGag differs from
HIV-1 Vif, which acts to exclude APOBEC3 packaging via proteosomal degradation. Murine
APOBEC3 is not excluded from MLV virions, but is still unable to deaminate the virus. Viruses
lacking gGag contain viral cores that are less stable compared to cores within viruses expressing
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gGag (Stavrou, 2013).

It is possible that gGag is able to protect the reverse transcriptase

complex from APOBEC3, or that the resulting change in viral stability affects the
compartmentalization or release of APOBEC3. Because of this natural resistance to deamination
by murine APOBEC3, we used transgenic mice expressing human APOBECG, which is known to
cause significant G-to-A hypermutation of MLV in vitro (Bishop, 2004).
We showed that the antiretroviral AZT was effective against MLV both in vitro and in vivo,
and performed in vivo dosing experiments to determine the optimal dose for viral evolution
studies. Using a dose of MLV that allowed approximately 1-5% wild-type viral replication, we
showed that AZT and APOBEC3 had a synergistic effect on MLV replication. Both AZT and
APOBEC3G restrict virus at reverse transcription, which in turn leads to significantly less
integration products. The combination of both is able to substantially prevent new infections, and
increasing APOBEC3 activity may prove useful as a therapeutic tool to prevent or inhibit retroviral
infections in humans. The most significant increase in viral loads was seen within a few individual
mice within the AZT-treated groups, indicating a potential development of mutant escape viruses
in these groups.

Viral loads in untreated groups also increased on average, but in smaller

increments, indicative of continued viral replication and infection of new cellular targets in the
absence of the drug.
We sequenced a region of MLV pol from in vivo-isolated viruses to assess viral diversity.
We compared viruses from APOBEC3G-expressing mice in the presence or absence of AZT, a
presumed evolutionary pressure, to viruses obtained from APOBEC3-/- mice. We showed that
APOBEC3G causes an increase in G-to-A mutations in integrated proviruses early in infection.
However, analysis of integrated viruses is not necessarily the most suitable method for analyzing
the presence of specific mutations. Potential drug resistance mutations found in integrated
proviruses may not necessarily contribute to resistance within circulating virions, if these
resistance mutations are found within the only provirus in a cell and the provirus is otherwise
lethally mutated.
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Of note, the technology utilized also may not provide an accurate display of the actual
circulating viruses. Our clonal sequencing efforts may be too insignificant to accurately detect the
actual level of mutagenesis. The use of PCR-generated template and transformation of bacterial
cells prior to sequencing also provides two additional opportunities for erroneous mutations to
arise. Sequencing errors are also a major problem in high-throughput sequencing technology,
but samples typically require fewer rounds of PCR prior to sequencing, and samples do not need
to be amplified within bacteria. An additional experimental caveat is that the rate of cell turnover
after infection with MLV is unknown. MLV infects multiple different cell types, all of which have
varying half-lives, and although infection with MLV is not thought to affect cell lifespan, these
experiments have not directly been tested within this system. Thus, unlike in an HIV infection in
which the infected circulating T-cells represent the most recent rounds of infection, circulating
plasma MLV may be produced from the total population of infected cells. If resistance mutations
arise later in infection, detecting this resistant population would be more difficult than is the case
in HIV-infected patients.
Distinguishing between the mutagenic effects of error-prone reverse transcriptase and
APOBEC3 is still critical to determine the relative contribution of both to viral evolution,
pathogenesis, and drug resistance. To date, this has been impossible to study in vivo, as human
samples cannot be experimentally controlled for APOBEC3 expression or initial virus input. At
six-weeks post-infection, we found an increased level of G-to-A mutations in plasma virus of
APOBEC3G-expressing mice, confirming the ability of APOBEC3 to induce viral diversity during a
normal course of infection in vivo. Although viruses within APOBEC3-/- mice also showed some
viral diversity, the level of nucleotide mutation was significantly higher in APOBEC3G-expressing
mice, supporting this antiviral protein as an aid for increasing viral diversity in vivo. Interestingly,
overall diversity at the amino acid level was not significantly different between APOBEC3G and
APOBEC3-/- mice.

However, APOBEC3G-expressing mice had significantly higher G-to-A

mediated amino acid mutations, demonstrating that APOBEC3G affects the specific population of
residues targeted for G-to-A mutagenesis in vivo. However, our data shows that APOBEC3G
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produces a gradient of deamination, increasing from 5’ to 3’. This gradient suggests a lower level
of G-to-A mutations within pol than in other targets such as env or the 3’LTR. Thus, a different
selective pressure applied to the virus that targets a gene towards the 3’ end of the genome may
have a higher chance of being affected by APOBEC3G mutagenesis. Also of note, the rate of
viral replication could have an effect on the level of mutations. Increased viral replication allows
for additional attack by APOBEC3G, as well as new opportunities for polymerase errors, etc. Our
APOBEC3G AZT-treated mice had the lowest level of viral replication, yet still showed a diverse
collection of viruses. Thus, APOBEC3 may actually play a larger role in viral diversity than was
seen here, if level of nucleotide changes were normalized to number of replication cycles.
In sum, we have demonstrated the effect of APOBEC3G on murine retroviruses in vivo.
These effects are quite obviously antiviral in nature, in terms of reducing viral load. However,
APOBEC3G also increases the rate of viral variability even in a relatively short six-week time
period, which could easily aid the virus in escaping immune or drug pressures. Future studies
should monitor viral loads and mutagenesis over a longer time period to better understand the
long-term effects of APOBEC3. Although we did not see evidence of AZT-resistant viruses in our
system, use of different AZT concentrations, other antiretroviral drugs and high throughput next
generation sequencing technology may provide better methods for monitoring the influence of
APOBEC3G on drug resistance.

Chapter 4: Summary
Chapter 4.1: Discussion
APOBEC3 family members have been well characterized as intrinsic antiretroviral
factors. Many previous studies show its potent activity against a large array of viruses in vitro,
and several murine viruses in vivo. However, the large majority of studies have been performed
in vitro, including investigations into the antiviral mechanisms and the mutagenic effect on viral
evolution. Our work has helped elucidate the activity of APOBEC3 in vivo.
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Chapter 4.1.1: Antiviral mechanisms of endogenous murine APOBEC3 in vivo
The mechanism of viral restriction by APOBEC3 is undoubtedly a double-edge sword.
As an active cytidine deaminase enzyme, APOBEC3 targets newly synthesized DNA for G-to-A
mutations in the coding strand (Mangeat, 2003; Zhang, 2003; Harris, 2003). This mutagenic
effect is clearly active in vivo, as heavily mutated proviruses can be found in HIV-infected
patients, SIV-infected macaques, and HIV-infected humanized mice (Wain-Hobson, 1992;
Johnson, 1991; Sato, 2010). Endogenous virion-packaged murine APOBEC3 does not induce
cytidine deamination on nascent MMTV reverse transcription products. We have shown that this
is not due to an inability for the protein to catalyze the enzymatic reaction. However, significant
deamination simply does not occur during reverse transcription even though APOBEC3 is clearly
packaged within viral cores and potently affects virus via a cytidine deaminase-independent mode
of restriction.
This block to deamination is an interesting phenomenon, as murine retroviruses can be
targeted for mutation by APOBEC3 proteins from other species (Bishop, 2004). It is likely that
long-term evolution between retroviruses and their host has allowed the more quickly evolving
virus to evade the host restriction factors. The evolution of pathogen restriction factors is an
important topic in the field, as an understanding of this evolution allows insight into ancestral
functions and selective forces, and explains why certain populations are susceptible or resistant
to specific pathogens. Analysis of mouse APOBEC3 indicates that it has been in significant
genetic conflict during Mus evolution, although the specific causes of this conflict are unknown
(Sanville, 2010). Interestingly, six of the 10 codons of mAPOBEC3 under the strongest positive
selection are within the catalytically active cytidine deaminase domain, five of which encode
different amino acids in mouse strains that can or cannot restrict MLV and MMTV. This evolution
may have allowed the restrictive form of APOBEC3 to initiate cytidine deamination against
ancient retroviruses, but not more recently evolved present-day targets.
changes may be critical for deaminase-independent restriction.

Alternatively, these
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This method of restriction involves inhibiting RT-mediated elongation and accumulation of
reverse transcription products, which has been demonstrated for various APOBEC3 proteins in
vitro by several groups (Bishop, 2006; Iwatani, 2007; Li, 2007; Guo, 2007; Bishop, 2008).
Because in vitro systems typically use plasmid-based gene expression, it has been argued that
cytidine deaminase-independent inhibition is an artifact of APOBEC3 over-expression
(Schumacher, 2008; Miyagi, 2007). Our studies indicate that cytidine deaminase-independent
inhibition occurs in vivo, confirming its role as an important antiviral effect of APOBEC3.
The evolution of two main genetic variants of murine APOBEC3 is noteworthy, as mice
encode only a single APOBEC3 gene as opposed to the multiple genes expressed in higher
mammals such as cats, horses, and humans (Sanville, 2010). As previously mentioned, this
evolution has a significant effect in mice, as mice encoding the APOBEC3

C57BL/6

variant of the

gene are better able to control certain viruses (Santiago, 2008; Okeoma, 2010). The basis for
this functional difference has to date been unclear. We have shown that differential APOBEC3
expression levels are critical for this difference.

Mice encoding APOBEC3

C57BL/6

express

significantly higher levels at both the RNA and protein level, and are better able to restrict.
Heterozygous mice expressing lower levels of their respective APOBEC3 allele also show
decreased viral restriction. Thus, higher endogenous expression of APOBEC3 is beneficial for
viral restriction, and promotion of increased APOBEC3 expression may be a useful therapeutic
tool.

Chapter 4.1.2: APOBEC3-induced viral evolution of murine retroviruses in vivo
Although APOBEC3 clearly has antiviral means, viral targets may benefit from the
increased mutation rate offered via G-to-A mutagenesis. Murine retroviruses do not suffer the
lethal hypermutation seen in other viral-host systems, and the very low-level, sublethal mutation
rate that does occur could speed viral evolution. HIV-1 has evolved Vif as an anti-APOBEC3
device, causing rapid degradation and preventing incorporation of APOBEC3 into budding virions.
However, Vif is not always completely effective, either due to high APOBEC3 expression or
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defective Vif (Sato, 2010; Simon, 2005).

Therefore, APOBEC3 is sometimes able to cause

sublethal HIV mutations. This is of particular note because a considerable number of antiviral
drug resistance mutations are G-to-A based (Berkhout and de Ronde, 2004). These mutations
can even arise before drug exposure, allowing for a potential pool of resistant viruses ready for
rapid expansion once drug is administered (Mulder, 2008).
Our transgenic APOBEC3G-expressing mice provide an ideal system with which to test
the evolutionary effect of APOBEC3 in vivo. We present a first look into the timing and magnitude
of APOBEC3G mutations in MLV in comparison to mutations found in virus replicating in the
complete absence of APOBEC3. Viruses with significant G-to-A mutagenesis were found early in
infection at the level of integrated proviruses. After several additional weeks of viral replication,
we were able to detect G-to-A mutations within viruses of the circulating viral plasma population.
Although we did not see a significant impact on the development of drug resistance under
pressure of suboptimal doses of AZT, we did show a significantly higher rate of viral mutagenesis
within MLV pol within APOBEC3G-expressing mice.
This increase occurred even in the presence of APOBEC3G expression levels
considerably lower than those found in human PBMCs. Presumably, higher levels of transgene
expression would lead to increased mutation rate, which would have an improved antiviral effect
but could induce significantly faster viral evolution.

Our lab has also generated additional

transgenic mice expressing near-human levels of APOBEC3G. However, when these mice were
infected with M-MLV, the levels of infection were several logs lower than in non-transgenic mice
and some mice even cleared infection (Stavrou, manuscript in preparation). This is consistent
with in vitro data using APOBEC3G transfected cells, demonstrating that MLV is highly edited by
APOBEC3G. Thus we chose to use the A3G transgenic strain studied here so that we could limit
lethal mutations. This complex interplay between the antiviral activity of APOBEC3 versus a
potential proviral activity is one to be more closely considered, particularly in note of several
attempts to utilize APOBEC3 in therapeutic strategies (Cadima-Couto and Goncalves, 2010).
Increasing APOBEC3 levels in addition to antiretroviral drugs was beneficial to decrease viral
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replication in our system, as MLV is unable to degrade the protein. However, it is unknown if this
effect would be similar in an HIV-1 infection in the presence of an effective Vif that is able to
completely degrade the protein. It is possible that increasing the expression of APOBEC3 may
have little effect on reducing viral replication, if Vif can handle degradation of an increased level of
protein. However, it could increase viral diversity via sublethal mutagenesis, potentially aiding the
virus in evading recognition by antiviral cytotoxic T-lymphocytes or antibodies, as well as helping
create drug resistance mutations.
Although we did not see a significant increase in total levels of viral diversity at the
protein level in viruses isolated from APOBEC3G-expressing mice, we did see a specific trend
towards G-to-A induced amino acid changes. We believe that at later time points this increase in
G-to-A mediated amino acid changes will result in significantly higher levels of viral diversity, as
nucleotide mutations continue to accumulate.

Although the higher level of mutation at the

integrated provirus level is at least partially obscured from the circulating plasma virus pool
through purifying selection, we show that APOBEC3G does make substantial contributions to
viral sequence diversity.

Chapter 4.2: Future Directions
This work has focused on the mechanisms and impact of both antiviral and proviral
effects of APOBEC3 in vivo. Both remain important areas for future investigation. First, the
mechanism by which APOBEC3 interferes with reverse transcription and reduces accumulation of
viral cDNA is unknown. While MMTV and MLV provide excellent systems for studying viral-host
interactions in vivo, a better understanding of these mechanisms will likely require substantial in
vitro biochemical analysis. However, as murine APOBEC3 seems to rely solely on this cytidine
deaminase-independent mechanism to restrict murine retroviruses, it may serve as an
appropriate system to study in vitro.
Furthermore, the means by which murine retroviruses prevent the accumulation of
cytidine deaminase-mediated mutations should be further explored. Although gGag serves as a
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Vif-like factor for M-MLV, it does not seem to have a specific impact on preventing cytidine
deamination by endogenous murine APOBEC3, but instead prevents inhibition of reverse
transcription (Stavrou, 2013). Both MMTV and MLV may share a similar method for preventing
G-to-A hypermutation. Evolutionary analysis of both the viruses and murine APOBEC3 may
provide some insight into regions of the virus or protein that play an important role in this evasion.
The role of APOBEC3 on viral evolution and drug resistance is even less well
understood. Our model system of MLV-infected APOBEC3G-expressing mice could be utilized to
offer clarity in conjunction with our results. Our experimental model and results provide tools to
better design a larger study with better chances of determing the real role of APOBEC3 in viral
evolution. First, a long-term study of APOBEC3-mediated mutagenesis in the absence of any
selective pressure should be performed. Both integrated proviruses and circulating plasma virus
can be easily obtained at various time points without sacrificing animals. Additional data could be
obtained from mice expressing higher levels of the transgene to determine a dose effect. This
would provide a baseline to understand how viral diversity is affected without a direct evolutionary
pressure. Because APOBEC3G causes a 5’ to 3’ increasing gradient of hypermutation, utilization
of selective pressures that target a gene at the 3’ end of the genome may be most useful.
Many monoclonal antibodies to MLV exist, and the specific protein targets of these
antibodies are known. One potential experimental model would use a neutralizing monoclonal
antibody that targets a portion of the viral Env protein that contains specific amino acids residues
affected by G-to-A mutations. The monoclonal antibody could be injected into mice similarly to an
antiretroviral drug, and the level of viral binding carefully titrated to neutralize the virus to an
optimal level. Viral escape would then prevent specific antibody binding and thus neutralization.
This could provide an excellent alternative system in which to assess the evolutionary effect of
APOBEC3 in vivo. Deep sequencing could recover any viral genome containing mutations within
the antibody-targeted region, and these viruses could also be grown ex vivo in the presence of
the monoclonal antibody to assess the ability of the antibody to bind.
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A newly created MLV virus engineered to express HIV-1 Vif may also help elucidate the
effect of this critical anti-APOBEC3 factor on the level of APOBEC3G-mediated inhibition and
mutagenesis (Spiros Stavrou and Ed Browne, data unpublished). Mutations known to affect the
activity of Vif could also be engineered into the Vif-containing virus to determine absolute effects,
both on viral replication and evolution in vivo. For all of these studies, high-throughput next
generation sequencing would be extraordinarily beneficial.

This technology would allow

extensive sampling of the viral population. Furthermore, several mice from experimental and
control groups could be combined using barcoded primers for easy identification, to reduce cost
and increase sample size (Jabara, 2011).
Our model could also be used for continued studies of the effect of APOBEC3G on drug
resistance. Although the reverse transcriptase of MLV shares significant structural homology with
that of HIV-1, only a single known AZT-resistance mutation is known for MLV RT. However, this
mutation was engineered for experimental purposes, so naturally arising resistance mutations,
similar to those known for HIV, have not been identified. This mutation is not mediated by a G-toA mutation (Ndongwe, 2011). Regardless, it was not seen in virus isolated from any of our AZTtreated mice, irrespective of genotype. Although we initially reasoned that AZT would work well in
our system based on the requirement for multiple resistance mutations (TAMs), other drugs have
been used with better results in similar evolution studies in vitro. For example, lamivudine (3TC)
resistance arises via a single nucleotide substitution in HIV-1 reverse transcriptase, which is
mediated by an APOBEC3G targeted G-to-A mutation (at M184) (Kim, 2010). While this drug
has little activity against MLV, other drugs with a similarly distinct resistance mutation pattern may
work better within our murine model. In conclusion, our studies offer a basic foundation for an
almost unlimited collection of important data, which together could potentially affect therapeutic
prospects for HIV and other human retroviral pathogens.
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